{"e073e0c29b777658ae30bcc4bb30ae67c23e4e93": [["Guanine nucleotide exchange factors (GEFs) .", [["Guanine nucleotide", "CHEMICAL", 0, 18], ["Guanine nucleotide", "CHEMICAL", 0, 18], ["Guanine nucleotide exchange factors", "GENE_OR_GENE_PRODUCT", 0, 35], ["GEFs", "GENE_OR_GENE_PRODUCT", 37, 41], ["Guanine nucleotide exchange factors", "PROTEIN", 0, 35], ["GEFs", "PROTEIN", 37, 41], ["Guanine nucleotide exchange factors", "TREATMENT", 0, 35]]], ["Proteins that promote the release of GDP from guanin e-nucleotide-binding (G) proteins, which allows GTP to bind.", [["GDP", "CHEMICAL", 37, 40], ["GTP", "CHEMICAL", 101, 104], ["GDP", "CHEMICAL", 37, 40], ["GTP", "CHEMICAL", 101, 104], ["GDP", "SIMPLE_CHEMICAL", 37, 40], ["guanin e-nucleotide-binding (G)", "GENE_OR_GENE_PRODUCT", 46, 77], ["GTP", "SIMPLE_CHEMICAL", 101, 104], ["GDP", "PROTEIN", 37, 40], ["guanin e-nucleotide-binding (G) proteins", "PROTEIN", 46, 86], ["GDP", "TEST", 37, 40]]], ["These proteins often stabilize the nucleotide-free form and then are released upon GTP binding.", [["nucleotide", "CHEMICAL", 35, 45], ["GTP", "CHEMICAL", 83, 86], ["nucleotide", "CHEMICAL", 35, 45], ["GTP", "CHEMICAL", 83, 86], ["GTP", "SIMPLE_CHEMICAL", 83, 86], ["GTP binding", "PROBLEM", 83, 94]]]], "PMC7192321": [["Medical toxicology and infectious disease are not specialties traditionally associated with one another.", [["infectious disease", "DISEASE", 23, 41], ["infectious", "OBSERVATION", 23, 33]]]], "PMC7411005": [["IntroductionMultiple cases of pneumonia patients were linked to the coronavirus disease-2019 (COVID-19) occurred in December 2019 (Zhu et al., 2020).", [["pneumonia", "DISEASE", 30, 39], ["coronavirus disease", "DISEASE", 68, 87], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["pneumonia", "PROBLEM", 30, 39], ["the coronavirus disease", "PROBLEM", 64, 87], ["COVID", "TEST", 94, 99], ["pneumonia", "OBSERVATION", 30, 39], ["coronavirus", "ANATOMY", 68, 79]]], ["The virus 2019-nCoV demonstrated a substantial capability of inter-human transmissions (Chan et al., 2020) and has rapidly spread around the world, in particular South Korea and Japan (Li Q. et al., 2020).", [["The virus", "TEST", 0, 9], ["substantial", "OBSERVATION_MODIFIER", 35, 46], ["capability", "OBSERVATION_MODIFIER", 47, 57]]], ["Patients infected with COVID-19 had significantly varied symptoms and their outcomes ranged from mild to death, and the mortality rate was approximately 4.3% (Wang et al., 2020).", [["death", "DISEASE", 105, 110], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 23, 28], ["significantly varied symptoms", "PROBLEM", 36, 65], ["mild to death", "PROBLEM", 97, 110], ["the mortality rate", "TEST", 116, 134], ["infected", "OBSERVATION", 9, 17], ["mild", "OBSERVATION_MODIFIER", 97, 101]]], ["It is necessary to mention that 61.5% of the COVID-19 pneumonia patients with critical symptoms died within 28 days after admission (Yang X. et al., 2020).", [["pneumonia", "DISEASE", 54, 63], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["the COVID", "TEST", 41, 50], ["pneumonia", "PROBLEM", 54, 63], ["critical symptoms", "PROBLEM", 78, 95], ["pneumonia", "OBSERVATION", 54, 63]]], ["The discrimination of severely ill patients with COVID-19 from those with mild symptoms may help understand the individualized variations of the COVID-19 prognosis.", [["severely ill", "DISEASE", 22, 34], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["COVID", "TEST", 49, 54], ["mild symptoms", "PROBLEM", 74, 87], ["the COVID", "TEST", 141, 150], ["severely", "OBSERVATION_MODIFIER", 22, 30], ["ill", "OBSERVATION_MODIFIER", 31, 34]]], ["The knowledge may also facilitate the establishing of early diagnosis of the COVID-19 severeness.IntroductionThe diagnosis of COVID-19 heavily relies on the epidemiological features, clinical characteristics, imaging findings, and nucleic acid screening (Shi et al., 2020), etc. The delivery of the diagnosis result by these technologies was time consuming and error prone (Xie et al., 2020).", [["nucleic acid", "CHEMICAL", 231, 243], ["COVID-19", "CHEMICAL", 126, 134], ["the COVID", "TEST", 73, 82], ["COVID", "TEST", 126, 131], ["imaging findings", "TEST", 209, 225], ["nucleic acid screening", "TEST", 231, 253]]], ["Multiple types of clinical data were collected for a patient with COVID-19 infection and they were manually integrated by the clinicians to make the diagnosis decisions.", [["infection", "DISEASE", 75, 84], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["clinical data", "TEST", 18, 31], ["COVID-19 infection", "PROBLEM", 66, 84], ["infection", "OBSERVATION", 75, 84]]], ["The stochastic transmission model was also used to investigate how the COVID-19 transmitted locally and globally (Kucharski et al., 2020).", [["COVID-19", "DNA", 71, 79], ["the COVID", "TEST", 67, 76]]], ["Machine learning algorithms were widely used to integrate the heterogeneous biomedical data sources for the diagnosis decision (Thompson et al., 2018; Hu et al., 2019).", [["Machine learning algorithms", "TREATMENT", 0, 27]]], ["So they may also be utilized to produce more delicate prediction models for the severeness diagnosis of the COVID-19 patients.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125]]], ["The biomarkers used for an accurate diagnosis model of patients with COVID-19 may serve as the drug targets for this global infectious disease.IntroductionThis study investigated the detection of severely ill patients with COVID-19 from those with mild symptoms using the clinical information and the blood/urine test data.", [["blood", "ANATOMY", 301, 306], ["urine", "ANATOMY", 307, 312], ["COVID-19", "CHEMICAL", 69, 77], ["infectious disease", "DISEASE", 124, 142], ["severely ill", "DISEASE", 196, 208], ["COVID-19", "CHEMICAL", 69, 77], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 209, 217], ["blood", "ORGANISM_SUBSTANCE", 301, 306], ["urine", "ORGANISM_SUBSTANCE", 307, 312], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 209, 217], ["The biomarkers", "TEST", 0, 14], ["COVID", "TEST", 69, 74], ["this global infectious disease", "PROBLEM", 112, 142], ["This study", "TEST", 155, 165], ["COVID", "TEST", 223, 228], ["mild symptoms", "PROBLEM", 248, 261], ["the blood/urine test data", "TEST", 297, 322], ["infectious", "OBSERVATION", 124, 134]]], ["The clinical information consisted of age, sex, body temperature, heart rate, respiratory rate, and blood pressure.", [["body", "ANATOMY", 48, 52], ["heart", "ANATOMY", 66, 71], ["respiratory", "ANATOMY", 78, 89], ["blood", "ANATOMY", 100, 105], ["body", "ORGANISM_SUBDIVISION", 48, 52], ["heart", "ORGAN", 66, 71], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["body temperature", "TEST", 48, 64], ["heart rate", "TEST", 66, 76], ["respiratory rate", "TEST", 78, 94], ["blood pressure", "TEST", 100, 114], ["heart", "ANATOMY", 66, 71], ["respiratory rate", "OBSERVATION", 78, 94]]], ["The blood/urine tests may be carried out using the technically easy and cost-efficient procedures.", [["blood", "ANATOMY", 4, 9], ["urine", "ANATOMY", 10, 15], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["urine", "ORGANISM_SUBSTANCE", 10, 15], ["The blood/urine tests", "TEST", 0, 21], ["cost-efficient procedures", "TREATMENT", 72, 97]]], ["An accurate severeness detection model of the patients with COVID-19 based on those features above may improve the prognosis of this disease in large scale clinical practices.", [["patients", "ORGANISM", 46, 54], ["COVID-19", "DNA", 60, 68], ["patients", "SPECIES", 46, 54], ["COVID", "TEST", 60, 65], ["this disease", "PROBLEM", 128, 140]]], ["The following sections will firstly describe the data collection and modeling methods, and then utilized the popular machine learning algorithms to build the best severeness detection model.Data Collection ::: Materials and MethodsThis study recruited 137 clinically confirmed cases of COVID-19, which were collected from the Tongji Hospital Affiliated to Huazhong University of Science and Technology.", [["sections", "ANATOMY", 14, 22], ["the data collection", "TEST", 45, 64], ["modeling methods", "TEST", 69, 85], ["Methods", "TREATMENT", 224, 231], ["This study", "TEST", 231, 241], ["COVID", "TEST", 286, 291]]], ["Patients were hospitalized from January 18, 2020, to February 13, 2020.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The cohort consisted of 17 mild cases, 45 moderate ones and 75 severely ill patients.", [["ill", "DISEASE", 72, 75], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84]]], ["21 of the severe cases eventually died.", [["severe", "OBSERVATION_MODIFIER", 10, 16]]], ["This study investigated the binary classification problem between 75 severe/deceased cases and 62 mild/moderate ones.", [["This study", "TEST", 0, 10], ["mild/moderate ones", "PROBLEM", 98, 116], ["mild", "OBSERVATION_MODIFIER", 98, 102], ["moderate", "OBSERVATION_MODIFIER", 103, 111]]], ["Each participant was regarded as a sample in this study.", [["participant", "SPECIES", 5, 16], ["this study", "TEST", 45, 55]]], ["This study was approved by the Ethics Commission of the First Hospital of Jilin University (2020-236).", [["This study", "TEST", 0, 10]]], ["With informed consent was waived for this emerging infectious disease.Data Collection ::: Materials and MethodsPatient information including age, sex, body temperature, heart rate, respiratory rate, blood pressure and the blood/urine tests data.", [["body", "ANATOMY", 151, 155], ["heart", "ANATOMY", 169, 174], ["respiratory", "ANATOMY", 181, 192], ["blood", "ANATOMY", 199, 204], ["blood", "ANATOMY", 222, 227], ["urine", "ANATOMY", 228, 233], ["infectious disease", "DISEASE", 51, 69], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["heart", "ORGAN", 169, 174], ["blood", "ORGANISM_SUBSTANCE", 199, 204], ["blood", "ORGANISM_SUBSTANCE", 222, 227], ["urine", "ORGANISM_SUBSTANCE", 228, 233], ["Patient", "SPECIES", 111, 118], ["body temperature", "TEST", 151, 167], ["heart rate", "TEST", 169, 179], ["respiratory rate", "TEST", 181, 197], ["blood pressure", "TEST", 199, 213], ["the blood/urine tests data", "TEST", 218, 244], ["heart", "ANATOMY", 169, 174]]], ["Each clinically obtained value was regarded as a feature in this study.", [["this study", "TEST", 60, 70]]], ["In summary, each sample has 100 features, consisting of 8 clinical, 76 blood test, and 16 urine test values.Data Pre-processing ::: Materials and MethodsThe missing entries were filled in the following procedure.", [["blood", "ANATOMY", 71, 76], ["urine", "ANATOMY", 90, 95], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["urine", "ORGANISM_SUBSTANCE", 90, 95], ["each sample", "TEST", 12, 23], ["blood test", "TEST", 71, 81], ["urine test values", "TEST", 90, 107], ["Methods", "TREATMENT", 146, 153], ["the following procedure", "TREATMENT", 188, 211], ["filled", "OBSERVATION_MODIFIER", 178, 184]]], ["We assumed a missing entry to be within the normal range and filled this entry with the median of that normal range.", [["normal range", "OBSERVATION", 103, 115]]], ["If there is no normal range for a missing entry, we filled it with zero (0).", [["no", "UNCERTAINTY", 12, 14], ["normal range", "OBSERVATION_MODIFIER", 15, 27]]], ["The samples were randomly split into 80% as training and 20% as test datasets in a stratified fashion.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["test datasets", "TEST", 64, 77]]], ["The categorial features were encoded by the one-hot strategy.Feature Selection ::: Materials and MethodsThe principle of Occam\u2019s razor suggested that a model using fewer features was preferred over a complicated model with a similar prediction performance (Koller and Sahami, 1996).", [["Occam", "PROTEIN", 121, 126]]], ["Feature selection algorithms may be utilized to remove those unrelated features (Ebrahimpour et al., 2017) and may usually increase the model prediction performances (Zhang et al., 2019; Yang S. et al., 2020).Feature Selection ::: Materials and MethodsThe student t-test (abbreviated as T-test) is a filter algorithm and it evaluates the statistical association of each feature with the disease severeness of a sample.", [["The student t-test", "TEST", 252, 270], ["a filter algorithm", "TEST", 298, 316], ["the disease severeness", "PROBLEM", 383, 405], ["disease", "OBSERVATION", 387, 394]]], ["The features with the T-test calculated P-values below 0.05 were usually considered to be statistically significantly associated with the disease severeness (Govindan et al., 2019; Peng et al., 2019).Prediction Algorithms ::: Materials and MethodsThis study evaluated several classification algorithms to build the prediction models of the severely ill patients with COVID-19.", [["ill", "DISEASE", 349, 352], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 353, 361], ["the T-test", "TEST", 18, 28], ["the disease severeness", "PROBLEM", 134, 156], ["This study", "TEST", 247, 257], ["COVID", "TEST", 367, 372], ["disease", "OBSERVATION", 138, 145], ["severely", "OBSERVATION_MODIFIER", 340, 348]]], ["The predictive logistic regression (LR) model is a regression analysis for the dataset with the binary dependent variable, i.e., the class label (Kleinbaum et al., 2002).", [["The predictive logistic regression (LR)", "TREATMENT", 0, 39], ["a regression analysis", "TEST", 49, 70]]], ["LR has been widely used to build clinical decision models (Luo et al., 2019; Heijnen et al., 2020).", [["LR", "PROTEIN", 0, 2], ["LR", "TREATMENT", 0, 2]]], ["LR firstly calculates the log\u2212oddsl = logb[p/(1\u2212p)] = \u03b20 + \u03b21x + \u2026 + \u03b2nx, and the probability p = 1/[1 + \u03b2\u2212(\u03b20 + \u03b21x + \u2026 + \u03b2nx)], where \u03b2i is the model parameter.Prediction Algorithms ::: Materials and MethodsSupport vector machine (SVM) is a supervised machine learning algorithm that may accomplish both classification and regression tasks (Suykens and Vandewalle, 1999).", [["\u2026 + \u03b2nx", "SIMPLE_CHEMICAL", 65, 72], ["\u2026 + \u03b2nx", "SIMPLE_CHEMICAL", 119, 126], ["LR", "PROTEIN", 0, 2], ["\u03b21x", "PROTEIN", 59, 62], ["\u2026", "PROTEIN", 65, 66], ["\u03b2nx", "PROTEIN", 69, 72], ["\u03b2nx", "PROTEIN", 123, 126], ["\u03b2i", "PROTEIN", 136, 138], ["LR", "TEST", 0, 2], ["log\u2212oddsl", "TEST", 26, 35], ["logb", "TEST", 38, 42], ["\u2026", "TEST", 65, 66], ["\u03b2nx", "TEST", 69, 72], ["probability", "TEST", 82, 93], ["\u03b2", "TEST", 113, 114], ["\u2026", "TEST", 119, 120], ["MethodsSupport vector machine", "TREATMENT", 202, 231], ["a supervised machine learning algorithm", "TREATMENT", 241, 280]]], ["SVM tries to find a hyperplane to separate data by the highest margin.", [["highest", "OBSERVATION_MODIFIER", 55, 62], ["margin", "OBSERVATION_MODIFIER", 63, 69]]], ["The learning strategy of SVM is spacing maximization, which can be formalized as a problem of solving convex quadratic programming (Shilton et al., 2005).", [["spacing maximization", "PROBLEM", 32, 52], ["solving convex quadratic programming", "TREATMENT", 94, 130]]], ["This algorithm has been widely used to build the prediction models using the data of blood test (Li et al., 2014, 2018) and urine test (Osredkar et al., 2019; Zhou et al., 2019).Prediction Algorithms ::: Materials and MethodsRandom forest (RF) is an ensemble algorithm that summarizes the prediction results of multiple tree-based classifiers (Pal, 2005).", [["blood", "ANATOMY", 85, 90], ["urine", "ANATOMY", 124, 129], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["urine", "ORGANISM_SUBSTANCE", 124, 129], ["blood test", "TEST", 85, 95], ["urine test", "TEST", 124, 134]]], ["Its model complexity renders itself computation-intensive and RF runs slower than many prediction algorithms.", [["RF runs", "TEST", 62, 69], ["many prediction algorithms", "TEST", 82, 108], ["complexity", "OBSERVATION_MODIFIER", 10, 20], ["intensive", "OBSERVATION_MODIFIER", 48, 57]]], ["Nicholas Schaub et al. (2009) demonstrated that selecting the best biomarkers may be essential to improve the KNN models.Prediction Algorithms ::: Materials and MethodsThe boosting-based algorithm AdaBoost iteratively trained weak learners and summarized these weak learners\u2019 results into a weighted sum (Ratsch et al., 2001).", [["Methods", "TREATMENT", 161, 168]]], ["Multiple variants of Adaboost were proposed for recognizing human actions (Lv and Nevatia, 2006), diagnosing the dog hypoadrenocorticism (Reagan et al., 2019), and predicting protein binding sites (Qiao and Xie, 2019), etc.Prediction Algorithms ::: Materials and MethodsThe above algorithms are implemented using Python programming language (version 3.6) and Scikit-learn package (version 0.22).Prediction Performance Evaluation Metrics ::: Materials and MethodsThe binary classification model was evaluated using four classification performance metrics, as defined in the followings.", [["hypoadrenocorticism", "DISEASE", 117, 136], ["Adaboost", "GENE_OR_GENE_PRODUCT", 21, 29], ["human", "ORGANISM", 60, 65], ["dog", "ORGANISM", 113, 116], ["Adaboost", "DNA", 21, 29], ["protein binding sites", "PROTEIN", 175, 196], ["human", "SPECIES", 60, 65], ["dog", "SPECIES", 113, 116], ["human", "SPECIES", 60, 65], ["the dog hypoadrenocorticism", "PROBLEM", 109, 136], ["predicting protein binding sites", "PROBLEM", 164, 196], ["Python programming language", "TREATMENT", 313, 340]]], ["The severely ill patients were regarded as positive samples and the other patients constituted the negative dataset.", [["samples", "ANATOMY", 52, 59], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 74, 82], ["positive samples", "PROBLEM", 43, 59], ["severely", "OBSERVATION_MODIFIER", 4, 12], ["ill", "OBSERVATION_MODIFIER", 13, 16]]], ["The number of correctly predicted positive samples was defined as true positive (TP), and the number of the other positive samples was false negative (FN).", [["samples", "ANATOMY", 43, 50], ["samples", "ANATOMY", 123, 130], ["TP", "GENE_OR_GENE_PRODUCT", 81, 83], ["FN", "PROTEIN", 151, 153], ["true positive (TP)", "PROBLEM", 66, 84]]], ["The true negative (TN) and the false positive (FP) were defined as the numbers of correctly and incorrectly predicted negative samples, respectively.", [["samples", "ANATOMY", 127, 134], ["TN", "PROTEIN", 19, 21], ["negative", "OBSERVATION", 9, 17]]], ["So the overall accuracy Acc was defined as Acc = (TP + TN)/(TP + FN + TN + FP).", [["TP + FN", "GENE_OR_GENE_PRODUCT", 60, 67], ["TP", "PROTEIN", 50, 52], ["TN", "PROTEIN", 55, 57], ["TP", "PROTEIN", 60, 62], ["FN", "PROTEIN", 65, 67], ["TN", "PROTEIN", 70, 72], ["Acc", "TEST", 43, 46], ["TP", "TEST", 50, 52], ["TN", "TEST", 55, 57], ["TP", "TEST", 60, 62], ["FN", "TEST", 65, 67]]], ["The model\u2019s sensitivity (Sn) and specificity (Sp) were defined as Sn = TP/(TP + FN)andSp = TN/(TN + FP).", [["Sn", "CHEMICAL", 66, 68], ["Sn = TP", "GENE_OR_GENE_PRODUCT", 66, 73], ["TN + FP", "SIMPLE_CHEMICAL", 95, 102], ["Sn", "PROTEIN", 66, 68], ["TP", "PROTEIN", 75, 77], ["FN", "PROTEIN", 80, 82], ["TN", "PROTEIN", 91, 93], ["TN", "PROTEIN", 95, 97], ["specificity", "TEST", 33, 44], ["Sn", "TEST", 66, 68], ["TP", "TEST", 71, 73], ["TP", "TEST", 75, 77], ["andSp", "TEST", 83, 88], ["TN", "TEST", 91, 93]]], ["The three metrics Acc, Sn and Sp measured the percentages of correctly predicted all, positive and negative samples, respectively.", [["samples", "ANATOMY", 108, 115], ["Sn", "CHEMICAL", 23, 25], ["Acc", "GENE_OR_GENE_PRODUCT", 18, 21], ["Sn", "GENE_OR_GENE_PRODUCT", 23, 25], ["Sp", "GENE_OR_GENE_PRODUCT", 30, 32], ["Acc", "DNA", 18, 21], ["Sn", "PROTEIN", 23, 25], ["Sp", "PROTEIN", 30, 32]]], ["The Matthew\u2019s Correlation Coefficient (MCC) described the overall correlation of the predicted and the real class labels, and MCC was defined as MCC = (TP\u00d7TN\u2212TP\u00d7FN)/sqrt[(TP + FP)\u00d7(TP + FN)\u00d7(TN + FP)\u00d7(TN + FN)], where sqrt() was the square root function (Khurana et al., 2018; Cogan et al., 2019).Prediction Performance Evaluation Metrics ::: Materials and MethodsEach model was randomly trained for twenty runs with different random seeds and the metric averaged accuracy aAcc = [Acc(1) + Acc(2) + \u2026 + Acc(20)]/20, where Acc(i) was the accuracy of the ith model.", [["root", "ANATOMY", 240, 244], ["TP", "PROTEIN", 152, 154], ["TN", "PROTEIN", 155, 157], ["TP", "PROTEIN", 158, 160], ["FN", "PROTEIN", 161, 163], ["TP", "PROTEIN", 171, 173], ["TP", "PROTEIN", 181, 183], ["FN", "PROTEIN", 186, 188], ["TN", "PROTEIN", 191, 193], ["FP", "PROTEIN", 196, 198], ["TN", "PROTEIN", 201, 203], ["FN", "PROTEIN", 206, 208], ["MCC", "TEST", 126, 129], ["MCC", "TEST", 145, 148], ["TP", "TEST", 152, 154], ["TN", "TEST", 155, 157], ["TP", "TEST", 158, 160], ["FN", "TEST", 161, 163], ["sqrt", "TEST", 165, 169], ["TP", "TEST", 171, 173], ["FP", "TEST", 176, 178], ["\u00d7", "TEST", 179, 180], ["TP", "TEST", 181, 183], ["FN", "TEST", 186, 188], ["\u00d7", "TEST", 189, 190], ["TN", "TEST", 191, 193], ["FP", "TEST", 196, 198], ["\u00d7", "TEST", 199, 200], ["TN", "TEST", 201, 203], ["FN", "TEST", 206, 208], ["Prediction Performance Evaluation", "TEST", 297, 330], ["MethodsEach model", "TREATMENT", 357, 374], ["different random seeds", "TREATMENT", 417, 439], ["aAcc", "TEST", 473, 477], ["Acc", "TEST", 481, 484], ["Acc", "TEST", 490, 493], ["Acc", "TEST", 503, 506]]], ["The metrics aSn, aSp and aMCC were the averaged Sn, averaged Sp, and averaged MCC over the twenty random runs.Ethics Statement ::: Materials and MethodsThis study was approved by the Ethics Commission of the First Hospital of Jilin University (2020-236).", [["aSn", "DNA", 12, 15], ["aSp", "DNA", 17, 20], ["aMCC", "DNA", 25, 29], ["Sn", "PROTEIN", 48, 50], ["Sp", "PROTEIN", 61, 63], ["aSp", "TEST", 17, 20], ["This study", "TEST", 152, 162]]], ["With informed consent was waived for this emerging infectious disease.Baseline Characteristics of the 2019-nCoV Pneumonia Participants ::: ResultsThis study recruited 137 COVID-19 patients to build the detection model of severely ill (positive) samples against the patients with mild symptoms.", [["samples", "ANATOMY", 245, 252], ["infectious disease", "DISEASE", 51, 69], ["Pneumonia", "DISEASE", 112, 121], ["ill", "DISEASE", 230, 233], ["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 265, 273], ["Participants", "SPECIES", 122, 134], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 265, 273], ["This study", "TEST", 146, 156], ["COVID", "TEST", 171, 176], ["severely ill (positive) samples", "PROBLEM", 221, 252], ["mild symptoms", "PROBLEM", 279, 292], ["Pneumonia", "OBSERVATION", 112, 121], ["mild", "OBSERVATION_MODIFIER", 279, 283], ["symptoms", "OBSERVATION", 284, 292]]], ["All the 100 features were screened for their association with the class label, i.e., Positive or Negative.", [["Negative", "OBSERVATION", 97, 105]]], ["There were 8 clinical values, 76 blood test values and 16 urine test values, respectively.", [["blood", "ANATOMY", 33, 38], ["urine", "ANATOMY", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["urine", "ORGANISM_SUBSTANCE", 58, 63], ["blood test values", "TEST", 33, 50], ["urine test values", "TEST", 58, 75]]], ["Thirty-two features achieved the T-test P-value < 0.05, and were kept for further analysis in the following sections, as summarized in the Supplementary Table S1.Baseline Characteristics of the 2019-nCoV Pneumonia Participants ::: ResultsThe feature of the patient\u2019s age at diagnosis (Age) demonstrated a significant difference (P-value = 1.75e-6) between the two groups of samples, and the severely ill patients were on average 13.5695 years older than the patients with mild symptoms.", [["sections", "ANATOMY", 108, 116], ["samples", "ANATOMY", 374, 381], ["Pneumonia", "DISEASE", 204, 213], ["patient", "ORGANISM", 257, 264], ["patients", "ORGANISM", 404, 412], ["patients", "ORGANISM", 458, 466], ["Participants", "SPECIES", 214, 226], ["patient", "SPECIES", 257, 264], ["patients", "SPECIES", 404, 412], ["patients", "SPECIES", 458, 466], ["the T-test P", "TEST", 29, 41], ["further analysis", "TEST", 74, 90], ["a significant difference", "PROBLEM", 303, 327], ["P-value", "TEST", 329, 336], ["mild symptoms", "PROBLEM", 472, 485], ["Pneumonia", "OBSERVATION", 204, 213], ["significant", "OBSERVATION_MODIFIER", 305, 316], ["difference", "OBSERVATION_MODIFIER", 317, 327], ["severely", "OBSERVATION_MODIFIER", 391, 399], ["ill", "OBSERVATION_MODIFIER", 400, 403], ["mild", "OBSERVATION_MODIFIER", 472, 476], ["symptoms", "OBSERVATION", 477, 485]]], ["This supported the observation that patients aged around 65 years old tended to have more severe symptoms than those aged around 51 years old (Chen et al., 2020).", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["more severe symptoms", "PROBLEM", 85, 105]]], ["The sex also demonstrated severe-specific P-value = 7.71e-5, suggesting that male patients were at higher risks of developing severe symptoms (Huang et al., 2020), as shown in Figure 1A.Baseline Characteristics of the 2019-nCoV Pneumonia Participants ::: ResultsWe also summarized three blood test values and three urine test values with the most significant differences between the two groups of samples, as shown in Figure 1A.", [["blood", "ANATOMY", 287, 292], ["urine", "ANATOMY", 315, 320], ["samples", "ANATOMY", 397, 404], ["Pneumonia", "DISEASE", 228, 237], ["patients", "ORGANISM", 82, 90], ["blood", "ORGANISM_SUBSTANCE", 287, 292], ["urine", "ORGANISM_SUBSTANCE", 315, 320], ["patients", "SPECIES", 82, 90], ["Participants", "SPECIES", 238, 250], ["developing severe symptoms", "PROBLEM", 115, 141], ["blood test values", "TEST", 287, 304], ["three urine test values", "TEST", 309, 332], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["Pneumonia", "OBSERVATION", 228, 237]]], ["Overall, the blood test values demonstrated much more significant inter-group differences than the urine test values.", [["blood", "ANATOMY", 13, 18], ["urine", "ANATOMY", 99, 104], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["urine", "ORGANISM_SUBSTANCE", 99, 104], ["the blood test values", "TEST", 9, 30], ["the urine test values", "TEST", 95, 116], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["inter-group", "OBSERVATION", 66, 77]]], ["The summary data suggested that the percentage of neutrophil cells was significantly enriched in the blood of the severely ill patients, with P-values 4.14e-11.", [["neutrophil cells", "ANATOMY", 50, 66], ["blood", "ANATOMY", 101, 106], ["ill", "DISEASE", 123, 126], ["neutrophil cells", "CELL", 50, 66], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["patients", "ORGANISM", 127, 135], ["neutrophil cells", "CELL_TYPE", 50, 66], ["patients", "SPECIES", 127, 135], ["neutrophil cells", "PROBLEM", 50, 66], ["P-values", "TEST", 142, 150], ["neutrophil cells", "OBSERVATION", 50, 66]]], ["In addition, the serum calcium level and the monocyte percentage were also significantly lower in the severely ill patients than those mild ones.Baseline Characteristics of the 2019-nCoV Pneumonia Participants ::: ResultsThree urine test values demonstrated weak inter-group differential significances.", [["serum", "ANATOMY", 17, 22], ["monocyte", "ANATOMY", 45, 53], ["urine", "ANATOMY", 227, 232], ["calcium", "CHEMICAL", 23, 30], ["Pneumonia", "DISEASE", 187, 196], ["calcium", "CHEMICAL", 23, 30], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["calcium", "SIMPLE_CHEMICAL", 23, 30], ["monocyte", "CELL", 45, 53], ["patients", "ORGANISM", 115, 123], ["urine", "ORGANISM_SUBSTANCE", 227, 232], ["patients", "SPECIES", 115, 123], ["Participants", "SPECIES", 197, 209], ["the serum calcium level", "TEST", 13, 36], ["the monocyte percentage", "TEST", 41, 64], ["Three urine test values", "TEST", 221, 244], ["weak inter-group differential significances", "PROBLEM", 258, 301], ["significantly", "OBSERVATION_MODIFIER", 75, 88], ["lower", "OBSERVATION_MODIFIER", 89, 94], ["mild", "OBSERVATION_MODIFIER", 135, 139], ["Pneumonia", "OBSERVATION", 187, 196]]], ["The two values \u201cUrine | Urine protein\u201d and \u201cUrine | Red blood cell (occult)\u201d demonstrated the elevated levels in the severely ill patients with P-values 1.44e-2 and 2.83e-2, respectively.", [["Red blood cell", "ANATOMY", 52, 66], ["ill", "DISEASE", 126, 129], ["Urine", "ORGANISM_SUBSTANCE", 24, 29], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["The two values", "TEST", 0, 14], ["Urine", "TEST", 16, 21], ["Urine protein", "TEST", 24, 37], ["Urine", "TEST", 44, 49], ["Red blood cell", "TEST", 52, 66], ["the elevated levels", "PROBLEM", 90, 109], ["P", "TEST", 144, 145], ["values", "TEST", 146, 152], ["elevated", "OBSERVATION", 94, 102], ["severely", "OBSERVATION_MODIFIER", 117, 125], ["ill", "OBSERVATION_MODIFIER", 126, 129]]], ["But their variations were very larger, which rendered neither of them as good disease severeness biomarkers.", [["very", "OBSERVATION_MODIFIER", 26, 30], ["larger", "OBSERVATION_MODIFIER", 31, 37]]], ["A minor decrease (0.1028) in the urine pH value [feature \u201cUrine | PH(Urine)\u201d] in the severely ill patients achieved the inter-group differential significance P-value 4.25e-2.Baseline Characteristics of the 2019-nCoV Pneumonia Participants ::: ResultsIn the following sections.", [["urine", "ANATOMY", 33, 38], ["sections", "ANATOMY", 267, 275], ["Pneumonia", "DISEASE", 216, 225], ["urine", "ORGANISM_SUBSTANCE", 33, 38], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["Participants", "SPECIES", 226, 238], ["A minor decrease", "PROBLEM", 0, 16], ["the urine pH value", "TEST", 29, 47], ["Urine | PH", "TEST", 58, 68], ["Urine", "TEST", 69, 74], ["P", "TEST", 158, 159], ["value", "TEST", 160, 165], ["minor", "OBSERVATION_MODIFIER", 2, 7], ["decrease", "OBSERVATION_MODIFIER", 8, 16], ["Pneumonia", "OBSERVATION", 216, 225]]], ["The detailed summary may be found in the Supplementary Table S1.Evaluation of Feature Correlations With the Group Labels ::: ResultsWe firstly evaluated the correlation between the 32 features and the class label using Pearson Correlation Coefficient (PCC), as shown in Figure 1B.", [["Evaluation", "TEST", 64, 74]]], ["The PCC value ranges between \u22121 and 1.", [["The PCC value", "TEST", 0, 13]]], ["This study focused on the whether a feature was correlated with the class label.", [["This study", "TEST", 0, 10]]], ["So the absolute value of PCC was calculated in Figure 1B.Evaluation of Feature Correlations With the Group Labels ::: ResultsSome features showed strong correlations with the 2019-nCoV pneumonia severeness, which was the class label.", [["pneumonia", "DISEASE", 185, 194], ["PCC", "TEST", 25, 28], ["Evaluation", "TEST", 57, 67], ["nCoV pneumonia severeness", "PROBLEM", 180, 205], ["pneumonia", "OBSERVATION", 185, 194]]], ["The feature \u201cBlood | Neutrophil percentage\u201d demonstrated the largest PCC = 0.53 with the disease severeness (class label).", [["Blood", "ANATOMY", 13, 18], ["Neutrophil", "CELL", 21, 31], ["The feature", "TEST", 0, 11], ["Neutrophil percentage", "TEST", 21, 42], ["the largest PCC", "TEST", 57, 72], ["the disease severeness", "PROBLEM", 85, 107], ["largest", "OBSERVATION_MODIFIER", 61, 68]]], ["This provided another piece of evidence that the neutrophil cell percentage was positively correlated with the 2019-nCoV severeness.", [["neutrophil cell", "ANATOMY", 49, 64], ["neutrophil cell", "CELL", 49, 64], ["the neutrophil cell percentage", "TEST", 45, 75], ["neutrophil cell", "OBSERVATION", 49, 64]]], ["Another feature \u201cBlood | Calcium\u201d achieved the second-best PCC = 0.49.", [["Blood", "ANATOMY", 17, 22], ["Calcium", "CHEMICAL", 25, 32], ["Calcium", "CHEMICAL", 25, 32], ["Blood", "ORGANISM_SUBSTANCE", 17, 22], ["Blood", "TEST", 17, 22], ["Calcium", "TEST", 25, 32]]], ["The age at diagnosis (feature Age) achieved the third-best PCC = 0.40 with the class label, suggesting that the elder patients were under higher risks of developing severe symptoms.Evaluation of Feature Correlations With the Group Labels ::: ResultsFigure 1B suggested that some of the 32 features were highly correlated with the class label and they may facilitate the training of a reasonably-accurate detection model for the 2019-nCoV pneumonia severeness.", [["pneumonia", "DISEASE", 438, 447], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["developing severe symptoms", "PROBLEM", 154, 180], ["Evaluation", "TEST", 181, 191], ["nCoV pneumonia severeness", "PROBLEM", 433, 458], ["severe", "OBSERVATION_MODIFIER", 165, 171], ["symptoms", "OBSERVATION", 172, 180], ["pneumonia", "OBSERVATION", 438, 447]]], ["The existence of high inter-feature correlations suggested that some redundant features may need to be removed to further improve the detection model.Comparison of Different Prediction Algorithms ::: ResultsFive prediction algorithms were evaluated for their detection performances using their default parameters on all the 98 features of the 2019-nCoV pneumonia patients, as shown in Figure 2.", [["pneumonia", "DISEASE", 353, 362], ["patients", "ORGANISM", 363, 371], ["patients", "SPECIES", 363, 371], ["some redundant features", "PROBLEM", 64, 87], ["the detection model", "TEST", 130, 149], ["prediction algorithms", "TEST", 212, 233], ["their detection performances", "TEST", 253, 281], ["nCoV pneumonia", "PROBLEM", 348, 362], ["high inter-feature", "OBSERVATION_MODIFIER", 17, 35], ["pneumonia", "OBSERVATION", 353, 362]]], ["Firstly, all the five prediction algorithms achieved at least 0.7130 in Acc on all the 32 features, suggesting that the severely ill COVID-19 patients may have severeness-specific patterns.", [["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["the severely ill COVID", "PROBLEM", 116, 138]]], ["The prediction algorithm SVM achieved the best prediction accuracy Acc = 0.7926 and its standard deviation in Acc was only 0.0715.", [["The prediction algorithm SVM", "TEST", 0, 28], ["Acc", "TEST", 110, 113]]], ["SVM achieved the sensitivity Sn = 0.7666 much better than the specificity Sp = 0.6993.", [["SVM", "TEST", 0, 3], ["the sensitivity Sn", "TEST", 13, 31]]], ["The prediction sensitivity was the detection accuracy of the positive samples, i.e., the severely ill patients.", [["samples", "ANATOMY", 70, 77], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["The prediction sensitivity", "TEST", 0, 26]]], ["So the following sections used the prediction algorithm SVM as the default predictor and the prediction model was further refined by optimizing the SVM parameters and selecting the best features.Choosing the Best Threshold ::: ResultsA threshold may be tuned to find the balanced model performances for both positive and negative samples, as shown in Figure 3.", [["sections", "ANATOMY", 17, 25], ["the SVM parameters", "TEST", 144, 162], ["the balanced model performances", "TEST", 267, 298]]], ["Youden\u2019s (1950) index assigns equal weights for sensitivity and specificity and tries to maximize the index value J = (Sn + Sp\u22121).", [["Sn", "PROTEIN", 119, 121], ["sensitivity", "TEST", 48, 59], ["specificity", "TEST", 64, 75]]], ["Figure 3 illustrated the changing curves of Sn and Sp with different thresholds for the prediction scores of the samples.", [["samples", "ANATOMY", 113, 120], ["Sn", "CHEMICAL", 44, 46], ["Sn", "PROTEIN", 44, 46], ["Sp", "PROTEIN", 51, 53]]], ["The maximal value of J was achieved at the threshold 0.7318, and averaged accuracy of SVM was improved to 0.8148.Choosing the Best Threshold ::: ResultsThe Youden\u2019s index was used to find the best threshold of the SVM models with different parameters and features in the following sections.Tuning the Parameters of the SVM Model ::: ResultsThe grid search strategy was carried out to evaluate how different parameter values affected the disease severeness detection model, as shown in Figure 4.", [["sections", "ANATOMY", 281, 289], ["SVM", "TEST", 86, 89], ["The grid search strategy", "TEST", 340, 364], ["the disease severeness detection model", "PROBLEM", 433, 471]]], ["So this section randomly split the training dataset into 80% sub-training dataset and 20% validation dataset.", [["this section", "TREATMENT", 3, 15]]], ["Each model was trained using the sub-training dataset and the performance was calculated on the validation dataset.", [["the sub-training dataset", "TREATMENT", 29, 53]]], ["The model detection performance didn\u2019t change with the linear kernel and different choices of the parameter Gamma, as shown in Figure 4B.", [["The model detection performance", "TEST", 0, 31], ["the linear kernel", "TREATMENT", 51, 68]]], ["And the best accuracy = 0.8636 of the linear kernel SVM was achieved when C = 0.1 or 1.", [["the best accuracy", "TEST", 4, 21], ["the linear kernel SVM", "TEST", 34, 55], ["C", "TEST", 74, 75]]], ["The best model with the RBF kernel achieved Acc = 0.9091 for the validation dataset, where C = 100 and Gamma = 0.0010.", [["RBF kernel", "DNA", 24, 34], ["the RBF kernel", "TEST", 20, 34], ["Acc", "TEST", 44, 47], ["the validation dataset", "TEST", 61, 83], ["C", "TEST", 91, 92], ["Gamma", "TEST", 103, 108]]], ["The other three metrics Sp = 1.0000, Sn = 0.8333, and MCC = 0.8333 were also the best values in Figure 4.", [["Sn", "TEST", 37, 39], ["MCC", "TEST", 54, 57]]], ["The SVM model with the above-mentioned parameters achieved Acc = 0.8148 on the independent test dataset.", [["The SVM model", "TEST", 0, 13], ["Acc", "TEST", 59, 62]]], ["So the following sections used these two choices of the parameters C and Gamma.Remove Redundant Features to Improve the Model ::: ResultsThe existence of strong inter-feature correlations in Figure 1B suggested that some features may be removed to further improve the model.", [["sections", "ANATOMY", 17, 25], ["Gamma", "ANATOMY", 73, 78]]], ["This section carried out a conservative recursive feature elimination (cRFE) strategy to eliminate the redundant features while ensuring the model performance was not decreased.", [["This section", "TEST", 0, 12], ["the redundant features", "PROBLEM", 99, 121], ["the model performance", "TEST", 137, 158], ["decreased", "OBSERVATION_MODIFIER", 167, 176]]], ["Then, the detection model was evaluated by eliminating each feature.", [["the detection model", "TEST", 6, 25]]], ["A feature was eliminated if the model\u2019s AUC was improved with its removal.", [["the model\u2019s AUC", "TEST", 28, 43], ["its removal", "TREATMENT", 62, 73]]], ["The final feature set was returned after all the features were evaluated.Remove Redundant Features to Improve the Model ::: ResultsThe feature selection procedure should avoid using the test samples, so this section calculated the performance metrics on the validation dataset using the model trained over the sub-training dataset, as shown in Figure 5.", [["The feature selection procedure", "TREATMENT", 131, 162], ["the test samples", "TEST", 182, 198], ["this section", "TEST", 203, 215], ["the sub-training dataset", "TREATMENT", 306, 330]]], ["The heuristic cRFE strategy ensured by its nature that the model performance would not be decreased, and the rising line segment indicated the removal of the feature on the horizontal axis.", [["the rising line segment", "PROBLEM", 105, 128], ["the removal", "TREATMENT", 139, 150], ["decreased", "OBSERVATION_MODIFIER", 90, 99], ["removal", "OBSERVATION_MODIFIER", 143, 150], ["horizontal axis", "OBSERVATION_MODIFIER", 173, 188]]], ["Four features were removed, i.e., \u201cAge,\u201d \u201cBlood | Interleukin-10,\u201d \u201cBlood | Prothrombin time,\u201d and \u201cBlood | Oxygen partial pressure.\u201d", [["Blood", "ANATOMY", 68, 73], ["Blood", "ANATOMY", 100, 105], ["Oxygen", "CHEMICAL", 108, 114], ["Interleukin-10", "GENE_OR_GENE_PRODUCT", 50, 64], ["Blood", "ORGANISM_SUBSTANCE", 68, 73], ["Prothrombin", "GENE_OR_GENE_PRODUCT", 76, 87], ["Blood", "ORGANISM_SUBSTANCE", 100, 105], ["Blood", "TEST", 42, 47], ["Interleukin", "TEST", 50, 61], ["Blood", "TEST", 68, 73], ["Prothrombin time", "TEST", 76, 92], ["\u201d", "TEST", 93, 94], ["Blood", "TEST", 100, 105], ["Oxygen partial pressure", "TEST", 108, 131], ["pressure", "OBSERVATION_MODIFIER", 123, 131]]], ["Figure 1B illustrated that all these four features were strongly correlated with some other features, with the PCC values at least 0.51.Remove Redundant Features to Improve the Model ::: ResultsThe remaining 28 features achieved Acc = 0.9917 on the validation dataset, and Acc = 0.8148 on the independent test dataset.", [["the PCC values", "TEST", 107, 121], ["Acc", "TEST", 229, 232], ["the validation dataset", "TEST", 245, 267], ["Acc", "TEST", 273, 276], ["28 features", "OBSERVATION_MODIFIER", 208, 219]]], ["Although the COVID-19 severeness detection performance was not improved, the model complexity was reduced and the clinical screening cost was reduced with fewer features.Remove Redundant Features to Improve the Model ::: ResultsA web site was established to help the clinicians to try this COVID-19 infection severity estimation model, and the users may access: http://dVirusSeverity.HealthInformaticsLab.org/.DiscussionThe emergence of SARS-CoV-2 marked the third of highly pathogenic coronavirus in humans in the twenty-first century, after severe acute respiratory syndrome (SARS) in 2003, and Middle East respiratory syndrome (MERS) in 2012 (Drosten et al., 2003; Zaki et al., 2012).", [["infection", "DISEASE", 299, 308], ["SARS", "DISEASE", 437, 441], ["coronavirus", "DISEASE", 486, 497], ["acute respiratory syndrome", "DISEASE", 550, 576], ["SARS", "DISEASE", 578, 582], ["Middle East respiratory syndrome", "DISEASE", 597, 629], ["SARS-CoV-2", "ORGANISM", 437, 447], ["coronavirus", "ORGANISM", 486, 497], ["humans", "ORGANISM", 501, 507], ["COVID-19", "DNA", 13, 21], ["ResultsA web site", "DNA", 221, 238], ["coronavirus", "SPECIES", 486, 497], ["humans", "SPECIES", 501, 507], ["SARS-CoV", "SPECIES", 437, 445], ["humans", "SPECIES", 501, 507], ["the COVID", "TEST", 9, 18], ["the clinical screening cost", "TEST", 110, 137], ["this COVID", "TREATMENT", 285, 295], ["infection severity estimation model", "PROBLEM", 299, 334], ["SARS", "PROBLEM", 437, 441], ["CoV", "TEST", 442, 445], ["highly pathogenic coronavirus in humans", "PROBLEM", 468, 507], ["severe acute respiratory syndrome", "PROBLEM", 543, 576], ["SARS", "PROBLEM", 578, 582], ["Middle East respiratory syndrome", "PROBLEM", 597, 629], ["improved", "OBSERVATION_MODIFIER", 63, 71], ["complexity", "OBSERVATION_MODIFIER", 83, 93], ["reduced", "OBSERVATION_MODIFIER", 98, 105], ["pathogenic", "OBSERVATION_MODIFIER", 475, 485], ["coronavirus", "OBSERVATION", 486, 497], ["severe", "OBSERVATION_MODIFIER", 543, 549], ["acute", "OBSERVATION_MODIFIER", 550, 555], ["respiratory syndrome", "OBSERVATION", 556, 576], ["Middle", "ANATOMY_MODIFIER", 597, 603], ["respiratory syndrome", "OBSERVATION", 609, 629]]], ["SARS-CoV-2 belongs to the coronavirus family, \u03b2-coronavirus genera and belongs to the cluster of betacoronaviruses (Chen Y. et al., 2020).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["coronavirus", "ORGANISM", 26, 37], ["coronavirus", "SPECIES", 26, 37], ["SARS-CoV", "SPECIES", 0, 8]]], ["Based on Sequence analysis, the amino acid sequences of SARS-CoV-2 showed 94.4% identity with SARS-CoV (Zhou et al., 2020).", [["amino acid", "CHEMICAL", 32, 42], ["SARS", "DISEASE", 94, 98], ["amino acid", "CHEMICAL", 32, 42], ["amino acid", "AMINO_ACID", 32, 42], ["SARS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 94, 102], ["Sequence analysis", "TEST", 9, 26], ["the amino acid sequences", "TEST", 28, 52], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64], ["SARS", "TEST", 94, 98]]], ["It is suggested that SARS-CoV-2 was more closely related to SARS-like bat CoV.", [["SARS", "DISEASE", 21, 25], ["SARS", "DISEASE", 60, 64], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["SARS", "PROBLEM", 21, 25], ["CoV", "TEST", 26, 29], ["SARS", "PROBLEM", 60, 64]]], ["In comparison, SARS-CoV-2 was more distant from the MERS-CoV (Lu et al., 2020; Wu et al., 2020).", [["SARS", "DISEASE", 15, 19], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["SARS-CoV", "SPECIES", 15, 23], ["MERS-CoV", "SPECIES", 52, 60], ["SARS-CoV", "TEST", 15, 23]]], ["The mortality of critically ill patients with COVID-19 is considerable.", [["critically ill", "DISEASE", 17, 31], ["COVID-19", "CHEMICAL", 46, 54], ["COVID-19", "CHEMICAL", 46, 54], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 46, 51]]], ["The survival time of the dead patients may be within 1\u20132 weeks after ICU admission (Yang X. et al., 2020).DiscussionThe present diagnosis of COVID-19 didn\u2019t achieve a satisfying accuracy.", [["COVID-19", "CHEMICAL", 141, 149], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["COVID", "TEST", 141, 146]]], ["Both false positives and false negatives need to be decreased (Li D. et al., 2020; Li Z. et al., 2020; Yan et al., 2020).", [["false negatives", "TEST", 25, 40], ["false positives", "OBSERVATION", 5, 20], ["false negatives", "OBSERVATION", 25, 40]]], ["The clinical decisions of COVID-19 infections are usually confirmed by epidemiological features, clinical manifestations, imaging factors, and nucleic acid screenings, etc. Some of the COVID-19 patients may develop severe symptoms and these patients are at a much higher mortality rate than the other patients.", [["infections", "DISEASE", 35, 45], ["nucleic acid", "CHEMICAL", 143, 155], ["COVID-19", "ORGANISM", 26, 34], ["nucleic acid", "SIMPLE_CHEMICAL", 143, 155], ["patients", "ORGANISM", 194, 202], ["patients", "ORGANISM", 241, 249], ["patients", "ORGANISM", 301, 309], ["patients", "SPECIES", 194, 202], ["patients", "SPECIES", 241, 249], ["patients", "SPECIES", 301, 309], ["COVID-19", "SPECIES", 26, 34], ["COVID-19 infections", "PROBLEM", 26, 45], ["clinical manifestations", "PROBLEM", 97, 120], ["imaging factors", "TEST", 122, 137], ["nucleic acid screenings", "TEST", 143, 166], ["the COVID", "TEST", 181, 190], ["severe symptoms", "PROBLEM", 215, 230], ["severe", "OBSERVATION_MODIFIER", 215, 221]]], ["This challenge raised the scientific question of finding the COVID-19 severeness specific biomarkers, which may help reduce the overall mortality.DiscussionThis study investigated the binary classification problem between 75 severely illed COVID-19 infected patients and the other 62 patients with mild symptoms.", [["COVID-19 infected", "DISEASE", 240, 257], ["patients", "ORGANISM", 258, 266], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 258, 266], ["patients", "SPECIES", 284, 292], ["the COVID", "TEST", 57, 66], ["This study", "TEST", 156, 166], ["mild symptoms", "PROBLEM", 298, 311], ["mild", "OBSERVATION_MODIFIER", 298, 302], ["symptoms", "OBSERVATION", 303, 311]]], ["A comprehensive optimization procedure led to the best SVM-based COVID-19 severeness detection model using only 28 features.", [["A comprehensive optimization procedure", "TREATMENT", 0, 38], ["SVM", "TEST", 55, 58], ["COVID", "TEST", 65, 70]]], ["The experimental data suggested that the severely illed patients had a higher serum level of neutrophil percentage and lower serum levels of monocyte percentage and calcium compared with those mild ones.", [["serum", "ANATOMY", 78, 83], ["neutrophil", "ANATOMY", 93, 103], ["serum", "ANATOMY", 125, 130], ["monocyte", "ANATOMY", 141, 149], ["calcium", "CHEMICAL", 165, 172], ["calcium", "CHEMICAL", 165, 172], ["patients", "ORGANISM", 56, 64], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["neutrophil", "CELL", 93, 103], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["monocyte", "CELL", 141, 149], ["calcium", "SIMPLE_CHEMICAL", 165, 172], ["patients", "SPECIES", 56, 64], ["The experimental data", "TEST", 0, 21], ["neutrophil percentage", "TEST", 93, 114], ["lower serum levels", "TEST", 119, 137], ["monocyte percentage", "TEST", 141, 160], ["calcium", "TEST", 165, 172], ["those mild ones", "PROBLEM", 187, 202]]], ["Urine test contributed three weak group-specific biomarkers, i.e., urine pH value, urine protein and urine red blood cell.", [["Urine", "ANATOMY", 0, 5], ["urine", "ANATOMY", 67, 72], ["urine", "ANATOMY", 83, 88], ["urine red blood cell", "ANATOMY", 101, 121], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["urine", "ORGANISM_SUBSTANCE", 67, 72], ["urine", "ORGANISM_SUBSTANCE", 83, 88], ["urine", "ORGANISM_SUBSTANCE", 101, 106], ["red blood cell", "CELL", 107, 121], ["urine protein", "PROTEIN", 83, 96], ["urine red blood cell", "CELL_TYPE", 101, 121], ["Urine test", "TEST", 0, 10], ["urine pH value", "TEST", 67, 81], ["urine protein", "TEST", 83, 96], ["urine red blood cell", "TEST", 101, 121]]], ["Compared with the urine pH value, the variations of urine protein and urine red blood cell were very large and these two urine features may not serve well as COVID-19 infection severeness biomarkers.", [["urine", "ANATOMY", 18, 23], ["urine", "ANATOMY", 52, 57], ["urine red blood cell", "ANATOMY", 70, 90], ["urine", "ANATOMY", 121, 126], ["infection", "DISEASE", 167, 176], ["urine", "ORGANISM_SUBSTANCE", 18, 23], ["urine", "ORGANISM_SUBSTANCE", 52, 57], ["urine", "ORGANISM_SUBSTANCE", 70, 75], ["red blood cell", "CELL", 76, 90], ["urine", "ORGANISM_SUBSTANCE", 121, 126], ["urine protein", "PROTEIN", 52, 65], ["urine red blood cell", "CELL_TYPE", 70, 90], ["the urine pH value", "TEST", 14, 32], ["urine protein", "TEST", 52, 65], ["urine red blood cell", "TEST", 70, 90], ["these two urine features", "TEST", 111, 135], ["COVID", "TEST", 158, 163], ["infection severeness biomarkers", "PROBLEM", 167, 198], ["large", "OBSERVATION_MODIFIER", 101, 106]]], ["The blood test features demonstrated much more significant inter-group differences than the urine test features.", [["blood", "ANATOMY", 4, 9], ["urine", "ANATOMY", 92, 97], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["urine", "ORGANISM_SUBSTANCE", 92, 97], ["The blood test features", "TEST", 0, 23], ["the urine test features", "TEST", 88, 111], ["much more", "OBSERVATION_MODIFIER", 37, 46], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["inter-group", "OBSERVATION", 59, 70]]], ["The summary data suggested these three blood test features as candidate severeness biomarkers, i.e., serum ferritin, hs-CRP, interleukin-2R, and tumor necrosis factor-\u03b1.DiscussionCOVID-19 severeness detection model achieved the overall accuracy 0.8148 on the independent test dataset with only 28 clinical biomarkers.", [["blood", "ANATOMY", 39, 44], ["serum", "ANATOMY", 101, 106], ["tumor necrosis", "DISEASE", 145, 159], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["ferritin", "GENE_OR_GENE_PRODUCT", 107, 115], ["hs-CRP", "GENE_OR_GENE_PRODUCT", 117, 123], ["interleukin-2R", "GENE_OR_GENE_PRODUCT", 125, 139], ["tumor necrosis factor-\u03b1.", "GENE_OR_GENE_PRODUCT", 145, 169], ["serum ferritin", "PROTEIN", 101, 115], ["CRP", "PROTEIN", 120, 123], ["interleukin-2R", "PROTEIN", 125, 139], ["tumor necrosis factor", "PROTEIN", 145, 166], ["blood test features", "TEST", 39, 58], ["severeness biomarkers", "TEST", 72, 93], ["serum ferritin", "TEST", 101, 115], ["hs", "TEST", 117, 119], ["CRP", "TEST", 120, 123], ["interleukin", "TEST", 125, 136], ["tumor necrosis factor", "PROBLEM", 145, 166], ["DiscussionCOVID", "TEST", 169, 184], ["the independent test dataset", "TEST", 255, 283], ["clinical biomarkers", "TEST", 297, 316], ["tumor necrosis", "OBSERVATION", 145, 159]]], ["Twenty-one out of these 28 biomarkers were investigated in the coronavirus.", [["coronavirus", "DISEASE", 63, 74], ["coronavirus", "ORGANISM", 63, 74], ["these 28 biomarkers", "TEST", 18, 37], ["the coronavirus", "PROBLEM", 59, 74]]], ["Two serum values \u201cBlood | Tumor necrosis factor-\u03b1\u201d (56 papers) and \u201cBlood | Sodium\u201d (57 papers) were known to be associated with the coronavirus infections.", [["serum", "ANATOMY", 4, 9], ["Blood", "ANATOMY", 68, 73], ["necrosis", "DISEASE", 32, 40], ["Sodium", "CHEMICAL", 76, 82], ["coronavirus infections", "DISEASE", 133, 155], ["Sodium", "CHEMICAL", 76, 82], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["Tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 26, 49], ["coronavirus", "ORGANISM", 133, 144], ["Two serum values", "TEST", 0, 16], ["Blood", "TEST", 18, 23], ["Tumor necrosis factor", "TEST", 26, 47], ["Blood", "TEST", 68, 73], ["Sodium", "TEST", 76, 82], ["the coronavirus infections", "PROBLEM", 129, 155], ["necrosis", "OBSERVATION", 32, 40], ["coronavirus infections", "OBSERVATION", 133, 155]]], ["The tumor necrosis factor-alpha (TNF-alpha) was observed to have elevated expression levels in the serum of the coronavirus-infected mice (Zalinger et al., 2015).", [["serum", "ANATOMY", 99, 104], ["tumor", "DISEASE", 4, 9], ["necrosis", "DISEASE", 10, 18], ["coronavirus-infected", "DISEASE", 112, 132], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 4, 31], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 33, 42], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["coronavirus", "ORGANISM", 112, 123], ["mice", "ORGANISM", 133, 137], ["tumor necrosis factor-alpha", "PROTEIN", 4, 31], ["TNF-alpha", "PROTEIN", 33, 42], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 133, 137], ["The tumor necrosis factor", "PROBLEM", 0, 25], ["alpha (TNF-alpha)", "TEST", 26, 43], ["elevated expression levels", "PROBLEM", 65, 91], ["the serum", "TEST", 95, 104], ["the coronavirus", "PROBLEM", 108, 123], ["tumor", "OBSERVATION_MODIFIER", 4, 9], ["necrosis", "OBSERVATION", 10, 18], ["alpha", "OBSERVATION_MODIFIER", 26, 31], ["elevated", "OBSERVATION", 65, 73], ["coronavirus", "ANATOMY", 112, 123]]], ["The serum sodium level was slightly increased by 2.01% in the severely ill patients in the cohort used in this study.", [["serum", "ANATOMY", 4, 9], ["sodium", "CHEMICAL", 10, 16], ["sodium", "CHEMICAL", 10, 16], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["sodium", "SIMPLE_CHEMICAL", 10, 16], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["The serum sodium level", "TEST", 0, 22], ["slightly increased", "PROBLEM", 27, 45], ["this study", "TEST", 106, 116], ["slightly", "OBSERVATION_MODIFIER", 27, 35], ["increased", "OBSERVATION_MODIFIER", 36, 45]]], ["Hoffman et al. (2018) proposed that the pulmonary complication were more frequently observed in the hypernatremia patients.", [["pulmonary", "ANATOMY", 40, 49], ["pulmonary complication", "DISEASE", 40, 62], ["hypernatremia", "DISEASE", 100, 113], ["pulmonary", "ORGAN", 40, 49], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["the pulmonary complication", "PROBLEM", 36, 62], ["the hypernatremia", "PROBLEM", 96, 113], ["pulmonary", "ANATOMY", 40, 49], ["complication", "OBSERVATION", 50, 62], ["hypernatremia", "OBSERVATION", 100, 113]]], ["So it would be interesting to investigate the underlining mechanism of how the serum sodium may induce the COVID-19 severeness.", [["serum", "ANATOMY", 79, 84], ["sodium", "CHEMICAL", 85, 91], ["sodium", "CHEMICAL", 85, 91], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["sodium", "SIMPLE_CHEMICAL", 85, 91], ["the serum sodium", "TEST", 75, 91], ["the COVID", "TEST", 103, 112]]], ["The feature \u201cUrine | PH(Urine)\u201d is the pH level in the urine, and quite a few investigations observed the aberrant pH levels in the body fluid or fecal matter of the coronavirus-infected animals (Raabis et al., 2018; Yuan et al., 2018).", [["urine", "ANATOMY", 55, 60], ["body fluid", "ANATOMY", 132, 142], ["fecal matter", "ANATOMY", 146, 158], ["Urine", "ORGANISM_SUBSTANCE", 13, 18], ["Urine", "ORGANISM_SUBSTANCE", 24, 29], ["urine", "ORGANISM_SUBSTANCE", 55, 60], ["body fluid", "ORGANISM_SUBSTANCE", 132, 142], ["fecal", "ORGANISM_SUBDIVISION", 146, 151], ["coronavirus", "ORGANISM", 166, 177], ["Urine | PH", "TEST", 13, 23], ["Urine", "TEST", 24, 29], ["the pH level", "TEST", 35, 47], ["the urine", "TEST", 51, 60], ["a few investigations", "TEST", 72, 92], ["the aberrant pH levels", "PROBLEM", 102, 124], ["the body fluid", "TEST", 128, 142], ["fecal matter", "PROBLEM", 146, 158], ["the coronavirus", "PROBLEM", 162, 177], ["aberrant", "OBSERVATION_MODIFIER", 106, 114], ["pH levels", "OBSERVATION", 115, 124], ["body", "ANATOMY", 132, 136], ["fluid", "OBSERVATION", 137, 142], ["fecal matter", "ANATOMY", 146, 158], ["coronavirus", "ANATOMY", 166, 177], ["infected", "OBSERVATION_MODIFIER", 178, 186]]], ["Although the urine pH level was not investigated in the coronavirus-infected animals, this may be worth of an investigation.", [["urine", "ANATOMY", 13, 18], ["coronavirus-infected", "DISEASE", 56, 76], ["urine", "ORGANISM_SUBSTANCE", 13, 18], ["coronavirus", "ORGANISM", 56, 67], ["the urine pH level", "TEST", 9, 27], ["the coronavirus", "PROBLEM", 52, 67], ["an investigation", "TEST", 107, 123], ["infected", "OBSERVATION", 68, 76]]], ["The sex bias was also observed that coronavirus tended to infect males (Habib et al., 2019; Petrarca et al., 2019).", [["coronavirus", "ORGANISM", 36, 47], ["coronavirus", "PROBLEM", 36, 47]]], ["Our data suggested that males were at a higher risk to be infected by COVID-19 and to develop more severe symptoms.DiscussionAn accurate severeness detection model of the patients with COVID-19 based on those features may improve the prognosis of this disease in large scale clinical practices, and reduce the incidence of COVID-19 severeness and mortality.", [["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["Our data", "TEST", 0, 8], ["COVID", "TEST", 70, 75], ["more severe symptoms", "PROBLEM", 94, 114], ["COVID", "TEST", 185, 190], ["this disease", "PROBLEM", 247, 259], ["COVID", "TEST", 323, 328], ["infected", "OBSERVATION", 58, 66], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["symptoms", "OBSERVATION", 106, 114]]], ["The biomarkers used for an accurate diagnosis model of patients with COVID-19 may serve as the drug targets for this global infectious disease.DiscussionThere are some limitations that should be noted.", [["COVID-19", "CHEMICAL", 69, 77], ["infectious disease", "DISEASE", 124, 142], ["COVID-19", "CHEMICAL", 69, 77], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["The biomarkers", "TEST", 0, 14], ["COVID", "TEST", 69, 74], ["this global infectious disease", "PROBLEM", 112, 142], ["infectious", "OBSERVATION", 124, 134]]], ["First, the number of patients with COVID-19 is relatively small, which may limit the accuracy of severeness detection model.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["COVID", "TEST", 35, 40], ["relatively", "OBSERVATION_MODIFIER", 47, 57], ["small", "OBSERVATION_MODIFIER", 58, 63]]], ["Second, since all subjects in our study were Chinese patients with COVID-19, the results may not be applied to other ethnicities.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["our study", "TEST", 30, 39], ["COVID", "TEST", 67, 72]]], ["Third, the data of this study is only the preliminary establishment of COVID-19 severeness detection model.", [["this study", "TEST", 19, 29], ["COVID", "TEST", 71, 76]]], ["Further studies are still needed.DiscussionThis study utilized the machine learning algorithms to detect the COVID-19 severely ill patients from those with only mild symptoms.", [["severely ill", "DISEASE", 118, 130], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["Further studies", "TEST", 0, 15], ["This study", "TEST", 43, 53], ["the COVID", "TEST", 105, 114], ["mild symptoms", "PROBLEM", 161, 174], ["mild", "OBSERVATION_MODIFIER", 161, 165], ["symptoms", "OBSERVATION", 166, 174]]], ["Our experimental data demonstrated strong correlations with the COVID-19 severeness.", [["Our experimental data", "TEST", 0, 21], ["the COVID", "TEST", 60, 69]]], ["And the final COVID-19 severeness detection model achieved the accuracy 0.8148 on the independent test dataset using only 28 clinical biomarkers.", [["the final COVID", "TEST", 4, 19], ["the accuracy", "TEST", 59, 71], ["the independent test dataset", "TEST", 82, 110], ["clinical biomarkers", "TEST", 125, 144]]], ["The detection model itself is in urgent need for the current epidemic situation that the severely ill patients are at a very high mortality rate.", [["ill", "DISEASE", 98, 101], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["severely", "OBSERVATION_MODIFIER", 89, 97], ["ill", "OBSERVATION_MODIFIER", 98, 101]]], ["The 28 biomarkers may also be investigated for their underlining mechanisms of their roles in the COVID-19 severely ill patients.Data Availability StatementAll datasets presented in this study are included in the article/Supplementary Material.Ethics StatementThe studies involving human participants were reviewed and approved by Ethics Commission of the First Hospital of Jilin University.", [["severely ill", "DISEASE", 107, 119], ["patients", "ORGANISM", 120, 128], ["human", "ORGANISM", 282, 287], ["patients", "SPECIES", 120, 128], ["human", "SPECIES", 282, 287], ["participants", "SPECIES", 288, 300], ["human", "SPECIES", 282, 287], ["this study", "TEST", 182, 192], ["The studies", "TEST", 260, 271]]], ["Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.Author ContributionsNZ collected the data.", [["this study", "TEST", 64, 74]]], ["MD, TX, JP, EP, JH, YZ, and XX did literature search.", [["JP", "ANATOMY", 8, 10]]], ["HX, FZ, and GW conceived and designed this study.", [["HX", "CHEMICAL", 0, 2], ["FZ", "CHEMICAL", 4, 6], ["HX", "SIMPLE_CHEMICAL", 0, 2], ["this study", "TEST", 38, 48]]], ["The corresponding author had full access to all the study data and had final responsibility for the decision to submit for publication.", [["all the study data", "TEST", 44, 62]]]], "PMC6134756": [["IntroductionAfrican swine fever virus (ASFV) is the causal agent of a haemorrhagic and often-lethal porcine disease, African swine fever (ASF), which causes affected countries important economic losses.", [["IntroductionAfrican swine fever", "DISEASE", 0, 31], ["haemorrhagic", "DISEASE", 70, 82], ["porcine disease", "DISEASE", 100, 115], ["African swine fever", "DISEASE", 117, 136], ["ASF", "DISEASE", 138, 141], ["IntroductionAfrican swine fever virus", "ORGANISM", 0, 37], ["ASFV", "ORGANISM", 39, 43], ["porcine", "ORGANISM", 100, 107], ["African swine fever", "ORGANISM", 117, 136], ["swine fever virus", "SPECIES", 20, 37], ["porcine", "SPECIES", 100, 107], ["African swine fever", "SPECIES", 117, 136], ["IntroductionAfrican swine fever virus", "SPECIES", 0, 37], ["ASFV", "SPECIES", 39, 43], ["African swine fever (ASF)", "SPECIES", 117, 142], ["IntroductionAfrican swine fever virus (ASFV", "PROBLEM", 0, 43], ["a haemorrhagic", "PROBLEM", 68, 82], ["lethal porcine disease", "PROBLEM", 93, 115], ["African swine fever (ASF)", "PROBLEM", 117, 142], ["haemorrhagic", "OBSERVATION_MODIFIER", 70, 82], ["lethal porcine disease", "OBSERVATION", 93, 115], ["economic losses", "OBSERVATION", 186, 201]]], ["There is no vaccine available against the disease, albeit promising developments for future implementation are being currently developed [1].", [["vaccine", "TREATMENT", 12, 19], ["the disease", "PROBLEM", 38, 49], ["no", "UNCERTAINTY", 9, 11]]], ["ASF may range from an acute, highly lethal infection to subclinical chronic forms, depending on a complex contribution of viral and host factors [2].", [["infection", "DISEASE", 43, 52], ["ASF", "PROBLEM", 0, 3], ["an acute, highly lethal infection", "PROBLEM", 19, 52], ["subclinical chronic forms", "PROBLEM", 56, 81], ["viral and host factors", "PROBLEM", 122, 144], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["highly", "OBSERVATION_MODIFIER", 29, 35], ["lethal", "OBSERVATION_MODIFIER", 36, 42], ["infection", "OBSERVATION", 43, 52], ["subclinical chronic", "OBSERVATION_MODIFIER", 56, 75], ["viral", "OBSERVATION", 122, 127]]], ["The pig immune response to ASFV has been widely studied [3, 4], showing that the virus has effective mechanisms of evading pig defensive systems, thus contributing to the immune pathology observed during acute ASF, and to virus persistence in its hosts [5].", [["pig", "ORGANISM", 4, 7], ["ASFV", "ORGANISM", 27, 31], ["pig", "ORGANISM", 123, 126], ["pig", "SPECIES", 4, 7], ["pig", "SPECIES", 4, 7], ["ASFV", "SPECIES", 27, 31], ["pig", "SPECIES", 123, 126], ["ASFV", "PROBLEM", 27, 31], ["the virus", "PROBLEM", 77, 86], ["evading pig defensive systems", "PROBLEM", 115, 144], ["the immune pathology", "PROBLEM", 167, 187], ["acute ASF", "PROBLEM", 204, 213], ["virus", "OBSERVATION", 81, 86]]], ["Studies about virus-cells interaction have contributed significantly to unravel the mechanisms involved in pig response [3, 6\u201310].", [["cells", "ANATOMY", 20, 25], ["cells", "CELL", 20, 25], ["pig", "ORGANISM", 107, 110], ["pig", "SPECIES", 107, 110]]], ["In this regard, it has been shown that the ASFV genome encodes a large number of genes that have been identified as playing a role in host immune evasion including: interferon (IFN) inhibition by several multigene family members [11], the NF-\u03baB and NFAT inhibitor A238L or the apoptosis inhibitor A179L, among others.", [["interferon", "GENE_OR_GENE_PRODUCT", 165, 175], ["IFN", "GENE_OR_GENE_PRODUCT", 177, 180], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 239, 244], ["NFAT", "GENE_OR_GENE_PRODUCT", 249, 253], ["A238L", "GENE_OR_GENE_PRODUCT", 264, 269], ["ASFV genome", "DNA", 43, 54], ["interferon", "PROTEIN", 165, 175], ["IFN", "PROTEIN", 177, 180], ["NF-\u03baB", "PROTEIN", 239, 244], ["NFAT", "PROTEIN", 249, 253], ["ASFV", "SPECIES", 43, 47], ["the ASFV genome", "PROBLEM", 39, 54], ["interferon (IFN) inhibition", "TREATMENT", 165, 192], ["the NF", "TEST", 235, 241], ["NFAT inhibitor", "TREATMENT", 249, 263], ["the apoptosis inhibitor", "TREATMENT", 273, 296], ["ASFV genome", "OBSERVATION", 43, 54], ["large", "OBSERVATION_MODIFIER", 65, 70]]], ["In addition, it is known that ASFV controls host transcription and cellular machinery of protein synthesis [13] thus contributing to pathology.", [["cellular", "ANATOMY", 67, 75], ["ASFV", "ORGANISM", 30, 34], ["cellular", "CELL", 67, 75], ["ASFV", "SPECIES", 30, 34], ["ASFV controls host transcription", "TREATMENT", 30, 62], ["protein synthesis", "TEST", 89, 106], ["pathology", "TEST", 133, 142]]], ["The high complexity of ASFV, together with its tropism for the immune system of the host, complicates the understanding of ASF pathogenesis.", [["immune system", "ANATOMY", 63, 76], ["ASFV", "ORGANISM", 23, 27], ["ASF", "CANCER", 123, 126], ["ASFV", "SPECIES", 23, 27], ["ASF pathogenesis", "PROBLEM", 123, 139], ["high complexity", "OBSERVATION_MODIFIER", 4, 19], ["ASFV", "OBSERVATION", 23, 27]]], ["Both ASFV-specific antibodies [4] and CD8+ T-cells [3, 14], have been postulated as key players in the protection against ASFV.", [["CD8+ T-cells", "ANATOMY", 38, 50], ["ASFV", "ORGANISM", 5, 9], ["CD8", "GENE_OR_GENE_PRODUCT", 38, 41], ["ASFV", "ORGANISM", 122, 126], ["ASFV-specific antibodies", "PROTEIN", 5, 29], ["CD8", "PROTEIN", 38, 41], ["T-cells", "CELL_TYPE", 43, 50], ["ASFV", "SPECIES", 5, 9], ["ASFV", "SPECIES", 122, 126], ["Both ASFV", "TEST", 0, 9], ["specific antibodies", "TEST", 10, 29], ["CD8", "TEST", 38, 41]]], ["The dual role of the immune system during ASFV infection becomes evident again during chronic ASF-infections, characterized by mild clinical signs associated, on occasions, with immunopathological processes, such as immune complexes and swine IgM, IgG and C1q depositions [15].", [["immune system", "ANATOMY", 21, 34], ["infection", "DISEASE", 47, 56], ["ASF-infections", "DISEASE", 94, 108], ["ASFV", "ORGANISM", 42, 46], ["swine", "ORGANISM", 237, 242], ["IgM", "GENE_OR_GENE_PRODUCT", 243, 246], ["IgG", "GENE_OR_GENE_PRODUCT", 248, 251], ["C1q", "GENE_OR_GENE_PRODUCT", 256, 259], ["immune complexes", "PROTEIN", 216, 232], ["swine IgM", "PROTEIN", 237, 246], ["IgG", "PROTEIN", 248, 251], ["C1q", "PROTEIN", 256, 259], ["swine", "SPECIES", 237, 242], ["ASFV", "SPECIES", 42, 46], ["swine", "SPECIES", 237, 242], ["ASFV infection", "PROBLEM", 42, 56], ["chronic ASF-infections", "PROBLEM", 86, 108], ["mild clinical signs", "PROBLEM", 127, 146], ["immunopathological processes", "PROBLEM", 178, 206], ["immune complexes", "PROBLEM", 216, 232], ["swine IgM", "TEST", 237, 246], ["ASFV", "OBSERVATION_MODIFIER", 42, 46], ["infection", "OBSERVATION", 47, 56], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["infections", "OBSERVATION", 98, 108], ["mild", "OBSERVATION_MODIFIER", 127, 131]]], ["Swine macrophages are the main target for ASFV, and depending on multiple factors, including the virulence of the ASFV strain, the immune system can play a dual role during both, ASFV-protection but also contributing to the virus pathogenesis.", [["macrophages", "ANATOMY", 6, 17], ["immune system", "ANATOMY", 131, 144], ["Swine macrophages", "CELL", 0, 17], ["ASFV", "ORGANISM", 42, 46], ["ASFV strain", "ORGANISM", 114, 125], ["Swine macrophages", "CELL_TYPE", 0, 17], ["Swine", "SPECIES", 0, 5], ["ASFV", "SPECIES", 42, 46], ["ASFV", "SPECIES", 114, 118], ["ASFV", "SPECIES", 179, 183], ["ASFV", "PROBLEM", 42, 46], ["the ASFV strain", "PROBLEM", 110, 125], ["ASFV-protection", "TREATMENT", 179, 194], ["the virus pathogenesis", "PROBLEM", 220, 242], ["macrophages", "OBSERVATION", 6, 17], ["ASFV", "OBSERVATION", 42, 46], ["ASFV", "OBSERVATION", 114, 118], ["virus", "OBSERVATION", 224, 229]]], ["As mentioned above, virulent ASFV strains can evade the early recognition of the immune system, strategies that facilitate their replication and in vivo dissemination that, in the last stages of acute infection, provoke tissue destruction, leukopenia and total dysregulation of the immune system, reflected with the typical storm of cytokines thus contributing to ASF acute pathogenesis [16].", [["immune system", "ANATOMY", 81, 94], ["tissue", "ANATOMY", 220, 226], ["immune system", "ANATOMY", 282, 295], ["infection", "DISEASE", 201, 210], ["tissue destruction", "DISEASE", 220, 238], ["leukopenia", "DISEASE", 240, 250], ["ASFV strains", "ORGANISM", 29, 41], ["immune system", "ANATOMICAL_SYSTEM", 81, 94], ["tissue", "TISSUE", 220, 226], ["cytokines", "PROTEIN", 333, 342], ["ASFV", "SPECIES", 29, 33], ["virulent ASFV strains", "PROBLEM", 20, 41], ["acute infection", "PROBLEM", 195, 210], ["tissue destruction", "PROBLEM", 220, 238], ["leukopenia", "PROBLEM", 240, 250], ["total dysregulation of the immune system", "PROBLEM", 255, 295], ["cytokines", "PROBLEM", 333, 342], ["ASF acute pathogenesis", "PROBLEM", 364, 386], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["infection", "OBSERVATION", 201, 210], ["tissue", "ANATOMY", 220, 226], ["destruction", "OBSERVATION", 227, 238], ["leukopenia", "OBSERVATION", 240, 250]]], ["Conversely, infections with attenuated ASFV strains normally render subclinical infections that are rapidly recognized by the innate immune system and cleared from the body, yielding pigs capable of resisting homologous lethal challenge [16].IntroductionHere we extend these studies by presenting a comparative proteomic analysis using gastrohepatic lymph nodes (GLN) from pigs infected in vivo with either the attenuated E75CV1 strain or with E75, its parental virulent ASFV strain, at different days post-infection (dpi); a model system previously used to unmask some of the mechanisms involved in homologous protection against ASFV [16].", [["body", "ANATOMY", 168, 172], ["gastrohepatic lymph nodes", "ANATOMY", 336, 361], ["GLN", "ANATOMY", 363, 366], ["strain", "ANATOMY", 476, 482], ["infections", "DISEASE", 12, 22], ["infections", "DISEASE", 80, 90], ["E75", "CHEMICAL", 444, 447], ["ASFV strains", "ORGANISM", 39, 51], ["immune system", "ANATOMICAL_SYSTEM", 133, 146], ["body", "ORGANISM_SUBDIVISION", 168, 172], ["pigs", "ORGANISM", 183, 187], ["gastrohepatic lymph nodes", "MULTI-TISSUE_STRUCTURE", 336, 361], ["GLN", "MULTI-TISSUE_STRUCTURE", 363, 366], ["pigs", "ORGANISM", 373, 377], ["E75", "GENE_OR_GENE_PRODUCT", 444, 447], ["ASFV", "ORGANISM", 471, 475], ["ASFV", "ORGANISM", 630, 634], ["pigs", "SPECIES", 183, 187], ["pigs", "SPECIES", 373, 377], ["ASFV", "SPECIES", 39, 43], ["pigs", "SPECIES", 183, 187], ["pigs", "SPECIES", 373, 377], ["ASFV", "SPECIES", 471, 475], ["ASFV", "SPECIES", 630, 634], ["infections", "PROBLEM", 12, 22], ["attenuated ASFV strains", "PROBLEM", 28, 51], ["subclinical infections", "PROBLEM", 68, 90], ["resisting homologous lethal challenge", "TREATMENT", 199, 236], ["these studies", "TEST", 269, 282], ["a comparative proteomic analysis", "TEST", 297, 329], ["gastrohepatic lymph nodes (GLN)", "TREATMENT", 336, 367], ["the attenuated E75CV1 strain", "PROBLEM", 407, 435], ["its parental virulent ASFV strain", "PROBLEM", 449, 482], ["a model system", "TREATMENT", 524, 538], ["infections", "OBSERVATION", 12, 22], ["attenuated", "OBSERVATION_MODIFIER", 28, 38], ["ASFV", "OBSERVATION", 39, 43], ["subclinical", "OBSERVATION_MODIFIER", 68, 79], ["infections", "OBSERVATION", 80, 90], ["body", "ANATOMY", 168, 172], ["gastrohepatic", "ANATOMY", 336, 349], ["lymph nodes", "OBSERVATION", 350, 361], ["virulent", "OBSERVATION_MODIFIER", 462, 470], ["ASFV strain", "OBSERVATION", 471, 482]]], ["Since ASFV-infection modifies the expression patterns of host cell proteins, the application of proteomic approaches might help to clarify the intrinsic mechanism involved in ASFV-host interactions, as has been demonstrated [10, 17].", [["cell", "ANATOMY", 62, 66], ["infection", "DISEASE", 11, 20], ["ASFV", "ORGANISM", 6, 10], ["host cell", "CELL", 57, 66], ["ASFV", "ORGANISM", 175, 179], ["host cell proteins", "PROTEIN", 57, 75], ["ASFV", "SPECIES", 6, 10], ["ASFV", "SPECIES", 175, 179], ["ASFV", "PROBLEM", 6, 10], ["infection", "PROBLEM", 11, 20], ["host cell proteins", "PROBLEM", 57, 75], ["proteomic approaches", "TREATMENT", 96, 116], ["infection", "OBSERVATION", 11, 20], ["host cell proteins", "OBSERVATION", 57, 75]]], ["These methodologies have contributed to better understandings of how some viruses reprogram cell resources for their own benefit, or avoid host defensive mechanisms to survive in their host [18], but a limited number of proteomic studies have been carried out with swine pathogens.", [["cell", "ANATOMY", 92, 96], ["cell", "CELL", 92, 96], ["swine", "ORGANISM", 265, 270], ["swine", "SPECIES", 265, 270], ["proteomic studies", "TEST", 220, 237], ["swine pathogens", "PROBLEM", 265, 280]]], ["Thus, proteomic strategies have been used to study the differences observed after in vitro infection of Vero cells with virulent or attenuated strains of porcine epidemic diarrhoea virus [19], or PK-15 cells infected with classical swine fever virus [20].", [["Vero cells", "ANATOMY", 104, 114], ["PK-15 cells", "ANATOMY", 196, 207], ["infection", "DISEASE", 91, 100], ["porcine epidemic diarrhoea", "DISEASE", 154, 180], ["swine fever", "DISEASE", 232, 243], ["Vero cells", "CELL", 104, 114], ["porcine epidemic diarrhoea virus", "ORGANISM", 154, 186], ["PK-15 cells", "CELL", 196, 207], ["classical swine fever virus", "ORGANISM", 222, 249], ["Vero cells", "CELL_LINE", 104, 114], ["porcine epidemic diarrhoea virus", "SPECIES", 154, 186], ["swine fever virus", "SPECIES", 232, 249], ["porcine epidemic diarrhoea virus", "SPECIES", 154, 186], ["PK-15", "SPECIES", 196, 201], ["swine fever virus", "SPECIES", 232, 249], ["proteomic strategies", "TREATMENT", 6, 26], ["Vero cells", "PROBLEM", 104, 114], ["virulent", "PROBLEM", 120, 128], ["porcine epidemic diarrhoea virus", "PROBLEM", 154, 186], ["PK", "TEST", 196, 198], ["classical swine fever virus", "PROBLEM", 222, 249], ["Vero cells", "OBSERVATION", 104, 114]]], ["Additionally, our group has previously described the protein profile of lymph nodes of piglets inoculated with Porcine circovirus type 2 (PCV2) [21].", [["lymph nodes", "ANATOMY", 72, 83], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 72, 83], ["piglets", "ORGANISM", 87, 94], ["Porcine circovirus type 2", "ORGANISM", 111, 136], ["PCV2", "ORGANISM", 138, 142], ["piglets", "SPECIES", 87, 94], ["Porcine circovirus", "SPECIES", 111, 129], ["Porcine circovirus type 2 (PCV2)", "SPECIES", 111, 143], ["lymph nodes of piglets", "PROBLEM", 72, 94], ["Porcine circovirus type", "TREATMENT", 111, 134], ["lymph nodes", "OBSERVATION", 72, 83], ["Porcine circovirus", "OBSERVATION", 111, 129]]], ["Two proteomic studies have been published so far for ASFV infection: the first one focussed on proteins differentially expressed after ASFV-macrophage infection, although they were not specifically identified [17] and the second one, using Vero cells infected with the 608VR13 ASFV isolate, identifying proteins involved in apoptosis or in the transcription modulation [10].IntroductionIn this work, we have conducted the first 2-DE proteomic approach and bioinformatic data analysis using lymph node tissue from pigs infected with two homologous ASFV strains with distinct virulence: the tissue culture adapted E75CV1, an attenuated virus, and its parental virulent E75 virus.", [["macrophage", "ANATOMY", 140, 150], ["Vero cells", "ANATOMY", 240, 250], ["lymph node tissue", "ANATOMY", 490, 507], ["tissue culture", "ANATOMY", 589, 603], ["ASFV infection", "DISEASE", 53, 67], ["infection", "DISEASE", 151, 160], ["ASFV", "ORGANISM", 53, 57], ["ASFV", "ORGANISM", 135, 139], ["macrophage", "CELL", 140, 150], ["Vero cells", "CELL", 240, 250], ["608VR13 ASFV", "ORGANISM", 269, 281], ["lymph node tissue", "TISSUE", 490, 507], ["pigs", "ORGANISM", 513, 517], ["ASFV", "ORGANISM", 547, 551], ["tissue", "TISSUE", 589, 595], ["E75CV1", "ORGANISM", 612, 618], ["E75 virus", "ORGANISM", 667, 676], ["Vero cells", "CELL_LINE", 240, 250], ["pigs", "SPECIES", 513, 517], ["ASFV", "SPECIES", 53, 57], ["ASFV", "SPECIES", 135, 139], ["ASFV", "SPECIES", 277, 281], ["pigs", "SPECIES", 513, 517], ["ASFV", "SPECIES", 547, 551], ["E75 virus", "SPECIES", 667, 676], ["Two proteomic studies", "TEST", 0, 21], ["ASFV infection", "PROBLEM", 53, 67], ["ASFV", "PROBLEM", 135, 139], ["macrophage infection", "PROBLEM", 140, 160], ["Vero cells infected", "PROBLEM", 240, 259], ["apoptosis", "PROBLEM", 324, 333], ["bioinformatic data analysis", "TEST", 456, 483], ["lymph node tissue", "TREATMENT", 490, 507], ["two homologous ASFV strains", "PROBLEM", 532, 559], ["the tissue culture", "TEST", 585, 603], ["an attenuated virus", "PROBLEM", 620, 639], ["its parental virulent E75 virus", "PROBLEM", 645, 676], ["infection", "OBSERVATION", 58, 67], ["macrophage", "OBSERVATION_MODIFIER", 140, 150], ["infection", "OBSERVATION", 151, 160], ["lymph node tissue", "OBSERVATION", 490, 507]]], ["In order to reach a deeper understanding of pig-ASFV interactions and swine immune responses, samples were obtained at different times post-infection.", [["samples", "ANATOMY", 94, 101], ["pig", "ORGANISM", 44, 47], ["ASFV", "ORGANISM", 48, 52], ["swine", "ORGANISM", 70, 75], ["pig", "SPECIES", 44, 47], ["swine", "SPECIES", 70, 75], ["pig", "SPECIES", 44, 47], ["ASFV", "SPECIES", 48, 52], ["swine", "SPECIES", 70, 75], ["pig-ASFV interactions", "TREATMENT", 44, 65], ["samples", "TEST", 94, 101]]], ["This large- scale proteomic study should provide a complete view of the major and important functions and pathways altered during the infection process, and hopefully, it could be used in the future to develop anti-ASFV strategies.Experimental design for the in vivo experiment ::: Materials and methodsThe in vivo experiment has been previously described and the animals and samples used in this analysis are the same as those used in experiment 2 of our previous study [16].", [["samples", "ANATOMY", 376, 383], ["infection", "DISEASE", 134, 143], ["anti-ASFV", "CANCER", 210, 219], ["This large- scale proteomic study", "TEST", 0, 33], ["the infection process", "PROBLEM", 130, 151], ["anti-ASFV strategies", "TREATMENT", 210, 230], ["this analysis", "TEST", 392, 405], ["our previous study", "TEST", 452, 470], ["large", "OBSERVATION_MODIFIER", 5, 10], ["infection", "OBSERVATION", 134, 143]]], ["Briefly, a group of 24 pigs was infected with 104 HAU50 of E75CV1, a second group of 18 pigs was infected using the same dose and route of the virulent E75 and finally a third group of 12 pigs remained uninfected (control group).", [["pigs", "ORGANISM", 23, 27], ["pigs", "ORGANISM", 88, 92], ["pigs", "ORGANISM", 188, 192], ["pigs", "SPECIES", 23, 27], ["pigs", "SPECIES", 88, 92], ["pigs", "SPECIES", 188, 192], ["pigs", "SPECIES", 23, 27], ["pigs", "SPECIES", 88, 92], ["pigs", "SPECIES", 188, 192], ["the virulent E75", "TREATMENT", 139, 155]]], ["Pigs from the three groups were sacrificed at days 1, 3 and 7 pi (6 or 3 per group and day) and 6 pigs from the attenuated E75CV1 and 3 from the control group were also sacrificed at day 31 pi.", [["Pigs", "ORGANISM", 0, 4], ["pigs", "ORGANISM", 98, 102], ["Pigs", "SPECIES", 0, 4], ["pigs", "SPECIES", 98, 102], ["pigs", "SPECIES", 98, 102], ["Pigs", "TREATMENT", 0, 4]]], ["Lymph node samples of all animals (54 pigs) were analysed by 2-DE and mass spectrometry (see below).Two-dimensional gel electrophoresis (2-DE) and image analysis ::: Materials and methodsGLN were subjected to mechanical dissociation in sample buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, 1% w/v DTT, 0.8% ampholytes, 0.2 M PMSF) by scraping and gentle squeezing.", [["Lymph node samples", "ANATOMY", 0, 18], ["urea", "CHEMICAL", 255, 259], ["urea", "CHEMICAL", 255, 259], ["thiourea", "CHEMICAL", 265, 273], ["CHAPS", "CHEMICAL", 282, 287], ["DTT", "CHEMICAL", 296, 299], ["PMSF", "CHEMICAL", 324, 328], ["Lymph node samples", "MULTI-TISSUE_STRUCTURE", 0, 18], ["pigs", "ORGANISM", 38, 42], ["urea", "SIMPLE_CHEMICAL", 255, 259], ["thiourea", "SIMPLE_CHEMICAL", 265, 273], ["v CHAPS", "SIMPLE_CHEMICAL", 280, 287], ["pigs", "SPECIES", 38, 42], ["pigs", "SPECIES", 38, 42], ["Lymph node samples", "TEST", 0, 18], ["mass spectrometry", "TEST", 70, 87], ["Two-dimensional gel electrophoresis", "TEST", 100, 135], ["image analysis", "TEST", 147, 161], ["methodsGLN", "TREATMENT", 180, 190], ["mechanical dissociation", "PROBLEM", 209, 232], ["urea", "TEST", 255, 259], ["thiourea", "TEST", 265, 273], ["v CHAPS", "TREATMENT", 280, 287], ["v DTT", "TREATMENT", 294, 299], ["0.8% ampholytes", "TREATMENT", 301, 316], ["Lymph node", "OBSERVATION", 0, 10]]], ["Each supernatant was recovered and, after clean up precipitation, lymph node protein extracts for each condition (control, E75-infected or E75CV1-infected) and day (1, 3, 7 and 31 dpi) were pooled and analyzed by 2-DE following previously published methods [22].", [["supernatant", "ANATOMY", 5, 16], ["lymph node", "ANATOMY", 66, 76], ["extracts", "ANATOMY", 85, 93], ["lymph node", "MULTI-TISSUE_STRUCTURE", 66, 76], ["extracts", "ORGANISM_SUBSTANCE", 85, 93], ["clean up precipitation", "TREATMENT", 42, 64], ["lymph node protein extracts", "TREATMENT", 66, 93], ["E75", "TEST", 123, 126], ["E75CV1", "TEST", 139, 145], ["lymph node", "OBSERVATION", 66, 76]]], ["Briefly, protein extracts were diluted in rehydration buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, 20 mM DTT, 0.5% Triton X-100, 0.5% ampholytes) and immobilized pH gradient strips of 17 cm (5\u20138 linear pH gradient, Bio-Rad) were rehydrated with 300 \u03bcL (500 \u03bcg) of each protein solution and focused in a PROTEAN IEF Cell (Bio-Rad) using the following parameters: (1) active rehydration at 50 V for 12 h; (2) at 250 V for 15 min without pause after rehydratation; (3) rapid ramp until reaching 10 000 V/h and (4) until 80 000 V/h with slow ramped voltage.", [["extracts", "ANATOMY", 17, 25], ["Cell", "ANATOMY", 316, 320], ["urea", "CHEMICAL", 66, 70], ["thiourea", "CHEMICAL", 76, 84], ["Triton X-100", "CHEMICAL", 116, 128], ["urea", "CHEMICAL", 66, 70], ["thiourea", "CHEMICAL", 76, 84], ["CHAPS", "CHEMICAL", 93, 98], ["DTT", "CHEMICAL", 106, 109], ["extracts", "ORGANISM_SUBSTANCE", 17, 25], ["urea", "SIMPLE_CHEMICAL", 66, 70], ["thiourea", "SIMPLE_CHEMICAL", 76, 84], ["v CHAPS", "SIMPLE_CHEMICAL", 91, 98], ["DTT", "SIMPLE_CHEMICAL", 106, 109], ["Triton X-100", "SIMPLE_CHEMICAL", 116, 128], ["ampholytes", "SIMPLE_CHEMICAL", 135, 145], ["Cell", "CELL", 316, 320], ["protein extracts", "TEST", 9, 25], ["rehydration buffer", "TREATMENT", 42, 60], ["urea", "TEST", 66, 70], ["thiourea", "TEST", 76, 84], ["v CHAPS", "TREATMENT", 91, 98], ["DTT", "TEST", 106, 109], ["0.5% ampholytes", "TREATMENT", 130, 145], ["immobilized pH gradient strips", "TEST", 151, 181], ["linear pH gradient", "TEST", 196, 214], ["Bio", "TEST", 216, 219], ["each protein solution", "TREATMENT", 265, 286], ["a PROTEAN IEF Cell", "TREATMENT", 302, 320], ["active rehydration", "TREATMENT", 367, 385], ["pause", "PROBLEM", 436, 441], ["slow ramped voltage", "PROBLEM", 534, 553], ["17 cm", "OBSERVATION_MODIFIER", 185, 190]]], ["Previously, protein profile was analyzed by 2-DE on 3\u201310 pH gradient strips, finding that the resolved spots were concentrated in the 5\u20138 pH range.", [["2-DE", "CHEMICAL", 44, 48], ["protein profile", "TEST", 12, 27], ["3\u201310 pH gradient strips", "TREATMENT", 52, 75], ["resolved", "OBSERVATION_MODIFIER", 94, 102], ["spots", "OBSERVATION_MODIFIER", 103, 108]]], ["Second dimension was performed on 12% SDS\u2013polyacrylamide gels using PROTEAN PlusTM Dodeca (Bio-Rad).", [["SDS\u2013polyacrylamide", "CHEMICAL", 38, 56], ["SDS\u2013polyacrylamide", "SIMPLE_CHEMICAL", 38, 56], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 91, 98], ["12% SDS\u2013polyacrylamide gels", "TREATMENT", 34, 61], ["PROTEAN PlusTM Dodeca", "TREATMENT", 68, 89]]], ["Four replicated for each of the conditions (virulent, attenuated or control) were analyzed simultaneously for each dpi.Two-dimensional gel electrophoresis (2-DE) and image analysis ::: Materials and methodsGels were stained with SYPRO Ruby protein gel stain (Bio-Rad).", [["Gels", "SIMPLE_CHEMICAL", 206, 210], ["SYPRO", "PROTEIN", 229, 234], ["Bio-Rad", "PROTEIN", 259, 266], ["virulent", "PROBLEM", 44, 52], ["Two-dimensional gel electrophoresis", "TEST", 119, 154], ["image analysis", "TEST", 166, 180], ["SYPRO Ruby protein gel stain", "TEST", 229, 257]]], ["Gel images were digitized with the FX Pro Plus Multi imager system (Bio-Rad) and analyzed with the PD Quest version 7.3 software (Bio-Rad).", [["Gel images", "TEST", 0, 10], ["the PD Quest version", "TEST", 95, 115], ["software", "TEST", 120, 128]]], ["Normalized protein spot volume (area multiplied by stain intensity) was calculated for each spot in the control sample and compared to its counterpart (sample from ASFV-infected animals).", [["sample", "ANATOMY", 112, 118], ["sample", "ANATOMY", 152, 158], ["ASFV", "ORGANISM", 164, 168], ["ASFV", "SPECIES", 164, 168], ["Normalized protein spot volume", "TEST", 0, 30], ["stain intensity", "TEST", 51, 66], ["ASFV", "TEST", 164, 168], ["protein", "OBSERVATION", 11, 18], ["spot volume", "OBSERVATION", 19, 30]]], ["Intensity data were used to calculate differences in protein expression between groups (controls vs. E75 or E75CV1 infected samples), for each dpi, using a Student\u2019s t test (p < 0.05) (two-tailed with unequal variances) after checking normality by the Wilks\u2013Shapiro test.", [["samples", "ANATOMY", 124, 131], ["samples", "CANCER", 124, 131], ["Intensity data", "TEST", 0, 14], ["Shapiro test", "TEST", 258, 270]]], ["Differentially expressed spots were selected for protein identification by mass spectrometry.Protein identification by mass spectrometry ::: Materials and methodsSpots were automatically excised in a ProPic station (Genomic Solutions) and digested with modified porcine trypsin (sequencing grade; Promega), by using a ProGest digestion station (Genomic Solutions), as previously described [22].", [["porcine", "ORGANISM", 262, 269], ["trypsin", "GENE_OR_GENE_PRODUCT", 270, 277], ["trypsin", "PROTEIN", 270, 277], ["porcine", "SPECIES", 262, 269], ["porcine", "SPECIES", 262, 269], ["Differentially expressed spots", "PROBLEM", 0, 30], ["protein identification", "TEST", 49, 71], ["mass spectrometry", "TEST", 75, 92], ["Protein identification", "TEST", 93, 115], ["a ProPic station (Genomic Solutions", "TREATMENT", 198, 233], ["modified porcine trypsin", "TREATMENT", 253, 277], ["a ProGest digestion station (Genomic Solutions", "TREATMENT", 316, 362]]], ["Briefly, gel pieces were destained with ammonium bicarbonate/acetonitrile (ACN), and subsequently subjected to dehydration/rehydration cycles and dried.", [["ammonium bicarbonate/acetonitrile", "CHEMICAL", 40, 73], ["ACN", "CHEMICAL", 75, 78], ["dehydration", "DISEASE", 111, 122], ["ammonium bicarbonate", "CHEMICAL", 40, 60], ["acetonitrile", "CHEMICAL", 61, 73], ["ACN", "CHEMICAL", 75, 78], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 40, 60], ["acetonitrile", "SIMPLE_CHEMICAL", 61, 73], ["ACN", "SIMPLE_CHEMICAL", 75, 78], ["gel pieces", "TREATMENT", 9, 19], ["ammonium bicarbonate", "TREATMENT", 40, 60], ["acetonitrile (ACN", "TREATMENT", 61, 78], ["dehydration", "PROBLEM", 111, 122], ["rehydration cycles", "TREATMENT", 123, 141], ["dehydration", "OBSERVATION", 111, 122], ["rehydration cycles", "OBSERVATION", 123, 141]]], ["Gel pieces were digested with trypsin, peptides extracted with trichloroacetic acid and desalted and concentrated by using \u03bcC-18 ZipTip columns (Millipore) in a ProMS station (Genomic Solutions).", [["trichloroacetic acid", "CHEMICAL", 63, 83], ["trichloroacetic acid", "CHEMICAL", 63, 83], ["trypsin", "GENE_OR_GENE_PRODUCT", 30, 37], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 63, 83], ["trypsin", "PROTEIN", 30, 37], ["Gel pieces", "TREATMENT", 0, 10], ["trypsin, peptides", "TREATMENT", 30, 47], ["trichloroacetic acid", "TREATMENT", 63, 83], ["\u03bcC-18 ZipTip columns (Millipore", "TREATMENT", 123, 154], ["a ProMS station (Genomic Solutions", "TREATMENT", 159, 193]]], ["After that were loaded onto a 4800 MALDI-TOF/TOF Analyzer (Applied Biosystems) in automatic mode with the following setting: for the Mass Spectrometry (MS) data, m/z range 800\u20134000 with an accelerating voltage of 20 kV, peak density of maximum 50 peaks per 200 Da, minimal S/N ratio of 10 and maximum peak at 65.", [["the Mass Spectrometry", "TEST", 129, 150], ["an accelerating voltage", "TEST", 186, 209], ["peak density", "TEST", 220, 232], ["minimal S/N ratio", "TEST", 265, 282], ["maximum peak", "TEST", 293, 305]]], ["Spectra were internally calibrated with peptides from trypsin autolysis (M + H+= 842.509, M + H+= 2211.104).", [["trypsin", "GENE_OR_GENE_PRODUCT", 54, 61], ["trypsin", "PROTEIN", 54, 61], ["Spectra", "TEST", 0, 7], ["peptides", "TEST", 40, 48], ["trypsin autolysis", "TEST", 54, 71]]], ["For the MS/MS data, fragment selection criteria were a minimum signal/noise (S/N) ratio of 5, a maximum number of peaks set at 65 and peak density of maximum 50 peaks per 200 Da.", [["the MS/MS data", "TEST", 4, 18], ["fragment selection criteria", "TEST", 20, 47], ["a minimum signal/noise (S/N) ratio", "TEST", 53, 87], ["peak density", "TEST", 134, 146], ["peak density", "OBSERVATION", 134, 146]]], ["For each precursor selected for MS/MS analysis, fragment mass values in the range from 60 to 10 Da below precursor mass were used to peptide identification.", [["MS/MS analysis", "TEST", 32, 46], ["fragment mass values", "PROBLEM", 48, 68], ["precursor mass", "PROBLEM", 105, 119], ["fragment", "OBSERVATION_MODIFIER", 48, 56], ["mass", "OBSERVATION", 57, 61], ["mass", "OBSERVATION", 115, 119]]], ["Protein identification was assigned by peptide mass fingerprinting and confirmed by MS/MS analysis of at least three peptides in each sample.", [["Protein identification", "TEST", 0, 22], ["peptide mass fingerprinting", "PROBLEM", 39, 66], ["MS/MS analysis", "TEST", 84, 98], ["mass", "OBSERVATION", 47, 51]]], ["Mascot 1.9 search engine (Matrixscience) was used for protein identification running on GPS software (Applied Biosystems) against the NCBI mammalian database (updated monthly).", [["Mascot", "TEST", 0, 6], ["protein identification", "TEST", 54, 76], ["GPS software", "TEST", 88, 100]]], ["Only those proteins with a significant protein score (p < 0.05) according to Mascot were taken into account in subsequent analysis.Functional analysis of the proteins ::: Materials and methodsDifferentially regulated proteins were analyzed through the use of Ingenuity Pathway Analysis software (IPA, Ingenuity\u00ae Systems).", [["Differentially regulated proteins", "PROTEIN", 192, 225], ["a significant protein score", "PROBLEM", 25, 52], ["Mascot", "TEST", 77, 83], ["subsequent analysis", "TEST", 111, 130], ["Analysis software", "TEST", 277, 294]]], ["This system identifies the functions and canonical pathways that are most significant to the data set, supported by canonical information stored in the Ingenuity Knowledge Base.", [["Base", "ANATOMY_MODIFIER", 172, 176]]], ["Fisher\u2019s exact test was used to calculate a p value determining the probability that the association between the proteins in the dataset and the functions and canonical pathways is explained by chance alone.", [["a p value", "TEST", 42, 51]]], ["These p-values are calculated based on the number of proteins that participate in a given function or pathway relative to the total number of occurrences of proteins in functions or pathway annotations stored in the Ingenuity Pathways Knowledge Base [21].", [["These p-values", "TEST", 0, 14]]], ["The whole Ingenuity Knowledge Base was considered as reference set.Two-dimensional electrophoresis reveals differential protein expression kinetics after in vivoinfection with either virulent E75 or attenuated E75CV1 ASFV-isolates ::: ResultsTo widen and deepen our understanding of the mechanisms underlying ASFV-pathogenesis and immune response to ASFV, we characterized the variation in GLN protein profiles of pigs infected with E75 (high virulence) and E75CV (low virulence) at different times post-infection using a 2-DE proteomics approach.", [["E75CV1 ASFV", "ORGANISM", 210, 221], ["ASFV", "ORGANISM", 309, 313], ["ASFV", "ORGANISM", 350, 354], ["GLN", "GENE_OR_GENE_PRODUCT", 390, 393], ["pigs", "ORGANISM", 414, 418], ["GLN protein", "PROTEIN", 390, 401], ["pigs", "SPECIES", 414, 418], ["ASFV", "SPECIES", 217, 221], ["ASFV", "SPECIES", 309, 313], ["ASFV", "SPECIES", 350, 354], ["pigs", "SPECIES", 414, 418], ["Two-dimensional electrophoresis", "TEST", 67, 98], ["differential protein expression kinetics", "PROBLEM", 107, 147], ["ASFV", "PROBLEM", 309, 313], ["pathogenesis", "PROBLEM", 314, 326], ["immune response to ASFV", "PROBLEM", 331, 354], ["GLN protein profiles", "TEST", 390, 410], ["pigs infected", "PROBLEM", 414, 427], ["E75CV (low virulence", "PROBLEM", 458, 478], ["a 2-DE proteomics approach", "TREATMENT", 520, 546], ["protein expression kinetics", "OBSERVATION", 120, 147], ["ASFV", "OBSERVATION", 309, 313], ["GLN protein", "OBSERVATION", 390, 401]]], ["Our previous study [16] allowed to verify homogeneity between animals and that no outlier there was among the pigs studied.", [["pigs", "ORGANISM", 110, 114], ["pigs", "SPECIES", 110, 114], ["pigs", "SPECIES", 110, 114], ["Our previous study", "TEST", 0, 18]]], ["To overcome the inherent experimental variations of this technique, we performed simultaneously four replicate (four gels) of each day and condition and more than 85% of the spots were common between gels.", [["this technique", "TREATMENT", 52, 66]]], ["After image analysis and visual confirmation of gels, around 800 spots were detected.", [["image analysis", "TEST", 6, 20], ["visual confirmation of gels", "TEST", 25, 52]]], ["Paired analyses between infected and control groups detected 80, 94, 62 and 39 differently changed spots with E75CV1 attenuated strain at 1, 3, 7 and 31 dpi respectively, corresponding to 42, 72, 53 and 33 different proteins.", [["Paired analyses", "TEST", 0, 15], ["E75CV1 attenuated strain", "PROBLEM", 110, 134], ["infected", "OBSERVATION", 24, 32]]], ["With E75 virulent isolate 57, 83 and 34 spots result differentially expressed at 1, 3 years, 7 dpi, corresponding to 33, 60 and 24 different proteins.", [["E75 virulent isolate", "TEST", 5, 25]]], ["In some cases, multiple spots were unambiguously identified as the same protein, it could arrive due to post-translational modification (crucial in the control of numerous regulatory pathways, degradation of proteins, biochemical alterations or pathogenesis), different isoforms derived from different genes of a multigen family, proteolytic damage or chemical modification of protein during sample preparation.Two-dimensional electrophoresis reveals differential protein expression kinetics after in vivoinfection with either virulent E75 or attenuated E75CV1 ASFV-isolates ::: ResultsDifferences in protein profiles were not only observed between virulent and attenuated ASFV strains, but also were shown between the different times post-infection tested.", [["sample", "ANATOMY", 392, 398], ["E75CV1 ASFV", "ORGANISM", 554, 565], ["ASFV", "ORGANISM", 673, 677], ["multigen family", "PROTEIN", 313, 328], ["ASFV", "SPECIES", 561, 565], ["ASFV", "SPECIES", 673, 677], ["multiple spots", "PROBLEM", 15, 29], ["post-translational modification", "PROBLEM", 104, 135], ["biochemical alterations", "PROBLEM", 218, 241], ["pathogenesis", "PROBLEM", 245, 257], ["proteolytic damage", "PROBLEM", 330, 348], ["chemical modification of protein during sample preparation", "TREATMENT", 352, 410], ["Two-dimensional electrophoresis", "TEST", 411, 442], ["differential protein expression kinetics", "PROBLEM", 451, 491], ["protein profiles", "TEST", 601, 617], ["virulent", "PROBLEM", 649, 657], ["attenuated ASFV strains", "PROBLEM", 662, 685], ["multiple", "OBSERVATION_MODIFIER", 15, 23], ["spots", "OBSERVATION", 24, 29], ["protein expression kinetics", "OBSERVATION", 464, 491], ["attenuated", "OBSERVATION_MODIFIER", 662, 672], ["ASFV strains", "OBSERVATION", 673, 685]]], ["The most dramatic changes found affected lymph nodes from pigs infected with E75 at day 7pi, coinciding with the late phase of the E75 lethal virus infection, probably reflects the massive tissue destruction observed at this time post-infection, with only a few intact cells being present, mostly corresponding to infiltrates of ASFV-infected macrophages [16].", [["lymph nodes", "ANATOMY", 41, 52], ["tissue", "ANATOMY", 189, 195], ["cells", "ANATOMY", 269, 274], ["macrophages", "ANATOMY", 343, 354], ["infection", "DISEASE", 148, 157], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 41, 52], ["pigs", "ORGANISM", 58, 62], ["E75 lethal virus", "ORGANISM", 131, 147], ["tissue", "TISSUE", 189, 195], ["cells", "CELL", 269, 274], ["ASFV", "ORGANISM", 329, 333], ["macrophages", "CELL", 343, 354], ["pigs", "SPECIES", 58, 62], ["pigs", "SPECIES", 58, 62], ["E75 lethal virus", "SPECIES", 131, 147], ["ASFV", "SPECIES", 329, 333], ["The most dramatic changes", "PROBLEM", 0, 25], ["affected lymph nodes", "PROBLEM", 32, 52], ["the E75 lethal virus infection", "PROBLEM", 127, 157], ["the massive tissue destruction", "PROBLEM", 177, 207], ["a few intact cells", "PROBLEM", 256, 274], ["infiltrates of ASFV", "PROBLEM", 314, 333], ["infected macrophages", "PROBLEM", 334, 354], ["most", "OBSERVATION_MODIFIER", 4, 8], ["dramatic", "OBSERVATION_MODIFIER", 9, 17], ["affected", "OBSERVATION_MODIFIER", 32, 40], ["lymph nodes", "OBSERVATION", 41, 52], ["pigs", "OBSERVATION_MODIFIER", 58, 62], ["infected", "OBSERVATION_MODIFIER", 63, 71], ["late phase", "OBSERVATION_MODIFIER", 113, 123], ["virus infection", "OBSERVATION", 142, 157], ["probably reflects", "UNCERTAINTY", 159, 176], ["massive", "OBSERVATION_MODIFIER", 181, 188], ["tissue", "OBSERVATION_MODIFIER", 189, 195], ["destruction", "OBSERVATION", 196, 207], ["few", "OBSERVATION_MODIFIER", 258, 261], ["intact cells", "OBSERVATION", 262, 274], ["infiltrates", "OBSERVATION", 314, 325], ["ASFV", "OBSERVATION_MODIFIER", 329, 333], ["infected", "OBSERVATION_MODIFIER", 334, 342], ["macrophages", "OBSERVATION", 343, 354]]], ["GLNs from day 7 E75-infected pigs showed most proteins downregulated while infection with the attenuated E75CV1 virus upregulates a larger number of proteins than the virulent E75 strain at days 1, 3 and 7 pi, respectively (Table 1).", [["GLNs", "ANATOMY", 0, 4], ["infection", "DISEASE", 75, 84], ["GLNs", "PATHOLOGICAL_FORMATION", 0, 4], ["E75", "GENE_OR_GENE_PRODUCT", 16, 19], ["pigs", "ORGANISM", 29, 33], ["E75CV1 virus", "ORGANISM", 105, 117], ["E75 strain", "ORGANISM", 176, 186], ["GLNs", "CELL_TYPE", 0, 4], ["pigs", "SPECIES", 29, 33], ["pigs", "SPECIES", 29, 33], ["E75CV1 virus", "SPECIES", 105, 117], ["GLNs", "TEST", 0, 4], ["infected pigs", "PROBLEM", 20, 33], ["infection", "PROBLEM", 75, 84], ["the attenuated E75CV1 virus", "PROBLEM", 90, 117], ["most proteins", "OBSERVATION_MODIFIER", 41, 54], ["downregulated", "OBSERVATION_MODIFIER", 55, 68], ["infection", "OBSERVATION", 75, 84], ["larger", "OBSERVATION_MODIFIER", 132, 138], ["number", "OBSERVATION_MODIFIER", 139, 145]]], ["As expected, there are a considerable number of spots in common that change after infection with the two isolates (36, 62 and 23 at 1, 3 and 7 dpi respectively), while the rest became altered only during the infection with one of the isolates (Additional files 1, 2, 3, 4 show the changes of expression of all proteins altered after infection and additional MS/MS information is available in Ref.", [["infection", "DISEASE", 82, 91], ["infection", "DISEASE", 208, 217], ["infection", "DISEASE", 333, 342], ["infection", "PROBLEM", 82, 91], ["the two isolates", "TEST", 97, 113], ["the infection", "PROBLEM", 204, 217], ["the isolates", "TEST", 230, 242], ["all proteins", "PROBLEM", 306, 318], ["infection", "PROBLEM", 333, 342], ["considerable", "OBSERVATION_MODIFIER", 25, 37], ["number", "OBSERVATION_MODIFIER", 38, 44], ["spots", "OBSERVATION", 48, 53], ["infection", "OBSERVATION", 82, 91], ["altered", "OBSERVATION", 184, 191], ["infection", "OBSERVATION", 208, 217]]], ["The proteins with the largest change in fold change are shown in Tables 2, 3, 4, 5.", [["the largest change in fold change", "PROBLEM", 18, 51], ["largest", "OBSERVATION_MODIFIER", 22, 29], ["change", "OBSERVATION", 30, 36], ["fold change", "OBSERVATION", 40, 51]]], ["Similarly, the expression of some proteins became apparent at specific times post-infection, while others were affected throughout the infection.", [["infection", "DISEASE", 135, 144], ["some proteins", "PROBLEM", 29, 42], ["the infection", "PROBLEM", 131, 144], ["some", "OBSERVATION_MODIFIER", 29, 33], ["proteins", "OBSERVATION", 34, 42], ["infection", "OBSERVATION", 135, 144]]], ["As good examples, albumin and cytoskeletal proteins such as actin-like proteins were commonly affected by both ASFV strains, while many other proteins were differentially affected, such as heat shock protein B1 (HSPB1), involved in stabilizing actin filaments after stress, that results up-regulated exclusively at 1 dpi with E75CV1 [25].", [["cytoskeletal", "ANATOMY", 30, 42], ["filaments", "ANATOMY", 250, 259], ["albumin", "GENE_OR_GENE_PRODUCT", 18, 25], ["cytoskeletal", "CELLULAR_COMPONENT", 30, 42], ["actin", "GENE_OR_GENE_PRODUCT", 60, 65], ["ASFV", "ORGANISM", 111, 115], ["heat shock protein B1", "GENE_OR_GENE_PRODUCT", 189, 210], ["HSPB1", "GENE_OR_GENE_PRODUCT", 212, 217], ["actin", "GENE_OR_GENE_PRODUCT", 244, 249], ["albumin", "PROTEIN", 18, 25], ["cytoskeletal proteins", "PROTEIN", 30, 51], ["actin", "PROTEIN", 60, 65], ["heat shock protein B1", "PROTEIN", 189, 210], ["HSPB1", "PROTEIN", 212, 217], ["actin", "PROTEIN", 244, 249], ["ASFV", "SPECIES", 111, 115], ["albumin and cytoskeletal proteins", "TEST", 18, 51], ["actin-like proteins", "PROBLEM", 60, 79], ["both ASFV strains", "PROBLEM", 106, 123], ["heat shock protein B1", "TEST", 189, 210], ["HSPB1", "TEST", 212, 217], ["cytoskeletal proteins", "OBSERVATION", 30, 51], ["ASFV strains", "OBSERVATION", 111, 123]]], ["Of special interest were the proteins differentially regulated after the infection with the E75CV1 attenuated strain, reflecting changes in the immune system.", [["immune system", "ANATOMY", 144, 157], ["infection", "DISEASE", 73, 82], ["the infection", "PROBLEM", 69, 82], ["the E75CV1 attenuated strain", "PROBLEM", 88, 116], ["changes in the immune system", "PROBLEM", 129, 157], ["infection", "OBSERVATION", 73, 82], ["immune system", "OBSERVATION", 144, 157]]], ["Interestingly, some of these proteins became upregulated as soon as day 1 pi with E75CV1 (Additional file 1), including proteasome activator complex (PSME 1 and 2).", [["Additional file 1", "GENE_OR_GENE_PRODUCT", 90, 107], ["proteasome activator complex (PSME 1", "GENE_OR_GENE_PRODUCT", 120, 156], ["E75CV1", "PROTEIN", 82, 88], ["proteasome activator complex", "PROTEIN", 120, 148], ["PSME 1 and 2", "PROTEIN", 150, 162], ["proteasome activator complex", "TEST", 120, 148], ["PSME", "TEST", 150, 154]]], ["Two proteins were inversely regulated after infection with the attenuated E75CV1 strain: HSPA1B and vimentin.", [["infection", "DISEASE", 44, 53], ["HSPA1B", "GENE_OR_GENE_PRODUCT", 89, 95], ["vimentin", "GENE_OR_GENE_PRODUCT", 100, 108], ["HSPA1B", "PROTEIN", 89, 95], ["vimentin", "PROTEIN", 100, 108], ["Two proteins", "PROBLEM", 0, 12], ["infection", "PROBLEM", 44, 53], ["HSPA1B", "TREATMENT", 89, 95], ["vimentin", "TREATMENT", 100, 108], ["infection", "OBSERVATION", 44, 53]]], ["While HPSA1B showed a downregulation, vimentin was upregulated at day 1 pi.", [["HPSA1B", "GENE_OR_GENE_PRODUCT", 6, 12], ["vimentin", "GENE_OR_GENE_PRODUCT", 38, 46], ["HPSA1B", "PROTEIN", 6, 12], ["vimentin", "PROTEIN", 38, 46], ["HPSA1B", "TEST", 6, 12], ["downregulation", "OBSERVATION", 22, 36]]], ["Other proteins specifically upregulated at day 1 pi with E75CV1 were HSPB1, enolase or lymphocyte cytosolic protein 1 (LCP-1) (Additional file 1).", [["E75CV1", "GENE_OR_GENE_PRODUCT", 57, 63], ["HSPB1", "GENE_OR_GENE_PRODUCT", 69, 74], ["enolase or lymphocyte cytosolic protein 1", "GENE_OR_GENE_PRODUCT", 76, 117], ["LCP-1", "GENE_OR_GENE_PRODUCT", 119, 124], ["E75CV1", "PROTEIN", 57, 63], ["HSPB1", "PROTEIN", 69, 74], ["enolase", "PROTEIN", 76, 83], ["lymphocyte cytosolic protein 1", "PROTEIN", 87, 117], ["LCP-1", "PROTEIN", 119, 124], ["E75CV1", "TEST", 57, 63], ["HSPB1", "TEST", 69, 74], ["enolase", "TEST", 76, 83], ["lymphocyte cytosolic protein", "TEST", 87, 115], ["LCP", "TEST", 119, 122]]], ["As expected, the early events described at day 1 pi with E75CV1, correlate with the profile of upregulated proteins specifically found by day 31 pi and related with the immune response (Additional file 4), including immunoglobulin component fractions, such as IGKC and IGHG3, or components of the proteasome such as PMSA1 and PMSA6.", [["E75CV1", "GENE_OR_GENE_PRODUCT", 57, 63], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 216, 230], ["IGKC", "GENE_OR_GENE_PRODUCT", 260, 264], ["IGHG3", "GENE_OR_GENE_PRODUCT", 269, 274], ["PMSA1", "GENE_OR_GENE_PRODUCT", 316, 321], ["PMSA6", "GENE_OR_GENE_PRODUCT", 326, 331], ["E75CV1", "PROTEIN", 57, 63], ["upregulated proteins", "PROTEIN", 95, 115], ["IGKC", "PROTEIN", 260, 264], ["IGHG3", "PROTEIN", 269, 274], ["proteasome", "PROTEIN", 297, 307], ["PMSA1", "PROTEIN", 316, 321], ["PMSA6", "PROTEIN", 326, 331], ["upregulated proteins", "PROBLEM", 95, 115], ["the immune response", "PROBLEM", 165, 184], ["immunoglobulin component fractions", "PROBLEM", 216, 250], ["IGKC", "PROBLEM", 260, 264], ["IGHG3", "TREATMENT", 269, 274], ["the proteasome", "TREATMENT", 293, 307], ["PMSA1", "TREATMENT", 316, 321], ["PMSA6", "TREATMENT", 326, 331]]], ["The up-regulation of retinol-binding protein 4 (responsible for retinol transport), galactose mutarotase or calreticulin are also of interest.", [["retinol", "CHEMICAL", 21, 28], ["retinol", "CHEMICAL", 64, 71], ["galactose", "CHEMICAL", 84, 93], ["retinol", "CHEMICAL", 21, 28], ["retinol", "CHEMICAL", 64, 71], ["galactose", "CHEMICAL", 84, 93], ["retinol-binding protein 4", "GENE_OR_GENE_PRODUCT", 21, 46], ["retinol", "SIMPLE_CHEMICAL", 64, 71], ["galactose mutarotase", "GENE_OR_GENE_PRODUCT", 84, 104], ["calreticulin", "GENE_OR_GENE_PRODUCT", 108, 120], ["retinol-binding protein 4", "PROTEIN", 21, 46], ["galactose mutarotase", "PROTEIN", 84, 104], ["calreticulin", "PROTEIN", 108, 120], ["retinol-binding protein", "TREATMENT", 21, 44], ["retinol transport", "TREATMENT", 64, 81], ["galactose mutarotase", "TREATMENT", 84, 104]]]], "PMC7151312": [["The COVID-19 pandemic has brought sweeping change to the delivery of health care throughout the United States and other parts of the world.", [["The COVID", "TEST", 0, 9], ["the delivery of health care", "TREATMENT", 53, 80]]], ["Not only does this affect our patients, but in many cases it affects our physicians, residents, nurses, technologists, and support staff.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["Outpatient clinics have been closed, and elective or semielective procedures have been postponed or canceled.", [["elective or semielective procedures", "TREATMENT", 41, 76]]], ["The Society for Vascular Surgery has released guidance as to which procedures should be postponed.1 We do not yet know how much stress the pandemic will put on the U.S. health care system, but most hospitals and health care systems have wisely adopted a strategy to prepare for the worst.2", [["Vascular", "ANATOMY", 16, 24], ["Vascular", "MULTI-TISSUE_STRUCTURE", 16, 24], ["Vascular Surgery", "TREATMENT", 16, 32], ["Vascular", "ANATOMY", 16, 24]]]], "PMC7337629": [["Study Population ::: METHODSIn February and March 2020, comprehensive nationwide surveillance and contact tracing as part of Singapore\u2019s public health strategy identified 3 potential SARS-CoV-2 seeding incidents in 3 separate educational settings [4, 5].", [["contact tracing", "TEST", 98, 113]]], ["Clinical and epidemiological data of the confirmed cases and their contacts from school were extracted for analysis.Interventions and Investigations ::: METHODSAll close contacts (eg, students from the same class) were placed under quarantine (14 days from last exposure).", [["analysis", "TEST", 107, 115]]], ["Quarantined individuals who developed fever or any respiratory symptom were immediately sent for medical evaluation of COVID-19 and admitted for isolation.", [["respiratory", "ANATOMY", 51, 62], ["fever", "DISEASE", 38, 43], ["individuals", "ORGANISM", 12, 23], ["fever", "PROBLEM", 38, 43], ["any respiratory symptom", "PROBLEM", 47, 70], ["medical evaluation", "TEST", 97, 115], ["COVID", "TEST", 119, 124], ["isolation", "TREATMENT", 145, 154]]], ["All students/parents of the school were advised to monitor for symptoms and were similarly admitted for COVID-19 evaluation if they were unwell within the 14-day incubation period.", [["symptoms", "PROBLEM", 63, 71], ["COVID-19 evaluation", "TEST", 104, 123], ["unwell", "PROBLEM", 137, 143]]], ["All admitted cases required at least 2 negative nasopharyngeal (NP) swabs to be taken on 2 separate calendar days before being discharged from the hospital.", [["nasopharyngeal", "ANATOMY", 48, 62], ["nasopharyngeal", "CANCER", 48, 62], ["nasopharyngeal (NP) swabs", "TREATMENT", 48, 73], ["nasopharyngeal", "ANATOMY", 48, 62]]], ["These included terminal cleaning of the schools and measures to reduce student mixing, such as suspension of extracurricular or sport activities and staggered recess breaks.", [["student mixing", "TREATMENT", 71, 85], ["staggered recess breaks", "PROBLEM", 149, 172], ["recess breaks", "OBSERVATION", 159, 172]]], ["For the third incident (preschool 2), in addition to the above measures, the preschool was closed for 14 days following quick detection of an increasing number of staff members with COVID-19.", [["the above measures", "TREATMENT", 53, 71], ["COVID", "TEST", 182, 187]]], ["Furthermore, a single NP swab screening for SARS-CoV-2 among asymptomatic children attending the preschool was also initiated to identify potential asymptomatic cases.Interventions and Investigations ::: METHODSThe study was approved by the Singhealth Centralised Institutional Review Board.", [["SARS-CoV-2", "ORGANISM", 44, 54], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["SARS-CoV", "SPECIES", 44, 52], ["a single NP swab screening", "TEST", 13, 39], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["METHODSThe study", "TEST", 204, 220]]], ["Written informed consent was waived in light of the need to inform public health outbreak control policies.Symptomatic Screening of Secondary School and Preschool 1 ::: RESULTSA 12-year-old student who attended secondary school and a 5-year-old who attended preschool were both found to be SARS-CoV-2 positive from contact tracing following their exposures to adult family household members who were part of a community cluster.", [["SARS", "DISEASE", 290, 294], ["SARS", "PROBLEM", 290, 294], ["CoV", "TEST", 295, 298], ["contact tracing", "TEST", 315, 330]]], ["Both students attended their respective educational settings on the first day of their symptoms before subsequently being diagnosed with COVID-19 and isolated in the hospital.Symptomatic Screening of Secondary School and Preschool 1 ::: RESULTSIn the secondary school setting, a total of 8 students from the school developed symptoms and were screened for SARS-CoV-2 during the incubation period.", [["COVID-19", "CHEMICAL", 137, 145], ["SARS", "DISEASE", 356, 360], ["SARS-CoV", "SPECIES", 356, 364], ["their symptoms", "PROBLEM", 81, 95], ["COVID", "TEST", 137, 142], ["symptoms", "PROBLEM", 325, 333], ["SARS", "PROBLEM", 356, 360]]], ["(Table 1) The most common presenting symptom was cough (87.5%), followed by rhinorrhea (37.5%).", [["cough", "DISEASE", 49, 54], ["rhinorrhea", "DISEASE", 76, 86], ["cough", "PROBLEM", 49, 54], ["rhinorrhea", "PROBLEM", 76, 86]]], ["All 8 symptomatic student contacts tested negative from that school.Symptomatic Screening of Secondary School and Preschool 1 ::: RESULTSIn the preschool setting (preschool 1), a total of 34 preschool student contacts developed symptoms during the incubation period postexposure and hence were swabbed for SARS-CoV-2.", [["SARS-CoV", "SPECIES", 306, 314], ["symptoms", "PROBLEM", 228, 236], ["SARS", "PROBLEM", 306, 310]]], ["Similar to the secondary school setting, the common presenting symptoms were cough (94.1%) and rhinorrhea (41.2%).", [["cough", "DISEASE", 77, 82], ["rhinorrhea", "DISEASE", 95, 105], ["the common presenting symptoms", "PROBLEM", 41, 71], ["cough", "PROBLEM", 77, 82], ["rhinorrhea", "PROBLEM", 95, 105]]], ["Only 14\u22197% of them presented with fever.", [["fever", "DISEASE", 34, 39], ["fever", "PROBLEM", 34, 39], ["fever", "OBSERVATION", 34, 39]]], ["All 34 symptomatic contacts at the preschool were found to be negative for SARS-CoV-2.Asymptomatic and Symptomatic Screening of Preschool 2 ::: RESULTSThe third incident involved a preschool cluster where the index case was an adult staff member.", [["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 75, 85], ["SARS-CoV", "SPECIES", 75, 83], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83], ["Asymptomatic", "PROBLEM", 86, 98]]], ["A total of 77 children from the preschool (about 73% of the total preschool student population) were evaluated.", [["children", "ORGANISM", 14, 22], ["children", "SPECIES", 14, 22]]], ["Of these, 8 were symptomatic and 69 were asymptomatic.", [["symptomatic", "PROBLEM", 17, 28], ["asymptomatic", "PROBLEM", 41, 53]]], ["The mean interval between last exposure to NP swab sampling was about 6 days and 10 days for symptomatic and asymptomatic children, respectively.", [["children", "ORGANISM", 122, 130], ["children", "SPECIES", 122, 130], ["NP swab sampling", "TEST", 43, 59], ["symptomatic and asymptomatic children", "PROBLEM", 93, 130]]], ["SARS-CoV-2 infection was not detectable from screening of all 77 children.", [["SARS-CoV-2 infection", "DISEASE", 0, 20], ["SARS-CoV-2", "ORGANISM", 0, 10], ["children", "ORGANISM", 65, 73], ["children", "SPECIES", 65, 73], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["2 infection", "PROBLEM", 9, 20], ["infection", "OBSERVATION", 11, 20]]], ["There was no significant difference in age or sex between those who provided an NP swab vs those who did not.", [["an NP swab", "TEST", 77, 87], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["The remaining 27% who chose not to provide an NP screening swab did not develop any symptoms while under close monitoring and quarantine.DISCUSSIONComprehensive surveillance and screening of symptomatic student contacts following exposure to an index COVID-19 student case up to the first day of symptom onset in a secondary school and a preschool setting found no evidence of disease transmission.", [["an NP screening swab", "TEST", 43, 63], ["any symptoms", "PROBLEM", 80, 92], ["close monitoring", "TEST", 105, 121], ["quarantine", "TREATMENT", 126, 136], ["DISCUSSIONComprehensive surveillance", "TEST", 137, 173], ["disease transmission", "PROBLEM", 377, 397], ["no evidence of", "UNCERTAINTY", 362, 376], ["disease", "OBSERVATION", 377, 384]]], ["In addition, screening of both symptomatic and asymptomatic children who were exposed to a major COVID-19 cluster of adult staff members in a separate preschool setting also did not detect any SARS-CoV-2 infection.DISCUSSIONPrior studies showed that the viral load of SARS-CoV-2 infection peaked soon after symptom onset and that it was possible for transmission to occur independent of symptoms [1, 6].", [["infection", "DISEASE", 204, 213], ["SARS", "DISEASE", 268, 272], ["infection", "DISEASE", 279, 288], ["children", "ORGANISM", 60, 68], ["CoV-2", "ORGANISM", 198, 203], ["SARS-CoV-2", "ORGANISM", 268, 278], ["children", "SPECIES", 60, 68], ["CoV-2", "SPECIES", 273, 278], ["SARS-CoV-2", "SPECIES", 268, 278], ["screening", "TEST", 13, 22], ["any SARS", "PROBLEM", 189, 197], ["CoV-2 infection", "PROBLEM", 198, 213], ["the viral load", "TEST", 250, 264], ["SARS", "PROBLEM", 268, 272], ["CoV", "TEST", 273, 276], ["2 infection", "PROBLEM", 277, 288], ["symptom", "PROBLEM", 307, 314], ["symptoms", "PROBLEM", 387, 395]]], ["Environmental viral contamination from a generally well pediatric COVID-19 case had also been demonstrated [7].", [["Environmental viral contamination", "PROBLEM", 0, 33], ["viral contamination", "OBSERVATION", 14, 33]]], ["However, during our investigations, evidence of COVID-19 disease was undetectable among symptomatic contacts in both secondary and preschool settings.", [["our investigations", "TEST", 16, 34], ["COVID-19 disease", "PROBLEM", 48, 64], ["symptomatic contacts", "PROBLEM", 88, 108]]], ["In the third transmission study (preschool 2), the attack rates among staff members in the preschool and their households were unsurprisingly high in view of the high R0 and attack rates reported in the community [8, 9].", [["the third transmission study", "TEST", 3, 31]]], ["Despite screening both symptomatic and asymptomatic children in preschool 2, SARS-CoV-2 infection was also undetectable.", [["SARS", "DISEASE", 77, 81], ["infection", "DISEASE", 88, 97], ["children", "ORGANISM", 52, 60], ["SARS-CoV-2", "ORGANISM", 77, 87], ["children", "SPECIES", 52, 60], ["SARS-CoV-2", "SPECIES", 77, 87], ["SARS-CoV-2 infection", "PROBLEM", 77, 97], ["symptomatic", "OBSERVATION_MODIFIER", 23, 34], ["infection", "OBSERVATION", 88, 97]]], ["Taken together, these findings suggest that the risk of SARS-CoV-2 transmission among children in schools, especially preschools, is likely to be low.", [["SARS", "DISEASE", 56, 60], ["SARS-CoV-2", "ORGANISM", 56, 66], ["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94], ["SARS", "PROBLEM", 56, 60], ["likely to be", "UNCERTAINTY", 133, 145], ["low", "OBSERVATION_MODIFIER", 146, 149]]], ["The only other published school transmission risk study involved a symptomatic 9-year-old child with COVID-19 who attended 3 different schools [10].", [["child", "ORGANISM", 90, 95], ["child", "SPECIES", 90, 95]]], ["Subsequent follow-up and testing of symptomatic children from the preschools also did not detect virus transmission.", [["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["virus transmission", "PROBLEM", 97, 115], ["virus", "OBSERVATION", 97, 102]]], ["The reason for this low attack rate among children is unclear.", [["children", "ORGANISM", 42, 50], ["children", "SPECIES", 42, 50], ["this low attack rate", "PROBLEM", 15, 35]]], ["A recent study using single-nucleus multiomic profiling of alveolar epithelial cells found that lung samples from young children expressed fewer genes (ACE2 and TMPRSS2) known to be utilized by SARS-CoV-2 for cell entry [11].", [["alveolar epithelial cells", "ANATOMY", 59, 84], ["lung samples", "ANATOMY", 96, 108], ["cell", "ANATOMY", 209, 213], ["alveolar epithelial cells", "CELL", 59, 84], ["lung samples", "CANCER", 96, 108], ["children", "ORGANISM", 120, 128], ["ACE2", "GENE_OR_GENE_PRODUCT", 152, 156], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 161, 168], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 194, 204], ["cell", "CELL", 209, 213], ["alveolar epithelial cells", "CELL_TYPE", 59, 84], ["ACE2", "DNA", 152, 156], ["TMPRSS2", "DNA", 161, 168], ["children", "SPECIES", 120, 128], ["A recent study", "TEST", 0, 14], ["alveolar epithelial cells", "PROBLEM", 59, 84], ["lung samples", "PROBLEM", 96, 108], ["ACE2 and TMPRSS2)", "TREATMENT", 152, 169], ["cell entry", "TEST", 209, 219], ["alveolar epithelial cells", "OBSERVATION", 59, 84], ["lung", "ANATOMY", 96, 100]]], ["Therefore, children may be more resistant to SARS-CoV-2 infection at a cellular level.DISCUSSIONOur data from SARS-CoV-2 screen testing performed at educational settings show that ensuring children with acute respiratory symptoms stay away from school, immediately from the first day of symptom onset, could be effective in preventing transmission of SARS-CoV-2.", [["cellular", "ANATOMY", 71, 79], ["respiratory", "ANATOMY", 209, 220], ["SARS", "DISEASE", 45, 49], ["infection", "DISEASE", 56, 65], ["SARS", "DISEASE", 351, 355], ["children", "ORGANISM", 11, 19], ["SARS-CoV-2", "ORGANISM", 45, 55], ["cellular", "CELL", 71, 79], ["children", "ORGANISM", 189, 197], ["SARS-CoV-2", "ORGANISM", 351, 361], ["children", "SPECIES", 11, 19], ["children", "SPECIES", 189, 197], ["SARS-CoV", "SPECIES", 351, 359], ["SARS", "PROBLEM", 45, 49], ["CoV-2 infection", "PROBLEM", 50, 65], ["CoV-2 screen testing", "TEST", 115, 135], ["acute respiratory symptoms", "PROBLEM", 203, 229], ["infection", "OBSERVATION", 56, 65]]], ["Blanket school closures may not be necessary to mitigate the risk of COVID-19 outbreaks in educational settings.", [["Blanket school closures", "TREATMENT", 0, 23], ["COVID", "TEST", 69, 74]]], ["School closures are associated with community-wide socioeconomic impact beyond the educational needs of children (eg, parents need to take leave from work to care for their house-bound children) [12].", [["children", "ORGANISM", 104, 112], ["children", "ORGANISM", 185, 193], ["children", "SPECIES", 104, 112], ["children", "SPECIES", 185, 193]]], ["They could even propagate the transmission of SARS-CoV-2, as unsupervised children can increase social activities in the community instead of practicing social distancing.", [["SARS", "DISEASE", 46, 50], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["SARS-CoV", "SPECIES", 46, 54]]], ["These findings could help inform exit strategies for current lockdowns.", [["current lockdowns", "TREATMENT", 53, 70]]], ["Allowing schools to reopen while maintaining other social distancing measures would have major advantages in terms of supporting essential workers, especially healthcare workers with children.DISCUSSIONIn the study, the mean interval between last exposure and NP swab sample date of contacts ranged from 5 to 11 days.", [["swab sample", "ANATOMY", 263, 274], ["children", "ORGANISM", 183, 191], ["children", "SPECIES", 183, 191], ["the study", "TEST", 205, 214], ["NP swab", "TEST", 260, 267]]], ["However, it was unlikely that timing of sample collection would have missed infected cases, since available viral load studies have shown both early viral load peaks and long duration of polymerase chain reaction (PCR) detection, especially in children [1, 6].", [["sample", "ANATOMY", 40, 46], ["children", "ORGANISM", 244, 252], ["children", "SPECIES", 244, 252], ["sample collection", "PROBLEM", 40, 57], ["infected cases", "PROBLEM", 76, 90], ["available viral load studies", "TEST", 98, 126], ["early viral load peaks", "PROBLEM", 143, 165], ["polymerase chain reaction", "PROBLEM", 187, 212], ["early", "OBSERVATION_MODIFIER", 143, 148], ["viral load peaks", "OBSERVATION", 149, 165]]], ["No serology was performed to assess the true burden of infection.", [["infection", "DISEASE", 55, 64], ["serology", "TEST", 3, 11], ["infection", "PROBLEM", 55, 64], ["infection", "OBSERVATION", 55, 64]]], ["High levels of herd immunity from asymptomatic transmission in children could have affected the findings, but this was unlikely in view of the very low number of pediatric cases detected in Singapore following a coordinated major containment effort in place since January 2020.", [["herd", "ORGANISM_SUBDIVISION", 15, 19], ["children", "ORGANISM", 63, 71], ["children", "SPECIES", 63, 71]]], ["Approximately 40% of symptomatic contacts were additionally tested via multiplex PCR and, of these, about half were positive for other viral respiratory pathogens (rhinovirus, adenovirus, and metapneumovirus).DISCUSSIONIn conclusion, our data suggest that children are not the primary drivers of SARS-CoV-2 transmission in schools, especially preschools.", [["respiratory pathogens", "DISEASE", 141, 162], ["rhinovirus, adenovirus, and metapneumovirus", "DISEASE", 164, 207], ["SARS", "DISEASE", 296, 300], ["rhinovirus", "ORGANISM", 164, 174], ["adenovirus", "ORGANISM", 176, 186], ["metapneumovirus", "ORGANISM", 192, 207], ["children", "ORGANISM", 256, 264], ["SARS-CoV-2", "ORGANISM", 296, 306], ["children", "SPECIES", 256, 264], ["SARS-CoV", "SPECIES", 296, 304], ["symptomatic contacts", "PROBLEM", 21, 41], ["multiplex PCR", "TEST", 71, 84], ["other viral respiratory pathogens", "PROBLEM", 129, 162], ["rhinovirus", "PROBLEM", 164, 174], ["adenovirus", "PROBLEM", 176, 186], ["metapneumovirus", "PROBLEM", 192, 207]]], ["We found that SARS-CoV-2 transmission among children in schools appears to be significantly lower than that observed for other respiratory viruses, such as influenza.", [["SARS", "DISEASE", 14, 18], ["respiratory viruses", "DISEASE", 127, 146], ["influenza", "DISEASE", 156, 165], ["SARS-CoV-2", "ORGANISM", 14, 24], ["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["other respiratory viruses", "PROBLEM", 121, 146], ["influenza", "PROBLEM", 156, 165], ["SARS", "OBSERVATION", 14, 18], ["respiratory", "ANATOMY", 127, 138], ["viruses", "OBSERVATION", 139, 146]]], ["This could help inform strategies for lifting of current lockdowns.", [["current lockdowns", "TREATMENT", 49, 66]]], ["Based on these findings, more targeted control measures for preschool settings such as keeping symptomatic children away from schools, instead of blanket closures, could be considered.", [["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115], ["these findings", "TEST", 9, 23], ["preschool settings", "TREATMENT", 60, 78], ["blanket closures", "TREATMENT", 146, 162]]]], "PMC7087872": [["IntroductionEmulsions (or collections of isolated droplets surrounded by a continuous and immiscible carrier fluid) have long been used in chemical and biological experimentation, with the millions of contained droplets serving as isolated vessels in which reactions or assays may be performed (Fig. 1a) (Griffiths and Tawfik 2006).", [["droplets", "ANATOMY", 50, 58], ["vessels", "ANATOMY", 240, 247], ["vessels", "MULTI-TISSUE_STRUCTURE", 240, 247], ["IntroductionEmulsions", "TREATMENT", 0, 21], ["isolated droplets", "PROBLEM", 41, 58], ["a continuous and immiscible carrier fluid)", "TREATMENT", 73, 115], ["assays", "TEST", 270, 276], ["vessels", "ANATOMY", 240, 247]]], ["The use of bulk shear forces, although efficient in making large numbers of droplets on short timescales, generates polydisperse droplet populations that prohibit quantitative experimentation (Huebner et al. 2007; Pekin et al. 2011; Juul et al. 2012).", [["bulk shear forces", "TREATMENT", 11, 28], ["polydisperse droplet populations", "TREATMENT", 116, 148], ["bulk shear forces", "OBSERVATION", 11, 28], ["large", "OBSERVATION_MODIFIER", 59, 64], ["numbers", "OBSERVATION_MODIFIER", 65, 72], ["polydisperse", "OBSERVATION_MODIFIER", 116, 128], ["droplet populations", "OBSERVATION", 129, 148]]], ["Conversely, and as will be shown subsequently, flow-based microfluidic systems can be used to generate similarly large numbers of droplets, but with an unprecedented degree of control over droplet size.", [["large", "OBSERVATION_MODIFIER", 113, 118], ["numbers", "OBSERVATION_MODIFIER", 119, 126], ["size", "OBSERVATION_MODIFIER", 197, 201]]], ["These features combined with the facility to adjust the chemical or biological payload at will make microfluidic droplets highly promising vehicles for large-scale biological experimentation.", [["the chemical", "TREATMENT", 52, 64], ["biological payload", "TREATMENT", 68, 86], ["microfluidic droplets", "TREATMENT", 100, 121]]]], "ed276d222dcdee71e13c0b46fdb9c70f06d5fcd9": [["T he risk of a pandemic human influenza strain emerging from coinfection of a human influenza carrier by avian influenza H5N1 virus is small (1); however, the potential global public health impact could be catastrophic.", [["influenza", "DISEASE", 30, 39], ["coinfection", "DISEASE", 61, 72], ["influenza", "DISEASE", 84, 93], ["avian influenza H5N1 virus", "DISEASE", 105, 131], ["human", "ORGANISM", 24, 29], ["human", "ORGANISM", 78, 83], ["avian influenza H5N1 virus", "ORGANISM", 105, 131], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 78, 83], ["avian influenza H5N1 virus", "SPECIES", 105, 131], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 78, 83], ["H5N1 virus", "SPECIES", 121, 131], ["a pandemic human influenza strain", "PROBLEM", 13, 46], ["a human influenza carrier", "TREATMENT", 76, 101], ["avian influenza H5N1 virus", "PROBLEM", 105, 131], ["catastrophic", "PROBLEM", 206, 218], ["small", "OBSERVATION_MODIFIER", 135, 140], ["catastrophic", "OBSERVATION_MODIFIER", 206, 218]]], ["The circumstances that would facilitate events of low probability may be highly prevalent, which increases the public health importance of such potential events.", [["low probability", "PROBLEM", 50, 65]]], ["Modern travel and transportation links would distribute a new human-transmissible influenza strain worldwide within days and overwhelm most healthcare systems within weeks.", [["influenza", "DISEASE", 82, 91], ["human", "ORGANISM", 62, 67], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["a new human-transmissible influenza strain", "PROBLEM", 56, 98]]]], "PMC6403333": [["IntroductionParasitic diseases not only cause millions of deaths per year, but also have serious health and economic consequences1.", [["IntroductionParasitic diseases", "DISEASE", 0, 30], ["deaths", "DISEASE", 58, 64], ["IntroductionParasitic diseases", "PROBLEM", 0, 30]]], ["Among all the parasitic diseases, protozoan parasites of the family Trypanosomatidae are responsible for devastating diseases in humans, dogs as well as livestock, resulting in severe illness or even death if left untreated1,2.", [["parasitic diseases", "DISEASE", 14, 32], ["protozoan parasites", "DISEASE", 34, 53], ["illness", "DISEASE", 184, 191], ["death", "DISEASE", 200, 205], ["Trypanosomatidae", "GENE_OR_GENE_PRODUCT", 68, 84], ["humans", "ORGANISM", 129, 135], ["dogs", "ORGANISM", 137, 141], ["humans", "SPECIES", 129, 135], ["dogs", "SPECIES", 137, 141], ["humans", "SPECIES", 129, 135], ["the parasitic diseases", "PROBLEM", 10, 32], ["protozoan parasites", "PROBLEM", 34, 53], ["devastating diseases in humans", "PROBLEM", 105, 135], ["severe illness", "PROBLEM", 177, 191], ["parasitic", "OBSERVATION_MODIFIER", 14, 23], ["diseases", "OBSERVATION", 24, 32], ["protozoan parasites", "OBSERVATION", 34, 53], ["responsible for", "UNCERTAINTY", 89, 104]]], ["The protozoa Trypanosoma cruzi (T. cruzi) and Leishmania spp. are the causative agents of Chagas disease and Leishmaniasis respectively3.", [["protozoa Trypanosoma cruzi", "DISEASE", 4, 30], ["Leishmania spp.", "DISEASE", 46, 61], ["Chagas disease", "DISEASE", 90, 104], ["Leishmaniasis", "DISEASE", 109, 122], ["protozoa", "ORGANISM", 4, 12], ["Trypanosoma cruzi", "ORGANISM", 13, 30], ["T. cruzi", "ORGANISM", 32, 40], ["Leishmania spp.", "ORGANISM", 46, 61], ["Trypanosoma cruzi", "SPECIES", 13, 30], ["T. cruzi", "SPECIES", 32, 40], ["Leishmania spp.", "SPECIES", 46, 61], ["Trypanosoma cruzi", "SPECIES", 13, 30], ["T. cruzi", "SPECIES", 32, 40], ["Leishmania spp.", "SPECIES", 46, 61], ["The protozoa Trypanosoma cruzi (T. cruzi)", "PROBLEM", 0, 41], ["Leishmania spp.", "PROBLEM", 46, 61], ["Chagas disease", "PROBLEM", 90, 104], ["Leishmaniasis", "PROBLEM", 109, 122], ["protozoa", "OBSERVATION_MODIFIER", 4, 12], ["Trypanosoma cruzi", "OBSERVATION", 13, 30], ["Chagas disease", "OBSERVATION", 90, 104], ["Leishmaniasis", "OBSERVATION", 109, 122]]], ["Even though these diseases are endemic in tropical and sub-tropical regions of the world, in the last decades there has been a re-emergence also in developed countries, with international travel being responsible for increases in reported cases of Trypanosomatidae infections in non-endemic countries1,4.", [["Trypanosomatidae infections", "DISEASE", 248, 275], ["these diseases", "PROBLEM", 12, 26], ["Trypanosomatidae infections", "PROBLEM", 248, 275], ["diseases", "OBSERVATION", 18, 26], ["endemic", "OBSERVATION_MODIFIER", 31, 38], ["tropical", "OBSERVATION_MODIFIER", 42, 50], ["sub", "OBSERVATION_MODIFIER", 55, 58], ["tropical", "ANATOMY_MODIFIER", 59, 67], ["regions", "ANATOMY_MODIFIER", 68, 75], ["Trypanosomatidae infections", "OBSERVATION", 248, 275]]], ["Consequently, these parasitic infections have become a more important public health issue of global relevance.", [["parasitic infections", "DISEASE", 20, 40], ["these parasitic infections", "PROBLEM", 14, 40], ["parasitic", "OBSERVATION_MODIFIER", 20, 29], ["infections", "OBSERVATION", 30, 40]]], ["Even though there are several methods available for the screening of parasitic infections, however, they have not yet changed dramatically the diagnosis in developing countries.", [["parasitic infections", "DISEASE", 69, 89], ["the screening", "TEST", 52, 65], ["parasitic infections", "PROBLEM", 69, 89], ["parasitic", "OBSERVATION_MODIFIER", 69, 78], ["infections", "OBSERVATION", 79, 89]]], ["Microscopic identification and parasite cultivation are still the primary diagnostic tools employed in many regions where Leishmaniasis is endemic5.", [["Leishmaniasis", "DISEASE", 122, 135], ["Microscopic identification", "TEST", 0, 26], ["parasite cultivation", "PROBLEM", 31, 51], ["Leishmaniasis", "PROBLEM", 122, 135], ["parasite cultivation", "OBSERVATION", 31, 51], ["Leishmaniasis", "OBSERVATION", 122, 135]]], ["On the other hand, standard serological approaches that could potentially prove to be timely and cost effective for diagnosing parasitic infections are of limited value, as most patients do not develop a significant antibody response7.", [["parasitic infections", "DISEASE", 127, 147], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["diagnosing parasitic infections", "PROBLEM", 116, 147], ["a significant antibody response7", "PROBLEM", 202, 234], ["significant", "OBSERVATION_MODIFIER", 204, 215], ["antibody", "OBSERVATION", 216, 224]]], ["In addition, and problematically for clinicians attempting to make an accurate diagnosis, T. cruzi and Leishmania spp. share various antigens that cause cross-reactivity in serological diagnosis when complex antigenic mixtures are used8.", [["T. cruzi", "DISEASE", 90, 98], ["T. cruzi", "ORGANISM", 90, 98], ["Leishmania spp", "ORGANISM", 103, 117], ["antigens", "PROTEIN", 133, 141], ["T. cruzi", "SPECIES", 90, 98], ["T. cruzi", "SPECIES", 90, 98], ["T. cruzi and Leishmania spp", "PROBLEM", 90, 117], ["complex antigenic mixtures", "PROBLEM", 200, 226], ["Leishmania spp", "OBSERVATION", 103, 117]]], ["As a result, Nucleic Acid Testing (NAT) methodologies have become valuable methods for the routine and accurate assessment of parasitic infectious diseases.", [["parasitic infectious diseases", "DISEASE", 126, 155], ["Nucleic Acid", "SIMPLE_CHEMICAL", 13, 25], ["Nucleic Acid Testing", "TEST", 13, 33], ["the routine", "TEST", 87, 98], ["accurate assessment", "TEST", 103, 122], ["parasitic infectious diseases", "PROBLEM", 126, 155], ["parasitic", "OBSERVATION_MODIFIER", 126, 135], ["infectious", "OBSERVATION", 136, 146]]], ["NAT benefits from the presence of specific nucleic acid fragments for determining the presence/absence of pathogens3,9\u201313.", [["nucleic acid", "CHEMICAL", 43, 55], ["specific nucleic acid fragments", "PROBLEM", 34, 65], ["pathogens", "PROBLEM", 106, 115], ["acid fragments", "OBSERVATION", 51, 65]]], ["There are different methods ranging from probe hybridization, amplification of genomic targets and sequencing of nucleic acid fragments.", [["nucleic acid", "CHEMICAL", 113, 125], ["nucleic acid fragments", "PROTEIN", 113, 135], ["different methods", "PROBLEM", 10, 27], ["probe hybridization", "TEST", 41, 60], ["genomic targets", "TREATMENT", 79, 94], ["nucleic acid fragments", "PROBLEM", 113, 135], ["different", "OBSERVATION_MODIFIER", 10, 19], ["nucleic", "OBSERVATION", 113, 120], ["acid fragments", "OBSERVATION", 121, 135]]], ["The use of Nucleic Acid Amplification Techniques (NAATs) such as Polymerase Chain Reaction (PCR), real-time PCR or Nucleic Acid Sequence Based Amplification (NASBA) can be very useful in detecting infections and post-treatment monitoring9,13,14, including detection and distinguishing of parasites using single base resolution methods such as Single Base Extension (SBE).", [["infections", "DISEASE", 197, 207], ["Nucleic Acid Amplification Techniques (NAATs)", "TREATMENT", 11, 56], ["Polymerase Chain Reaction (PCR", "TREATMENT", 65, 95], ["real-time PCR", "TEST", 98, 111], ["Nucleic Acid Sequence", "TREATMENT", 115, 136], ["post-treatment monitoring9", "TEST", 212, 238], ["detection", "TEST", 256, 265], ["parasites", "PROBLEM", 288, 297], ["single base resolution methods", "TREATMENT", 304, 334]]], ["Primers are designed to hybridize to a complementary nucleic acid region such that the 3\u2032 end of the primer finishes immediately before the nucleotide under interrogation15.", [["nucleic acid", "CHEMICAL", 53, 65], ["nucleotide", "CHEMICAL", 140, 150], ["nucleotide", "CHEMICAL", 140, 150], ["complementary nucleic acid region", "DNA", 39, 72], ["3\u2032 end", "DNA", 87, 93], ["a complementary nucleic acid region", "PROBLEM", 37, 72]]], ["However, while NAT has the advantage of being sensitive, there are some limitations, as the NAT methodologies have complex protocols, require technical expertise to run and interpret data (not cost-effective), and utilize equipment that is incompatible with use in remote and low-resource locations, such as developing countries where diagnostic laboratories are often poorly resourced and sparsely distributed16.", [["complex protocols", "TREATMENT", 115, 132], ["diagnostic laboratories", "TEST", 335, 358]]], ["Thus, there is an urgent need for early detection of infectious disease with improved, simple and low-cost alternative tests not requiring expensive laboratory equipment to be performed.", [["infectious disease", "DISEASE", 53, 71], ["infectious disease", "PROBLEM", 53, 71], ["simple and low-cost alternative tests", "PROBLEM", 87, 124], ["expensive laboratory equipment", "TREATMENT", 139, 169], ["infectious", "OBSERVATION", 53, 63]]], ["To sum up, while laboratory-based models require benchtop laboratory facilities and complex procedures, Point-of-Care testing allows a more decentralized diagnostic analysis with additional advantages such as portability, automation, shorter time-to-results and lower cost17\u201319.", [["complex procedures", "TREATMENT", 84, 102], ["diagnostic analysis", "TEST", 154, 173], ["automation", "TEST", 222, 232]]], ["The World Health Organization (WHO) is consistently encouraging developers to implement these new diagnostic technologies for improved effective clinical management and treatment of the major infections suitable in developing countries context20,21.", [["infections", "DISEASE", 192, 202], ["clinical management", "TREATMENT", 145, 164], ["treatment", "TREATMENT", 169, 178], ["the major infections", "PROBLEM", 182, 202], ["major", "OBSERVATION_MODIFIER", 186, 191], ["infections", "OBSERVATION", 192, 202]]], ["Following this encouragement, Zhang et al. recently developed a low-cost CRISPR-based diagnostic (CRISPR-Dx) for detecting DNA or RNA molecules of pathogenic species with single mismatch specificity24,25.IntroductionBesides the tests available today19,26, our group has recently reported the successful detection and differentiation of three Trypanosomatids species, by detecting Single Nucleotide Fingerprint (SNF) markers using a dynamic chemical approach for nucleic acid reading (ChemNAT technology)27,28 in combination with MALDI-ToF29.", [["nucleic acid", "CHEMICAL", 462, 474], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["nucleic acid", "SIMPLE_CHEMICAL", 462, 474], ["CRISPR", "DNA", 73, 79], ["CRISPR", "DNA", 98, 104], ["Dx", "DNA", 105, 107], ["Single Nucleotide Fingerprint (SNF) markers", "PROTEIN", 380, 423], ["ToF29", "PROTEIN", 535, 540], ["a low-cost CRISPR", "PROBLEM", 62, 79], ["DNA", "PROBLEM", 123, 126], ["RNA molecules of pathogenic species", "PROBLEM", 130, 165], ["single mismatch specificity", "TEST", 171, 198], ["the tests", "TEST", 224, 233], ["three Trypanosomatids species", "PROBLEM", 336, 365], ["Single Nucleotide Fingerprint (SNF)", "TREATMENT", 380, 415], ["a dynamic chemical approach", "TREATMENT", 430, 457], ["nucleic acid", "TEST", 462, 474], ["low", "OBSERVATION_MODIFIER", 64, 67], ["pathogenic species", "OBSERVATION", 147, 165], ["Trypanosomatids species", "OBSERVATION", 342, 365]]], ["SNF markers are single nucleotide variations that occur at specific positions in conserved target nucleic acid sequences, allowing the differentiation of pathogenic species.", [["nucleic acid", "CHEMICAL", 98, 110], ["SNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["SNF markers", "PROTEIN", 0, 11], ["conserved target nucleic acid sequences", "DNA", 81, 120], ["SNF markers", "TREATMENT", 0, 11], ["single nucleotide variations", "PROBLEM", 16, 44], ["target nucleic acid sequences", "TEST", 91, 120], ["pathogenic species", "PROBLEM", 154, 172], ["markers", "OBSERVATION", 4, 11], ["pathogenic species", "OBSERVATION", 154, 172]]], ["As a result, these SNF represents the perfect target to be interrogated by the ChemNAT technology through the specific dynamic incorporation of aldehyde-modified SMART-Nucleobases into the abasic position of abasic PNA probes.", [["aldehyde", "CHEMICAL", 144, 152], ["aldehyde", "CHEMICAL", 144, 152], ["aldehyde", "SIMPLE_CHEMICAL", 144, 152], ["PNA", "SIMPLE_CHEMICAL", 215, 218], ["SNF", "DNA", 19, 22], ["aldehyde-modified SMART-Nucleobases", "PROTEIN", 144, 179], ["aldehyde-modified SMART-Nucleobases", "TREATMENT", 144, 179], ["abasic PNA probes", "PROBLEM", 208, 225], ["abasic", "OBSERVATION_MODIFIER", 208, 214], ["PNA", "OBSERVATION", 215, 218]]], ["Despite its high specificity, the use of this method has limitations, with higher cost and complex instrumentation (MALDI-ToF) required, making this approach unsuitable for diagnosis of parasitic infections in developing countries.IntroductionHere, we report the adaptation of our previous method onto a colorimetric reverse dot-blot30\u201335 assay that has the potential to fulfil the WHO ASSURED criteria, for the diagnosis of Leishmaniasis and Chagas disease.", [["parasitic infections", "DISEASE", 186, 206], ["Leishmaniasis", "DISEASE", 425, 438], ["Chagas disease", "DISEASE", 443, 457], ["this method", "TREATMENT", 41, 52], ["higher cost and complex instrumentation (MALDI-ToF)", "TREATMENT", 75, 126], ["parasitic infections", "PROBLEM", 186, 206], ["a colorimetric reverse dot-blot", "TEST", 302, 333], ["Leishmaniasis", "PROBLEM", 425, 438], ["Chagas disease", "PROBLEM", 443, 457], ["high specificity", "OBSERVATION_MODIFIER", 12, 28], ["parasitic", "OBSERVATION_MODIFIER", 186, 195], ["infections", "OBSERVATION", 196, 206], ["Leishmaniasis", "OBSERVATION", 425, 438], ["Chagas disease", "OBSERVATION", 443, 457]]], ["This novel method combines ChemNAT technology with a simple colorimetric end-point assay on a porous nylon membrane contained within a micro Spin-Tube device (Spin-Tube).", [["nylon membrane", "ANATOMY", 101, 115], ["a porous nylon membrane", "TREATMENT", 92, 115], ["a micro Spin-Tube device (Spin-Tube", "TREATMENT", 133, 168], ["nylon membrane", "OBSERVATION", 101, 115], ["Tube device", "OBSERVATION", 146, 157]]], ["The assay uses a singleplex PCR to amplify a highly conserved sequence of DNA, which encodes the RNA component of the large ribosome subunit with SNF markers for the two different parasite species under interrogation.", [["DNA", "CELLULAR_COMPONENT", 74, 77], ["singleplex PCR", "DNA", 17, 31], ["ribosome subunit", "PROTEIN", 124, 140], ["SNF markers", "PROTEIN", 146, 157], ["The assay", "TEST", 0, 9], ["a singleplex PCR", "TREATMENT", 15, 31], ["DNA", "PROBLEM", 74, 77], ["SNF markers", "TREATMENT", 146, 157], ["the two different parasite species", "PROBLEM", 162, 196], ["large", "OBSERVATION_MODIFIER", 118, 123], ["ribosome subunit", "OBSERVATION", 124, 140], ["parasite species", "OBSERVATION", 180, 196]]], ["This amplicon is later interrogated by the ChemNAT technology that relies on a dynamic chemical approach for nucleic acid testing.", [["nucleic acid", "CHEMICAL", 109, 121], ["nucleic acid", "SIMPLE_CHEMICAL", 109, 121], ["nucleic acid testing", "TEST", 109, 129]]], ["As shown in Fig. 1, the SNF sequence analysis is based on combining biotinylated aldehyde-modified cytosine (SMART-C-Biotin) with unique abasic PNA probes to target PCR amplicon strands, such that a nucleobase-free position on the PNA strand (known as \u2018abasic\u2019 position) lies opposite to two different nucleotides under interrogation on the DNA amplicons.", [["aldehyde", "CHEMICAL", 81, 89], ["cytosine", "CHEMICAL", 99, 107], ["SMART-C-Biotin", "CHEMICAL", 109, 123], ["nucleobase", "CHEMICAL", 199, 209], ["aldehyde", "CHEMICAL", 81, 89], ["cytosine", "CHEMICAL", 99, 107], ["C-Biotin", "CHEMICAL", 115, 123], ["nucleobase", "CHEMICAL", 199, 209], ["nucleotides", "CHEMICAL", 302, 313], ["aldehyde", "SIMPLE_CHEMICAL", 81, 89], ["cytosine", "SIMPLE_CHEMICAL", 99, 107], ["SMART-C-Biotin", "SIMPLE_CHEMICAL", 109, 123], ["DNA", "CELLULAR_COMPONENT", 341, 344], ["SNF sequence", "DNA", 24, 36], ["PCR amplicon strands", "DNA", 165, 185], ["PNA strand", "DNA", 231, 241], ["DNA amplicons", "DNA", 341, 354], ["the SNF sequence analysis", "TEST", 20, 45], ["combining biotinylated aldehyde", "TREATMENT", 58, 89], ["modified cytosine", "TREATMENT", 90, 107], ["SMART-C-Biotin)", "TREATMENT", 109, 124], ["unique abasic PNA probes", "TREATMENT", 130, 154], ["target PCR amplicon strands", "PROBLEM", 158, 185], ["a nucleobase", "TREATMENT", 197, 209], ["the PNA strand", "PROBLEM", 227, 241], ["the DNA amplicons", "TREATMENT", 337, 354], ["PNA", "OBSERVATION", 144, 147], ["PNA", "OBSERVATION", 231, 234]]], ["A reversible reaction between the SMART-C-Biotin and a free secondary amine on the abasic PNA probes generates an iminium intermediate, which can be chemically reduced to a stable tertiary amine.", [["SMART-C-Biotin", "CHEMICAL", 34, 48], ["amine", "CHEMICAL", 70, 75], ["iminium", "CHEMICAL", 114, 121], ["amine", "CHEMICAL", 189, 194], ["C-Biotin", "CHEMICAL", 40, 48], ["secondary amine", "CHEMICAL", 60, 75], ["iminium", "CHEMICAL", 114, 121], ["tertiary amine", "CHEMICAL", 180, 194], ["SMART-C-Biotin", "SIMPLE_CHEMICAL", 34, 48], ["secondary amine", "SIMPLE_CHEMICAL", 60, 75], ["iminium", "SIMPLE_CHEMICAL", 114, 121], ["tertiary amine", "SIMPLE_CHEMICAL", 180, 194], ["A reversible reaction", "PROBLEM", 0, 21], ["the SMART", "TEST", 30, 39], ["Biotin", "TREATMENT", 42, 48], ["a free secondary amine", "TREATMENT", 53, 75], ["the abasic PNA probes", "TREATMENT", 79, 100], ["reversible", "OBSERVATION_MODIFIER", 2, 12], ["reaction", "OBSERVATION", 13, 21], ["abasic", "OBSERVATION_MODIFIER", 83, 89], ["PNA", "OBSERVATION", 90, 93], ["iminium intermediate", "OBSERVATION", 114, 134], ["stable", "OBSERVATION_MODIFIER", 173, 179]]], ["Within the novel Spin-Tube, the dynamic chemistry reaction mixture is added to the nylon membranes on which the abasic PNA probes have been immobilized following a specific spot pattern (Fig. 1, Step 1).", [["nylon membranes", "ANATOMY", 83, 98], ["nylon", "CHEMICAL", 83, 88], ["membranes", "CELLULAR_COMPONENT", 89, 98], ["the dynamic chemistry reaction mixture", "TREATMENT", 28, 66], ["the nylon membranes", "TREATMENT", 79, 98], ["the abasic PNA probes", "TREATMENT", 108, 129], ["Tube", "OBSERVATION", 22, 26], ["nylon membranes", "OBSERVATION", 83, 98], ["abasic", "OBSERVATION_MODIFIER", 112, 118], ["PNA", "OBSERVATION", 119, 122]]], ["The PCR amplicons act as template molecules and drive the specific incorporation of SMART-C-Biotin molecules into a specific abasic PNA according to Watson-Crick DNA base pairing model in which the SMART-Cytosine, in this case carrying a biotin tag, is ONLY recognized by a guanidine nucleotide (Fig. 1, Step 2).", [["Cytosine", "CHEMICAL", 204, 212], ["guanidine nucleotide", "CHEMICAL", 274, 294], ["Cytosine", "CHEMICAL", 204, 212], ["biotin", "CHEMICAL", 238, 244], ["guanidine nucleotide", "CHEMICAL", 274, 294], ["SMART-C", "GENE_OR_GENE_PRODUCT", 84, 91], ["DNA", "CELLULAR_COMPONENT", 162, 165], ["Cytosine", "SIMPLE_CHEMICAL", 204, 212], ["biotin", "SIMPLE_CHEMICAL", 238, 244], ["ONLY", "SIMPLE_CHEMICAL", 253, 257], ["guanidine nucleotide", "SIMPLE_CHEMICAL", 274, 294], ["PCR amplicons", "DNA", 4, 17], ["SMART-C-Biotin molecules", "PROTEIN", 84, 108], ["SMART", "DNA", 198, 203], ["biotin tag", "DNA", 238, 248], ["The PCR amplicons", "TREATMENT", 0, 17], ["SMART", "TEST", 84, 89], ["Biotin molecules", "PROBLEM", 92, 108], ["a specific abasic PNA", "PROBLEM", 114, 135], ["the SMART-Cytosine", "TREATMENT", 194, 212], ["a biotin tag", "PROBLEM", 236, 248], ["a guanidine nucleotide (Fig", "TREATMENT", 272, 299], ["PNA", "OBSERVATION", 132, 135], ["biotin tag", "OBSERVATION", 238, 248]]], ["The labelling is then achieved by streptavidin alkaline phosphatase (Streptavidin-ALP) to produce colorimetric signal (blue precipitate) patterns when the chromogenic substrate (NBT/BCIP, nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-indolyl phosphate) is added.", [["NBT", "CHEMICAL", 178, 181], ["nitro blue tetrazolium chloride", "CHEMICAL", 188, 219], ["5-Bromo-4-chloro-3-indolyl phosphate", "CHEMICAL", 220, 256], ["NBT", "CHEMICAL", 178, 181], ["BCIP", "CHEMICAL", 182, 186], ["nitro blue tetrazolium chloride", "CHEMICAL", 188, 219], ["5-Bromo-4-chloro-3-indolyl phosphate", "CHEMICAL", 220, 256], ["streptavidin alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 34, 67], ["Streptavidin-ALP", "GENE_OR_GENE_PRODUCT", 69, 85], ["NBT", "SIMPLE_CHEMICAL", 178, 181], ["BCIP", "SIMPLE_CHEMICAL", 182, 186], ["nitro blue tetrazolium chloride", "SIMPLE_CHEMICAL", 188, 219], ["5-Bromo-4-chloro-3-indolyl phosphate", "SIMPLE_CHEMICAL", 220, 256], ["streptavidin alkaline phosphatase", "PROTEIN", 34, 67], ["Streptavidin", "PROTEIN", 69, 81], ["ALP", "PROTEIN", 82, 85], ["streptavidin alkaline phosphatase", "TEST", 34, 67], ["colorimetric signal (blue precipitate) patterns", "PROBLEM", 98, 145], ["the chromogenic substrate", "TEST", 151, 176], ["NBT", "TEST", 178, 181], ["BCIP", "TEST", 182, 186], ["nitro blue tetrazolium chloride", "TREATMENT", 188, 219], ["Bromo", "TREATMENT", 222, 227], ["chloro-3-indolyl phosphate)", "TREATMENT", 230, 257]]], ["Each parasite gives a unique colored spot pattern that can be read by naked-eye (Fig. 1, step 3).Conserved region amplification and abasic probes design ::: Results and DiscussionPCR amplification was carried out to amplify the conserved region encoding for the 28S ribosomal RNA delta genes.", [["eye", "ANATOMY", 76, 79], ["eye", "ORGAN", 76, 79], ["28S ribosomal RNA delta", "GENE_OR_GENE_PRODUCT", 262, 285], ["28S ribosomal RNA delta genes", "DNA", 262, 291], ["a unique colored spot pattern", "PROBLEM", 20, 49], ["DiscussionPCR amplification", "TEST", 169, 196], ["eye", "ANATOMY", 76, 79], ["ribosomal RNA", "OBSERVATION", 266, 279], ["delta genes", "OBSERVATION", 280, 291]]], ["As shown from the multiple sequence alignment in Fig. 2A, the PCR amplification of the target sequence was performed using a single pair of primers (singleplex PCR) which amplifies any of the parasite species present in the sample.", [["sample", "ANATOMY", 224, 230], ["the multiple sequence alignment", "TEST", 14, 45], ["the PCR amplification", "TEST", 58, 79], ["the target sequence", "TEST", 83, 102], ["a single pair of primers", "TREATMENT", 123, 147], ["singleplex PCR", "TEST", 149, 163], ["the parasite species", "PROBLEM", 188, 208], ["parasite species", "OBSERVATION", 192, 208]]], ["The target region is highly conserved among the TrypanosomatidsT. cruzi and L. major, except for five SNFs.", [["cruzi", "ORGANISM", 66, 71], ["L. major", "ORGANISM", 76, 84], ["TrypanosomatidsT", "DNA", 48, 64], ["cruzi", "SPECIES", 66, 71], ["cruzi", "SPECIES", 66, 71], ["cruzi", "PROBLEM", 66, 71], ["L.", "OBSERVATION_MODIFIER", 76, 78], ["major", "OBSERVATION_MODIFIER", 79, 84]]], ["Amplified fragment analysis was performed using the previously described Spin-Tube.", [["Amplified fragment analysis", "TEST", 0, 27], ["the previously described Spin-Tube", "TREATMENT", 48, 82], ["Tube", "OBSERVATION", 78, 82]]], ["Briefly, abasic PNA probes, PNA1 and PNA2 were designed in order to hybridize efficiently with the amplified single strand sense DNA, with the important particularity that the abasic positions in the PNA probes are opposing the nucleobases under interrogation.", [["PNA1", "SIMPLE_CHEMICAL", 28, 32], ["PNA2", "SIMPLE_CHEMICAL", 37, 41], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["abasic PNA probes", "DNA", 9, 26], ["PNA1", "DNA", 28, 32], ["PNA2", "DNA", 37, 41], ["amplified single strand sense DNA", "DNA", 99, 132], ["PNA probes", "DNA", 200, 210], ["abasic PNA probes", "PROBLEM", 9, 26], ["PNA1", "PROBLEM", 28, 32], ["PNA2", "TREATMENT", 37, 41], ["the amplified single strand sense DNA", "PROBLEM", 95, 132], ["the PNA probes", "TREATMENT", 196, 210], ["abasic", "OBSERVATION_MODIFIER", 9, 15], ["PNA", "OBSERVATION", 16, 19], ["abasic positions", "OBSERVATION", 176, 192], ["PNA", "OBSERVATION", 200, 203], ["nucleobases", "ANATOMY_MODIFIER", 228, 239]]], ["Once the abasic PNA probes hybridize with target sequences, the SMART-C-Biotin dynamic incorporation takes place, enabling the unequivocal identification of the parasite present in the amplicon sample, because of the unique colorimetric pattern that each Trypanosomatid amplicon generates.", [["sample", "ANATOMY", 194, 200], ["Biotin", "SIMPLE_CHEMICAL", 72, 78], ["abasic PNA probes", "DNA", 9, 26], ["target sequences", "DNA", 42, 58], ["SMART-C", "DNA", 64, 71], ["Trypanosomatid amplicon", "DNA", 255, 278], ["the abasic PNA probes hybridize", "TREATMENT", 5, 36], ["target sequences", "TEST", 42, 58], ["the SMART", "TEST", 60, 69], ["C-Biotin dynamic incorporation", "TREATMENT", 70, 100], ["the parasite", "PROBLEM", 157, 169], ["the amplicon sample", "TEST", 181, 200], ["the unique colorimetric pattern", "PROBLEM", 213, 244], ["PNA", "OBSERVATION", 16, 19], ["parasite", "OBSERVATION", 161, 169], ["Trypanosomatid amplicon", "OBSERVATION", 255, 278]]], ["As shown in Fig. 2B, the abasic PNA1 probe was designed so that its abasic site lies opposite a guanidine nucleotide (at position + 32 of the amplicon), irrespective of the species, so as to give a positive result for both parasites, thus confirming the presence of one or both Trypanosomatids in the sample (see red arrow in Fig. 2A).", [["sample", "ANATOMY", 301, 307], ["guanidine nucleotide", "CHEMICAL", 96, 116], ["guanidine nucleotide", "CHEMICAL", 96, 116], ["PNA1", "GENE_OR_GENE_PRODUCT", 32, 36], ["guanidine nucleotide", "SIMPLE_CHEMICAL", 96, 116], ["abasic PNA1 probe", "DNA", 25, 42], ["abasic site", "DNA", 68, 79], ["the abasic PNA1 probe", "TREATMENT", 21, 42], ["its abasic site", "PROBLEM", 64, 79], ["a guanidine nucleotide", "TREATMENT", 94, 116], ["the amplicon", "TREATMENT", 138, 150], ["the species", "PROBLEM", 169, 180], ["both parasites", "PROBLEM", 218, 232], ["both Trypanosomatids in the sample", "PROBLEM", 273, 307], ["parasites", "OBSERVATION", 223, 232]]], ["At the same time, the abasic PNA2 is the probe that enables discrimination of the Trypanosomatid species.", [["PNA2", "GENE_OR_GENE_PRODUCT", 29, 33], ["abasic PNA2", "DNA", 22, 33], ["the abasic PNA2", "PROBLEM", 18, 33], ["the Trypanosomatid species", "PROBLEM", 78, 104], ["Trypanosomatid species", "OBSERVATION", 82, 104]]], ["As the target parasite T. cruzi has a guanidine at the position that lines up with the \u201cabasic\u201d position in the abasic PNA2 probe (SNF1 in Fig. 2B), the SMART-C-Biotin incorporation is templated, thereby covalently incorporating the biotin tag into the probe attached to the membrane, resulting in a blue spot after applying the labelling and color development protocol.", [["membrane", "ANATOMY", 275, 283], ["guanidine", "CHEMICAL", 38, 47], ["guanidine", "CHEMICAL", 38, 47], ["biotin", "CHEMICAL", 233, 239], ["parasite", "ORGANISM", 14, 22], ["T. cruzi", "ORGANISM", 23, 31], ["guanidine", "SIMPLE_CHEMICAL", 38, 47], ["SMART-C", "GENE_OR_GENE_PRODUCT", 153, 160], ["Biotin", "SIMPLE_CHEMICAL", 161, 167], ["biotin", "SIMPLE_CHEMICAL", 233, 239], ["membrane", "CELLULAR_COMPONENT", 275, 283], ["abasic PNA2 probe", "DNA", 112, 129], ["SNF1", "DNA", 131, 135], ["SMART", "PROTEIN", 153, 158], ["biotin tag", "PROTEIN", 233, 243], ["T. cruzi", "SPECIES", 23, 31], ["T. cruzi", "SPECIES", 23, 31], ["a guanidine", "TREATMENT", 36, 47], ["the \u201cabasic\u201d position", "TREATMENT", 83, 104], ["the abasic PNA2 probe", "TREATMENT", 108, 129], ["the SMART-C-Biotin incorporation", "TREATMENT", 149, 181], ["the biotin tag", "TREATMENT", 229, 243], ["a blue spot", "PROBLEM", 298, 309], ["the labelling", "TREATMENT", 325, 338], ["color development protocol", "TREATMENT", 343, 369], ["membrane", "ANATOMY", 275, 283], ["blue spot", "OBSERVATION", 300, 309]]], ["DNA coming from L. major has the same sequence but with an adenosine at the SNF1 position (instead of a guanine, see Fig. 2B).", [["adenosine", "CHEMICAL", 59, 68], ["guanine", "CHEMICAL", 104, 111], ["adenosine", "CHEMICAL", 59, 68], ["guanine", "CHEMICAL", 104, 111], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["L. major", "ORGANISM", 16, 24], ["adenosine", "SIMPLE_CHEMICAL", 59, 68], ["guanine", "SIMPLE_CHEMICAL", 104, 111], ["SNF1 position", "DNA", 76, 89], ["L. major", "SPECIES", 16, 24], ["DNA", "PROBLEM", 0, 3], ["an adenosine", "TREATMENT", 56, 68], ["a guanine", "TREATMENT", 102, 111]]], ["This DNA hybridizes with PNA2 but SMART-C-Biotin is not incorporated and so no signal is detected on abasic PNA2.", [["DNA", "CELLULAR_COMPONENT", 5, 8], ["PNA2", "GENE_OR_GENE_PRODUCT", 25, 29], ["SMART-C-Biotin", "GENE_OR_GENE_PRODUCT", 34, 48], ["PNA2", "GENE_OR_GENE_PRODUCT", 108, 112], ["PNA2", "DNA", 25, 29], ["SMART-C-Biotin", "DNA", 34, 48], ["abasic PNA2", "DNA", 101, 112], ["This DNA hybridizes", "PROBLEM", 0, 19], ["PNA2", "PROBLEM", 25, 29], ["SMART-C-Biotin", "TEST", 34, 48]]], ["In summary, this approach requires two specific molecular events to create a signal: (i) perfect hybridization between nucleic acid strands and complementary abasic PNA probes; and, (ii) specific molecular recognition, through guanidine-cytosine base-pairing to allow SMART-C-Biotin incorporation onto the abasic site of the PNA probes (Fig. 2C).Spin-Tube fabrication ::: Results and DiscussionThe ChemNAT technology with its colorimetric reverse dot blot assay (colorimetric ChemNAT assay) was integrated into a novel micro device, known as \u201cSpin-Tube\u201d (Fig. 3A).", [["nucleic acid", "CHEMICAL", 119, 131], ["guanidine", "CHEMICAL", 227, 236], ["cytosine", "CHEMICAL", 237, 245], ["guanidine", "CHEMICAL", 227, 236], ["cytosine", "CHEMICAL", 237, 245], ["guanidine-cytosine", "SIMPLE_CHEMICAL", 227, 245], ["Biotin", "SIMPLE_CHEMICAL", 276, 282], ["abasic site", "DNA", 306, 317], ["PNA probes", "DNA", 325, 335], ["nucleic acid strands", "PROBLEM", 119, 139], ["complementary abasic PNA probes", "PROBLEM", 144, 175], ["guanidine-cytosine base", "TREATMENT", 227, 250], ["SMART-C-Biotin incorporation", "TREATMENT", 268, 296], ["the PNA probes", "TREATMENT", 321, 335], ["its colorimetric", "TEST", 422, 438], ["blot assay", "TEST", 451, 461], ["colorimetric ChemNAT assay", "TEST", 463, 489], ["a novel micro device", "TREATMENT", 511, 531], ["abasic", "OBSERVATION_MODIFIER", 158, 164], ["PNA", "OBSERVATION", 165, 168], ["PNA", "OBSERVATION", 325, 328], ["Tube fabrication", "OBSERVATION", 351, 367], ["Tube", "OBSERVATION", 548, 552]]], ["As shown in Fig. 3B, the Spin-Tube consists of: (i) a centrifuge collection tube; (ii) an internal column for the assay; (iii) a nylon membrane (pre-spotted with abasic PNA probes) immobilized onto the bottom of the column via a plastic pressure ring (iv).", [["nylon membrane", "ANATOMY", 129, 143], ["tube", "TISSUE", 76, 80], ["membrane", "CELLULAR_COMPONENT", 135, 143], ["a centrifuge collection tube", "TREATMENT", 52, 80], ["the assay", "TEST", 110, 119], ["a nylon membrane", "TREATMENT", 127, 143], ["abasic PNA probes", "TREATMENT", 162, 179], ["a plastic pressure ring (iv)", "TREATMENT", 227, 255], ["Tube", "OBSERVATION", 30, 34], ["tube", "OBSERVATION", 76, 80], ["internal column", "ANATOMY", 90, 105], ["nylon membrane", "OBSERVATION", 129, 143], ["PNA", "OBSERVATION", 169, 172], ["bottom", "ANATOMY_MODIFIER", 202, 208], ["column", "ANATOMY", 216, 222], ["plastic", "OBSERVATION", 229, 236], ["pressure ring", "OBSERVATION", 237, 250]]], ["The abasic probes were amino-PEGylated at their N-terminal end and printed onto nylon membranes containing pre-activated carboxyl groups (Fig. 3C).", [["nylon membranes", "ANATOMY", 80, 95], ["amino-PEGylated", "CHEMICAL", 23, 38], ["amino", "CHEMICAL", 23, 28], ["N", "CHEMICAL", 48, 49], ["carboxyl", "CHEMICAL", 121, 129], ["amino-PEGylated", "SIMPLE_CHEMICAL", 23, 38], ["N-terminal end", "PROTEIN", 48, 62], ["The abasic probes", "TREATMENT", 0, 17], ["amino-PEGylated at their N-terminal end", "TREATMENT", 23, 62], ["nylon membranes", "TREATMENT", 80, 95], ["pre-activated carboxyl groups", "TREATMENT", 107, 136], ["nylon membranes", "OBSERVATION", 80, 95]]], ["An important stage in the construction of the Spin-Tube, apart from the immobilization of abasic PNAs, was the definition of the array probe layout (Fig. 3D).", [["the Spin-Tube", "TREATMENT", 42, 55], ["abasic PNAs", "PROBLEM", 90, 101], ["important", "OBSERVATION_MODIFIER", 3, 12], ["stage", "OBSERVATION_MODIFIER", 13, 18], ["Tube", "OBSERVATION", 51, 55], ["abasic PNAs", "OBSERVATION", 90, 101]]], ["Probes with fixed concentrations were printed with an automatic nano-plotter onto the nylon membrane, and optimization of signal strength and best signal to background ratios was undertaken.", [["nylon membrane", "ANATOMY", 86, 100], ["Probes", "ORGANISM_SUBSTANCE", 0, 6], ["nylon membrane", "CELLULAR_COMPONENT", 86, 100], ["fixed concentrations", "PROBLEM", 12, 32], ["an automatic nano-plotter onto the nylon membrane", "TREATMENT", 51, 100], ["background ratios", "TEST", 157, 174], ["fixed concentrations", "OBSERVATION", 12, 32], ["nylon membrane", "OBSERVATION", 86, 100], ["signal strength", "OBSERVATION", 122, 137]]], ["Taking into account the 8 mm membrane diameter, it was decided to create a 2 \u00d7 3 array.", [["membrane", "ANATOMY", 29, 37], ["membrane", "CELLULAR_COMPONENT", 29, 37], ["the 8 mm membrane diameter", "TREATMENT", 20, 46], ["8 mm", "OBSERVATION_MODIFIER", 24, 28]]], ["Abasic PNA1 and PNA2 were printed onto two parallel rows of three spots each (6 features in total, in red and blue in Fig. 3D respectively).", [["PNA1", "GENE_OR_GENE_PRODUCT", 7, 11], ["PNA2", "GENE_OR_GENE_PRODUCT", 16, 20], ["PNA1", "PROTEIN", 7, 11], ["PNA2", "DNA", 16, 20], ["Abasic PNA1", "PROBLEM", 0, 11], ["PNA2", "PROBLEM", 16, 20], ["PNA1", "OBSERVATION", 7, 11], ["rows", "OBSERVATION_MODIFIER", 52, 56]]], ["Two control biotin-labelled DNA oligomers were printed on the top row of the array, to identify array orientation and provide a labelling internal control (in yellow in Fig. 3D).", [["biotin", "CHEMICAL", 12, 18], ["biotin", "CHEMICAL", 12, 18], ["biotin", "SIMPLE_CHEMICAL", 12, 18], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["Two control biotin-labelled DNA oligomers", "TREATMENT", 0, 41], ["a labelling internal control", "TREATMENT", 126, 154]]], ["Following printing, performance of probes was initially checked by using synthetic mimic DNA oligomers and SMART-C-Biotin incorporation (data not shown).Abasic PNA probes design and synthesis ::: Results and DiscussionAbasic PNA1 and PNA2 were synthesized with amino-PEGylated groups in order to be covalently bonded and immobilized onto the solid substrate (nylon membranes).", [["nylon membranes", "ANATOMY", 359, 374], ["amino", "CHEMICAL", 261, 266], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["SMART-C", "SIMPLE_CHEMICAL", 107, 114], ["Biotin", "SIMPLE_CHEMICAL", 115, 121], ["PNA2", "SIMPLE_CHEMICAL", 234, 238], ["nylon membranes", "CELLULAR_COMPONENT", 359, 374], ["DiscussionAbasic PNA1", "PROTEIN", 208, 229], ["PNA2", "DNA", 234, 238], ["synthetic mimic DNA oligomers", "TREATMENT", 73, 102], ["SMART-C-Biotin incorporation", "TREATMENT", 107, 135], ["Abasic PNA probes", "PROBLEM", 153, 170], ["DiscussionAbasic PNA1", "TEST", 208, 229], ["PNA2", "TREATMENT", 234, 238], ["amino-PEGylated groups", "TREATMENT", 261, 283], ["the solid substrate (nylon membranes", "TREATMENT", 338, 374], ["PNA", "OBSERVATION", 160, 163]]], ["As previously described by our group, abasic neutral PNA probes immobilized onto solid surfaces have been found to lack stability and can exhibit a degree of undesirable deformation, flexing and/or bending36.", [["abasic neutral PNA probes", "TREATMENT", 38, 63], ["undesirable deformation", "PROBLEM", 158, 181], ["PNA", "OBSERVATION", 53, 56], ["stability", "OBSERVATION", 120, 129], ["degree", "OBSERVATION_MODIFIER", 148, 154], ["undesirable", "OBSERVATION_MODIFIER", 158, 169], ["deformation", "OBSERVATION", 170, 181], ["flexing", "OBSERVATION_MODIFIER", 183, 190]]], ["This affects the performance (e.g., specificity and/or sensitivity) of the abasic PNA probes in this assay \u2013 preventing maximum target binding and assay performance.", [["specificity", "TEST", 36, 47], ["the abasic PNA probes", "PROBLEM", 71, 92], ["this assay", "TEST", 96, 106], ["maximum target binding", "PROBLEM", 120, 142], ["assay performance", "TEST", 147, 164], ["PNA", "OBSERVATION", 82, 85]]], ["Abasic PNA1 and PNA2 were designed and synthesized with these solid surface challenges in mind, adding PNA monomers containing propanoic acid residues at their gamma positions across the probe backbone, improving the probe performance and reducing self-aggregation (Fig. 2B and Fig. S2 in SI).", [["propanoic acid", "CHEMICAL", 127, 141], ["propanoic acid", "CHEMICAL", 127, 141], ["PNA1", "GENE_OR_GENE_PRODUCT", 7, 11], ["PNA2", "SIMPLE_CHEMICAL", 16, 20], ["PNA monomers", "SIMPLE_CHEMICAL", 103, 115], ["propanoic acid", "SIMPLE_CHEMICAL", 127, 141], ["2B", "GENE_OR_GENE_PRODUCT", 271, 273], ["PNA1", "PROTEIN", 7, 11], ["PNA2", "PROTEIN", 16, 20], ["S2", "PROTEIN", 283, 285], ["Abasic PNA1", "PROBLEM", 0, 11], ["PNA2", "PROBLEM", 16, 20], ["these solid surface challenges", "TREATMENT", 56, 86], ["PNA monomers", "TREATMENT", 103, 115], ["propanoic acid residues", "TREATMENT", 127, 150], ["the probe backbone", "TREATMENT", 183, 201], ["the probe performance", "TEST", 213, 234], ["PNA1", "OBSERVATION", 7, 11], ["Fig", "OBSERVATION_MODIFIER", 278, 281], ["SI", "ANATOMY", 289, 291]]], ["Moreover, these gamma modifications give rise to a sterocenter, hence creating chiral PNAs molecules, being just the L-PNA monomers the ones producing PNA oligomers capable of hybridizing complementary natural nucleic acids37\u201340.", [["L-PNA", "CHEMICAL", 117, 122], ["L-PNA", "SIMPLE_CHEMICAL", 117, 122], ["PNA oligomers", "SIMPLE_CHEMICAL", 151, 164], ["these gamma modifications", "TREATMENT", 10, 35], ["a sterocenter", "TREATMENT", 49, 62], ["creating chiral PNAs molecules", "PROBLEM", 70, 100], ["PNA monomers", "PROBLEM", 119, 131], ["PNA oligomers", "PROBLEM", 151, 164], ["PNA", "OBSERVATION", 119, 122], ["PNA", "OBSERVATION", 151, 154]]], ["The result was that the L-propanoic abasic PNA probes bound to nylon membrane were more readily available to hybridize to complementary nucleic acid strands.", [["nylon membrane", "ANATOMY", 63, 77], ["nucleic acid", "CHEMICAL", 136, 148], ["L-propanoic", "SIMPLE_CHEMICAL", 24, 35], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["the L-propanoic abasic PNA probes bound", "PROBLEM", 20, 59], ["nylon membrane", "TREATMENT", 63, 77], ["PNA", "OBSERVATION", 43, 46], ["nylon membrane", "OBSERVATION", 63, 77]]], ["Still unknown was if such abasic PNA probes would prove to be less prone to flexing, bending or otherwise deforming from their \u201cnormal\u201d linear configuration36.", [["such abasic PNA probes", "PROBLEM", 21, 43], ["PNA", "OBSERVATION", 33, 36], ["linear", "OBSERVATION_MODIFIER", 136, 142]]], ["The modifications introduced led to the two probes demonstrating improved specificity and improved sensitivity towards a base complementary to the nucleobase of the DNA amplicon to be characterized.", [["nucleobase", "CHEMICAL", 147, 157], ["DNA", "CELLULAR_COMPONENT", 165, 168], ["DNA amplicon", "DNA", 165, 177], ["the DNA amplicon", "TREATMENT", 161, 177]]], ["The abasic position monomer was also modified with this propanoic acid chain at gamma position and with the same stereochemistry allowing a better dynamic incorporation of the SMART-C-Biotin because of the spatial orientation of the free secondary amine of the \u201cblank\u201d position (Fig. S2 in SI).Labelled SMART Nucleobase for the colorimetric detection ::: Results and DiscussionWhile our previous mass spectrometry method29 allowed parasite species detection and characterization by measurement of molecular weight differences between abasic PNA probes and aldehyde-modified nucleobases (SMART-Bases), in this Spin-Tube platform it was required that the SMART-Base were biotin-labelled (Figs S3\u2013S5 in SI)41,42.", [["amine", "CHEMICAL", 248, 253], ["aldehyde", "CHEMICAL", 556, 564], ["biotin", "CHEMICAL", 669, 675], ["propanoic acid", "CHEMICAL", 56, 70], ["C-Biotin", "CHEMICAL", 182, 190], ["secondary amine", "CHEMICAL", 238, 253], ["aldehyde", "CHEMICAL", 556, 564], ["nucleobases", "CHEMICAL", 574, 585], ["biotin", "CHEMICAL", 669, 675], ["propanoic acid", "SIMPLE_CHEMICAL", 56, 70], ["SMART-C-Biotin", "SIMPLE_CHEMICAL", 176, 190], ["amine", "SIMPLE_CHEMICAL", 248, 253], ["aldehyde-modified nucleobases", "SIMPLE_CHEMICAL", 556, 585], ["biotin", "SIMPLE_CHEMICAL", 669, 675], ["gamma position", "PROTEIN", 80, 94], ["SMART", "PROTEIN", 176, 181], ["S2", "PROTEIN", 284, 286], ["SMART Nucleobase", "PROTEIN", 303, 319], ["SMART-Base", "DNA", 653, 663], ["The abasic position monomer", "TREATMENT", 0, 27], ["this propanoic acid chain", "TREATMENT", 51, 76], ["the SMART-C-Biotin", "TREATMENT", 172, 190], ["the colorimetric detection", "TEST", 324, 350], ["our previous mass spectrometry", "TEST", 383, 413], ["parasite species detection", "TEST", 431, 457], ["molecular weight differences", "PROBLEM", 497, 525], ["abasic PNA probes", "TEST", 534, 551], ["this Spin-Tube platform", "TREATMENT", 604, 627], ["biotin", "TEST", 669, 675], ["abasic", "OBSERVATION_MODIFIER", 4, 10], ["position", "OBSERVATION_MODIFIER", 11, 19], ["monomer", "OBSERVATION_MODIFIER", 20, 27], ["SI", "ANATOMY", 290, 292], ["PNA", "OBSERVATION", 541, 544], ["Bases", "ANATOMY_MODIFIER", 593, 598], ["Base", "ANATOMY_MODIFIER", 659, 663]]], ["Here the color development reaction depends on the biotin recognition by a streptavidin-alkaline phosphatase complex, that transforms a colorless chromogenic substrate (NBT/BCIP, nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-indolyl phosphate) into a blue precipitate each time there is a biotin tag attached to the membrane.", [["membrane", "ANATOMY", 321, 329], ["biotin", "CHEMICAL", 51, 57], ["NBT", "CHEMICAL", 169, 172], ["nitro blue tetrazolium chloride", "CHEMICAL", 179, 210], ["5-Bromo-4-chloro-3-indolyl phosphate", "CHEMICAL", 211, 247], ["biotin", "CHEMICAL", 294, 300], ["biotin", "CHEMICAL", 51, 57], ["NBT", "CHEMICAL", 169, 172], ["BCIP", "CHEMICAL", 173, 177], ["nitro blue tetrazolium chloride", "CHEMICAL", 179, 210], ["5-Bromo-4-chloro-3-indolyl phosphate", "CHEMICAL", 211, 247], ["biotin", "CHEMICAL", 294, 300], ["biotin", "SIMPLE_CHEMICAL", 51, 57], ["streptavidin", "SIMPLE_CHEMICAL", 75, 87], ["NBT", "SIMPLE_CHEMICAL", 169, 172], ["BCIP", "SIMPLE_CHEMICAL", 173, 177], ["nitro blue tetrazolium chloride", "SIMPLE_CHEMICAL", 179, 210], ["5-Bromo-4-chloro-3-indolyl phosphate", "SIMPLE_CHEMICAL", 211, 247], ["biotin", "SIMPLE_CHEMICAL", 294, 300], ["membrane", "CELLULAR_COMPONENT", 321, 329], ["streptavidin-alkaline phosphatase complex", "PROTEIN", 75, 116], ["biotin tag", "PROTEIN", 294, 304], ["the color development reaction", "PROBLEM", 5, 35], ["the biotin recognition", "PROBLEM", 47, 69], ["a streptavidin-alkaline phosphatase complex", "TEST", 73, 116], ["a colorless chromogenic substrate", "TEST", 134, 167], ["NBT", "TEST", 169, 172], ["BCIP", "TEST", 173, 177], ["nitro blue tetrazolium chloride", "TREATMENT", 179, 210], ["Bromo", "TREATMENT", 213, 218], ["chloro", "TREATMENT", 221, 227], ["indolyl phosphate", "TREATMENT", 230, 247], ["a blue precipitate", "TREATMENT", 254, 272], ["a biotin tag", "TREATMENT", 292, 304], ["biotin tag", "OBSERVATION", 294, 304]]], ["The blue spots emerging correspond to those abasic PNA probes which have successfully hybridized with the complementary PCR products and in whose abasic positions SMART-C-Biotin has been incorporated through a guanosine template (Fig. 2).", [["guanosine", "CHEMICAL", 210, 219], ["guanosine", "CHEMICAL", 210, 219], ["SMART-C-Biotin", "GENE_OR_GENE_PRODUCT", 163, 177], ["guanosine", "SIMPLE_CHEMICAL", 210, 219], ["complementary PCR products", "DNA", 106, 132], ["The blue spots", "PROBLEM", 0, 14], ["those abasic PNA probes", "PROBLEM", 38, 61], ["the complementary PCR products", "TREATMENT", 102, 132], ["C-Biotin", "TREATMENT", 169, 177], ["a guanosine template", "TREATMENT", 208, 228], ["blue spots", "OBSERVATION", 4, 14], ["PNA", "OBSERVATION", 51, 54]]], ["The SMART-C-Biotin bears a PEG spacer to increase water solubility while at the same time distancing the nitrogenous base involved in the hydrogen bonding recognition from the biotin tag responsible for the color development43.Sequence analysis of genomic DNA ::: Results and DiscussionThe Spin-Tube platform was validated using PCR products from genomic DNA (gDNA) of both parasites.", [["PEG", "CHEMICAL", 27, 30], ["PEG", "CHEMICAL", 27, 30], ["hydrogen", "CHEMICAL", 138, 146], ["biotin", "CHEMICAL", 176, 182], ["SMART-C-Biotin", "SIMPLE_CHEMICAL", 4, 18], ["water", "SIMPLE_CHEMICAL", 50, 55], ["hydrogen", "SIMPLE_CHEMICAL", 138, 146], ["biotin", "SIMPLE_CHEMICAL", 176, 182], ["DNA", "CELLULAR_COMPONENT", 256, 259], ["DNA", "CELLULAR_COMPONENT", 355, 358], ["gDNA", "CELLULAR_COMPONENT", 360, 364], ["SMART-C", "DNA", 4, 11], ["biotin tag", "PROTEIN", 176, 186], ["genomic DNA", "DNA", 248, 259], ["PCR products", "DNA", 329, 341], ["genomic DNA", "DNA", 347, 358], ["The SMART-C-Biotin bears", "TREATMENT", 0, 24], ["a PEG spacer", "TREATMENT", 25, 37], ["water solubility", "TREATMENT", 50, 66], ["the hydrogen bonding recognition", "TREATMENT", 134, 166], ["the biotin tag", "TREATMENT", 172, 186], ["Sequence analysis", "TEST", 227, 244], ["The Spin-Tube platform", "TREATMENT", 286, 308], ["PCR products", "TREATMENT", 329, 341], ["water solubility", "OBSERVATION_MODIFIER", 50, 66], ["nitrogenous base", "OBSERVATION", 105, 121], ["hydrogen bonding", "OBSERVATION", 138, 154], ["both", "ANATOMY_MODIFIER", 369, 373], ["parasites", "OBSERVATION", 374, 383]]], ["Singleplex PCR was carried out to amplify the highly conserved segment of DNA containing the two single nucleotides under interrogation (Fig. 2).", [["nucleotides", "CHEMICAL", 104, 115], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["Singleplex PCR", "TEST", 0, 14]]], ["DNA amplicon products were denatured and then together with the dynamic chemistry reaction reagents added directly into the internal column of the Spin-Tube that supports the nylon membrane for the color-development assay (Fig. 4).", [["nylon membrane", "ANATOMY", 175, 189], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["nylon membrane", "CELLULAR_COMPONENT", 175, 189], ["DNA amplicon products", "TREATMENT", 0, 21], ["the dynamic chemistry reaction reagents", "TREATMENT", 60, 99], ["the Spin-Tube", "TREATMENT", 143, 156], ["the nylon membrane", "TREATMENT", 171, 189], ["the color", "TEST", 194, 203], ["internal", "ANATOMY_MODIFIER", 124, 132], ["column", "ANATOMY_MODIFIER", 133, 139], ["Tube", "OBSERVATION", 152, 156], ["nylon membrane", "OBSERVATION", 175, 189]]], ["Subsequently, the reaction was carried out at a constant temperature of 45 \u00b0C avoiding the need to make use of sophisticated apparatus.", [["the reaction", "PROBLEM", 14, 26]]], ["Single stranded DNA hybridizes with the abasic PNAs acting as template molecules, driving the error free incorporation of SMART-C-Biotin into the specific chemical pocket.", [["SMART-C-Biotin", "CHEMICAL", 122, 136], ["Biotin", "CHEMICAL", 130, 136], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["SMART-C-Biotin", "GENE_OR_GENE_PRODUCT", 122, 136], ["SMART", "PROTEIN", 122, 127], ["C", "PROTEIN", 128, 129], ["Single stranded DNA hybridizes", "PROBLEM", 0, 30], ["the abasic PNAs", "TREATMENT", 36, 51], ["SMART-C-Biotin", "TREATMENT", 122, 136], ["stranded DNA", "OBSERVATION", 7, 19], ["PNAs", "OBSERVATION", 47, 51], ["chemical pocket", "OBSERVATION", 155, 170]]], ["Finally, the incorporated SMART-C-Biotin is labelled with a streptavidin-ALP, so that a colorimetric signal pattern was generated when the chromogenic substrate is added.", [["SMART", "CHEMICAL", 26, 31], ["SMART-C-Biotin", "SIMPLE_CHEMICAL", 26, 40], ["streptavidin-ALP", "SIMPLE_CHEMICAL", 60, 76], ["SMART", "PROTEIN", 26, 31], ["C", "PROTEIN", 32, 33], ["streptavidin", "PROTEIN", 60, 72], ["ALP", "PROTEIN", 73, 76], ["a streptavidin-ALP", "TEST", 58, 76], ["a colorimetric signal pattern", "TEST", 86, 115], ["the chromogenic substrate", "TREATMENT", 135, 160]]], ["The signal pattern generated by the protocol allows the visual or photographic imaging of which species cause the patient infection.", [["infection", "DISEASE", 122, 131], ["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121], ["the protocol", "TEST", 32, 44], ["photographic imaging", "TEST", 66, 86], ["the patient infection", "PROBLEM", 110, 131], ["infection", "OBSERVATION", 122, 131]]], ["L. major gDNA generated a signal ONLY at the abasic PNA1 probe, as its abasic site lies opposite a guanidine at +32 position from the 5\u2032-terminus of amplicon (see red arrow in Fig. 2).", [["guanidine", "CHEMICAL", 99, 108], ["guanidine", "CHEMICAL", 99, 108], ["guanidine", "SIMPLE_CHEMICAL", 99, 108], ["abasic PNA1 probe", "DNA", 45, 62], ["abasic site", "DNA", 71, 82], ["5\u2032-terminus", "DNA", 134, 145], ["the abasic PNA1 probe", "TREATMENT", 41, 62], ["a guanidine", "TREATMENT", 97, 108]]], ["While, T. cruzi gDNA generated signals for both abasic PNA probes.", [["T. cruzi", "ORGANISM", 7, 15], ["gDNA", "ORGANISM", 16, 20], ["T. cruzi", "SPECIES", 7, 15], ["T. cruzi", "SPECIES", 7, 15], ["both abasic PNA probes", "PROBLEM", 43, 65], ["abasic", "OBSERVATION_MODIFIER", 48, 54], ["PNA", "OBSERVATION", 55, 58]]], ["The abasic sites of both PNA probes lie opposite a guanidine, allowing the incorporation of SMART-C-Biotin with its biotin tag, thus resulting in a blue spot after its incorporation.", [["guanidine", "CHEMICAL", 51, 60], ["SMART-C-Biotin", "CHEMICAL", 92, 106], ["guanidine", "CHEMICAL", 51, 60], ["Biotin", "CHEMICAL", 100, 106], ["biotin", "CHEMICAL", 116, 122], ["PNA", "SIMPLE_CHEMICAL", 25, 28], ["guanidine", "SIMPLE_CHEMICAL", 51, 60], ["SMART-C-Biotin", "SIMPLE_CHEMICAL", 92, 106], ["biotin tag", "SIMPLE_CHEMICAL", 116, 126], ["abasic sites", "DNA", 4, 16], ["SMART", "PROTEIN", 92, 97], ["biotin tag", "PROTEIN", 116, 126], ["both PNA probes", "TREATMENT", 20, 35], ["a guanidine", "TREATMENT", 49, 60], ["SMART-C-Biotin", "TREATMENT", 92, 106], ["its biotin tag", "TREATMENT", 112, 126], ["a blue spot", "PROBLEM", 146, 157], ["abasic", "OBSERVATION_MODIFIER", 4, 10], ["sites", "OBSERVATION_MODIFIER", 11, 16], ["both", "OBSERVATION_MODIFIER", 20, 24], ["PNA", "OBSERVATION", 25, 28], ["biotin tag", "OBSERVATION", 116, 126], ["blue spot", "OBSERVATION", 148, 157]]], ["Results in Fig. 4 show a successful identification of parasites present in samples, and in line with the expected results, showing (a) L. major positive for abasic PNA1 ONLY and (b) T. cruzi positive for both abasic PNA probes.Assay\u00a0specificity ::: Results and DiscussionBioinformatic along with experimental analysis were carried out to discard the possibility that the presence of human gDNA on the samples could affect the singleplex PCR.", [["samples", "ANATOMY", 75, 82], ["samples", "ANATOMY", 401, 408], ["samples", "CANCER", 75, 82], ["T. cruzi", "ORGANISM", 182, 190], ["human", "ORGANISM", 383, 388], ["gDNA", "GENE_OR_GENE_PRODUCT", 389, 393], ["human gDNA", "DNA", 383, 393], ["T. cruzi", "SPECIES", 182, 190], ["human", "SPECIES", 383, 388], ["T. cruzi", "SPECIES", 182, 190], ["human", "SPECIES", 383, 388], ["parasites", "PROBLEM", 54, 63], ["abasic PNA1", "PROBLEM", 157, 168], ["b) T. cruzi", "TEST", 179, 190], ["both abasic PNA probes", "PROBLEM", 204, 226], ["experimental analysis", "TEST", 296, 317], ["human gDNA", "PROBLEM", 383, 393], ["the samples", "TEST", 397, 408], ["the singleplex PCR", "TEST", 422, 440], ["parasites", "OBSERVATION", 54, 63], ["abasic", "OBSERVATION_MODIFIER", 209, 215], ["PNA", "OBSERVATION", 216, 219]]], ["Initially, a primer BLAST study was carried out using the NCBI primer BLAST tool and no human hits came out.", [["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["a primer BLAST study", "TEST", 11, 31], ["the NCBI primer BLAST tool", "TEST", 54, 80], ["human hits", "TEST", 88, 98]]], ["Primers specificity against human gDNA was experimentally checked.", [["human", "ORGANISM", 28, 33], ["gDNA", "CELL", 34, 38], ["human gDNA", "DNA", 28, 38], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["Primers specificity", "TEST", 0, 19], ["human gDNA", "TEST", 28, 38]]], ["20 ng of human gDNA were used as PCR template for its amplification with the set of primers described in our study and neither colorimetric signals nor bands were detected using the Spin-Tube and capillary electrophoresis analysis respectively (Fig. 5, column 2: 2A and 2B), hence probing the specificity when human gDNA is present.", [["human", "ORGANISM", 9, 14], ["gDNA", "CELL", 15, 19], ["capillary", "TISSUE", 196, 205], ["human", "ORGANISM", 310, 315], ["gDNA", "CELL", 316, 320], ["human gDNA", "DNA", 9, 19], ["PCR template", "DNA", 33, 45], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 310, 315], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 310, 315], ["human gDNA", "TREATMENT", 9, 19], ["PCR template", "TREATMENT", 33, 45], ["its amplification", "PROBLEM", 50, 67], ["our study", "TEST", 105, 114], ["colorimetric signals", "TEST", 127, 147], ["bands", "PROBLEM", 152, 157], ["the Spin", "TEST", 178, 186], ["capillary electrophoresis analysis", "TEST", 196, 230], ["human gDNA", "PROBLEM", 310, 320]]], ["We also mixed 20 ng of human gDNA with 20 ng of DNA from both Trypanosomatid species in order to perform PCR and amplicon analysis by capillary electrophoresis and Spin-Tube approaches (Fig. 5, column 3: 3A and 3B and column 4: 4A and 4B).", [["human", "ORGANISM", 23, 28], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["capillary", "TISSUE", 134, 143], ["human gDNA", "DNA", 23, 33], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["human gDNA", "TREATMENT", 23, 33], ["DNA", "PROBLEM", 48, 51], ["both Trypanosomatid species", "PROBLEM", 57, 84], ["PCR", "TEST", 105, 108], ["amplicon analysis", "TEST", 113, 130], ["capillary electrophoresis", "TEST", 134, 159], ["column", "TEST", 194, 200], ["Trypanosomatid species", "OBSERVATION", 62, 84]]], ["It was confirmed that amplicon formation of the Trypanosomatid species and their detection were not affected by the presence of the human gDNA.Assay\u00a0specificity ::: Results and DiscussionIn order to clarify the specificity of the PCR towards other microorganisms, an in silico study was carried out (data not shown).", [["human", "ORGANISM", 132, 137], ["gDNA", "CELL", 138, 142], ["human gDNA", "DNA", 132, 142], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["amplicon formation", "PROBLEM", 22, 40], ["the Trypanosomatid species", "PROBLEM", 44, 70], ["their detection", "TEST", 75, 90], ["the human gDNA", "PROBLEM", 128, 142], ["the PCR", "TEST", 226, 233], ["other microorganisms", "PROBLEM", 242, 262], ["an in silico study", "TEST", 264, 282], ["Trypanosomatid species", "OBSERVATION", 48, 70]]], ["28S ribosomal RNA delta gene sequences from Leishamania spp., Trypanosoma brucei and Trypanosoma cruzi were aligned using EMBL-EMI tool for multiple sequence alignment Clustal Omega to check that not only the primers but also the designed abasic PNA probes were suitable for the Spin-Tube and MALDI-ToF approaches.", [["28S ribosomal RNA delta", "GENE_OR_GENE_PRODUCT", 0, 23], ["Leishamania spp.", "ORGANISM", 44, 60], ["Trypanosoma brucei", "ORGANISM", 62, 80], ["Trypanosoma cruzi", "ORGANISM", 85, 102], ["28S ribosomal RNA delta gene sequences", "DNA", 0, 38], ["EMI", "DNA", 127, 130], ["abasic PNA probes", "DNA", 239, 256], ["Leishamania spp.", "SPECIES", 44, 60], ["Trypanosoma brucei", "SPECIES", 62, 80], ["Trypanosoma cruzi", "SPECIES", 85, 102], ["Leishamania spp.", "SPECIES", 44, 60], ["Trypanosoma brucei", "SPECIES", 62, 80], ["Trypanosoma cruzi", "SPECIES", 85, 102], ["28S ribosomal RNA delta gene sequences", "TEST", 0, 38], ["Leishamania spp.", "PROBLEM", 44, 60], ["Trypanosoma brucei and Trypanosoma cruzi", "PROBLEM", 62, 102], ["EMI tool", "TEST", 127, 135], ["multiple sequence alignment Clustal Omega", "TREATMENT", 140, 181], ["the primers", "PROBLEM", 205, 216], ["the designed abasic PNA probes", "PROBLEM", 226, 256], ["the Spin-Tube", "TREATMENT", 275, 288], ["MALDI-ToF approaches", "TREATMENT", 293, 313], ["Trypanosoma brucei", "OBSERVATION", 62, 80], ["Trypanosoma cruzi", "OBSERVATION", 85, 102], ["PNA", "OBSERVATION", 246, 249]]], ["This tool was also used to study which other Leishmania species were suitable to be submitted to this singleplex PCR.", [["Leishmania", "ORGANISM", 45, 55], ["other Leishmania species", "PROBLEM", 39, 63], ["this singleplex PCR", "TEST", 97, 116], ["Leishmania", "OBSERVATION", 45, 55]]], ["Forward and reverse primers were blasted towards other organisms using NCBI primer BLAST tool.", [["Forward and reverse primers", "DNA", 0, 27], ["Forward and reverse primers", "PROBLEM", 0, 27], ["NCBI primer BLAST tool", "TEST", 71, 93]]], ["It was found that mainly genome from Trypanosomatids species matched the designed primers.", [["genome", "CELLULAR_COMPONENT", 25, 31], ["Trypanosomatids species", "PROBLEM", 37, 60], ["the designed primers", "PROBLEM", 69, 89], ["mainly", "OBSERVATION_MODIFIER", 18, 24], ["genome", "OBSERVATION", 25, 31], ["Trypanosomatids species", "OBSERVATION", 37, 60]]], ["Although, a few other genome sequences could also be amplified by our designed primers (Schistosoma mansoni, Leptomonas pyrrhocoris, Aspergillus sclerotioniger and Aspergillus eucalypticola), all these infectious agents cause diseases with clinical manifestations very different from those manifested in Leishmaniasis and Chagas disease and therefore other diagnostic paths would be proposed.", [["Schistosoma mansoni", "DISEASE", 88, 107], ["Leishmaniasis", "DISEASE", 304, 317], ["Chagas disease", "DISEASE", 322, 336], ["Schistosoma mansoni", "ORGANISM", 88, 107], ["Leptomonas pyrrhocoris", "ORGANISM", 109, 131], ["Aspergillus sclerotioniger", "ORGANISM", 133, 159], ["Aspergillus eucalypticola", "ORGANISM", 164, 189], ["genome sequences", "DNA", 22, 38], ["Schistosoma mansoni", "SPECIES", 88, 107], ["Leptomonas pyrrhocoris", "SPECIES", 109, 131], ["Aspergillus sclerotioniger", "SPECIES", 133, 159], ["Aspergillus eucalypticola", "SPECIES", 164, 189], ["Schistosoma mansoni", "SPECIES", 88, 107], ["Leptomonas pyrrhocoris", "SPECIES", 109, 131], ["Aspergillus sclerotioniger", "SPECIES", 133, 159], ["Aspergillus eucalypticola", "SPECIES", 164, 189], ["a few other genome sequences", "PROBLEM", 10, 38], ["our designed primers (Schistosoma mansoni", "PROBLEM", 66, 107], ["Leptomonas pyrrhocoris", "PROBLEM", 109, 131], ["Aspergillus sclerotioniger", "PROBLEM", 133, 159], ["Aspergillus eucalypticola", "PROBLEM", 164, 189], ["diseases", "PROBLEM", 226, 234], ["clinical manifestations", "PROBLEM", 240, 263], ["Leishmaniasis", "PROBLEM", 304, 317], ["Chagas disease", "PROBLEM", 322, 336], ["Leishmaniasis", "OBSERVATION", 304, 317], ["Chagas disease", "OBSERVATION", 322, 336]]], ["Another key factor of the assay Spin-Tube is the signal emerges after the dynamic incorporation of SMART-C-Biotin into the abasic site of the abasic PNA probes.", [["SMART-C-Biotin", "CHEMICAL", 99, 113], ["SMART-C-Biotin", "GENE_OR_GENE_PRODUCT", 99, 113], ["SMART", "PROTEIN", 99, 104], ["C", "PROTEIN", 105, 106], ["abasic site", "DNA", 123, 134], ["abasic PNA probes", "DNA", 142, 159], ["SMART-C-Biotin", "TREATMENT", 99, 113], ["the abasic PNA probes", "PROBLEM", 138, 159], ["Tube", "OBSERVATION", 37, 41], ["abasic", "OBSERVATION_MODIFIER", 142, 148], ["PNA", "OBSERVATION", 149, 152]]], ["Even if off-target sequences are amplified, no colored spots will be observed.", [["off-target sequences", "DNA", 8, 28], ["colored spots", "PROBLEM", 47, 60]]], ["So, DNA strands coming from any off-target species will not create a signal, as that DNA strends will not have precise homology with both forward and reverse primers, as well as the region complementary to the abasic PNA within a narrow area of its genome.Assay sensitivity ::: Results and DiscussionClinically relevant sensitivity was achieved using the amplification and detection platform.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["DNA strands", "DNA", 4, 15], ["forward and reverse primers", "DNA", 138, 165], ["abasic PNA", "DNA", 210, 220], ["DNA strands", "PROBLEM", 4, 15], ["DNA strends", "PROBLEM", 85, 96], ["reverse primers", "TREATMENT", 150, 165], ["the abasic PNA", "PROBLEM", 206, 220], ["the amplification", "TEST", 351, 368], ["detection platform", "TEST", 373, 391], ["abasic", "OBSERVATION_MODIFIER", 210, 216], ["PNA", "OBSERVATION", 217, 220], ["narrow", "OBSERVATION_MODIFIER", 230, 236], ["area", "OBSERVATION_MODIFIER", 237, 241], ["its genome", "OBSERVATION", 245, 255]]], ["The assay was challenged by interrogating different PCR amplification reactions, using decreasing amounts of T. cruzi gDNA as starting material.", [["T. cruzi", "ORGANISM", 109, 117], ["gDNA", "ORGANISM", 118, 122], ["T. cruzi", "SPECIES", 109, 117], ["T. cruzi", "SPECIES", 109, 117], ["The assay", "TEST", 0, 9], ["different PCR amplification reactions", "PROBLEM", 42, 79], ["T. cruzi gDNA", "TREATMENT", 109, 122]]], ["Important to note in this study, 3 biotin markers were printed on the top row of the array, rather than 2 (Fig. 6A).", [["biotin", "CHEMICAL", 35, 41], ["biotin", "SIMPLE_CHEMICAL", 35, 41], ["biotin markers", "PROTEIN", 35, 49], ["this study", "TEST", 21, 31], ["3 biotin markers", "TEST", 33, 49]]], ["Instead of simple circular plastic-ring (see red arrow in Fig. S1-D in SI), here for the construction of Spin-Tube, pressure plastic-ring with three plastic teeth (see white arrow in Fig. S1-D in SI) were used.", [["teeth", "ANATOMY", 157, 162], ["S1-D", "GENE_OR_GENE_PRODUCT", 63, 67], ["teeth", "ORGAN", 157, 162], ["S1-D", "GENE_OR_GENE_PRODUCT", 188, 192], ["S1", "PROTEIN", 63, 65], ["S1", "PROTEIN", 188, 190], ["simple circular plastic-ring", "TREATMENT", 11, 39], ["Spin-Tube", "TREATMENT", 105, 114], ["pressure plastic-ring", "TREATMENT", 116, 137], ["three plastic teeth", "TREATMENT", 143, 162], ["simple", "OBSERVATION_MODIFIER", 11, 17], ["circular", "OBSERVATION_MODIFIER", 18, 26], ["Tube", "OBSERVATION", 110, 114], ["teeth", "ANATOMY", 157, 162]]], ["Six different amounts of gDNA (50 ng, 5 ng, 0.5 ng, 0.05 ng, 0.005 ng, 0.0005 ng) were studied (Table S1 in SI).", [["gDNA", "TEST", 25, 29], ["amounts", "OBSERVATION_MODIFIER", 14, 21]]], ["PCR amplifications were validated and quantified by capillary electrophoresis.", [["capillary", "TISSUE", 52, 61], ["PCR amplifications", "TEST", 0, 18], ["capillary electrophoresis", "TEST", 52, 77]]], ["All but the two lowest amounts of gDNA (0.005 ng and 0.0005 ng) produced amplicons which were able to be detected and quantified by capillary electrophoresis (Fig. 6B).", [["capillary", "TISSUE", 132, 141], ["gDNA (0.005 ng", "TREATMENT", 34, 48], ["amplicons", "PROBLEM", 73, 82], ["capillary electrophoresis", "TEST", 132, 157]]], ["The amplification products were then used as template for the dynamic incorporation of SMART-C-Biotin within the Spin-Tube.", [["SMART-C-Biotin", "SIMPLE_CHEMICAL", 87, 101], ["SMART", "PROTEIN", 87, 92], ["The amplification products", "TREATMENT", 0, 26], ["SMART-C-Biotin within the Spin-Tube", "TREATMENT", 87, 122], ["Tube", "OBSERVATION", 118, 122]]], ["Positive signals were obtained for both abasic PNAs as anticipated, confirming the presence of T. cruzi (Fig. 6C).Assay sensitivity ::: Results and DiscussionA relative quantification of the signal intensity was carried out using ImageJ software.", [["T. cruzi", "ORGANISM", 95, 103], ["T. cruzi", "SPECIES", 95, 103], ["T. cruzi", "SPECIES", 95, 103], ["both abasic PNAs", "PROBLEM", 35, 51], ["T. cruzi", "PROBLEM", 95, 103], ["the signal intensity", "PROBLEM", 187, 207], ["ImageJ software", "TEST", 230, 245], ["PNAs", "OBSERVATION", 47, 51]]], ["Average background signal intensity was taken and subtracted from all the measurements.", [["signal", "OBSERVATION_MODIFIER", 19, 25], ["intensity", "OBSERVATION_MODIFIER", 26, 35]]], ["Biotin signal intensity (marker) was used as reference representing 100% intensity.", [["Biotin", "CHEMICAL", 0, 6], ["Biotin", "GENE_OR_GENE_PRODUCT", 0, 6], ["Biotin signal intensity", "TEST", 0, 23], ["intensity", "OBSERVATION_MODIFIER", 14, 23]]], ["The signal intensity for each abasic PNA probe was extracted and expressed as a percentage of the biotin signal.", [["biotin", "CHEMICAL", 98, 104], ["biotin", "SIMPLE_CHEMICAL", 98, 104], ["each abasic PNA probe", "TREATMENT", 25, 46], ["the biotin signal", "TEST", 94, 111], ["signal", "OBSERVATION_MODIFIER", 4, 10], ["intensity", "OBSERVATION_MODIFIER", 11, 20], ["abasic", "OBSERVATION_MODIFIER", 30, 36], ["PNA", "OBSERVATION", 37, 40], ["biotin signal", "OBSERVATION", 98, 111]]], ["Almost no difference was observed by eye for the membranes in which 50 and 5 ng of T. cruzi gDNA was used as template for the PCR, whereas the relative signal intensity quantification by ImageJ software showed a slight lowering of signal as the genomic amounts decreased (Fig. 6C).", [["eye", "ANATOMY", 37, 40], ["membranes", "ANATOMY", 49, 58], ["eye", "ORGAN", 37, 40], ["membranes", "CELLULAR_COMPONENT", 49, 58], ["T. cruzi", "ORGANISM", 83, 91], ["gDNA", "ORGANISM", 92, 96], ["T. cruzi", "SPECIES", 83, 91], ["T. cruzi", "SPECIES", 83, 91], ["T. cruzi gDNA", "TREATMENT", 83, 96], ["the PCR", "TEST", 122, 129], ["ImageJ software", "TEST", 187, 202], ["a slight lowering of signal", "PROBLEM", 210, 237], ["eye", "ANATOMY", 37, 40], ["slight", "OBSERVATION_MODIFIER", 212, 218], ["lowering", "OBSERVATION_MODIFIER", 219, 227], ["amounts", "OBSERVATION_MODIFIER", 253, 260], ["decreased", "OBSERVATION_MODIFIER", 261, 270]]], ["These results confirm what had been already observed using capillary electrophoresis, further confirming that the limit of detection of the dynamic incorporation assay depends on the PCR yield to provide sufficient template.", [["capillary", "TISSUE", 59, 68], ["capillary electrophoresis", "TEST", 59, 84], ["the dynamic incorporation assay", "TEST", 136, 167], ["the PCR", "TEST", 179, 186]]], ["Negative control (made with H2O as template for the PCR) was also called as parasite free, being a true negative result.Analysis of spiked parasite gDNA in blood ::: Results and DiscussionVerma et al. in their previous study44 reported a mean Leishmania parasite load of 8,372 parasites/mL in a group of 29 visceral leishmaniasis patients.", [["blood", "ANATOMY", 156, 161], ["H2O", "CHEMICAL", 28, 31], ["visceral leishmaniasis", "DISEASE", 307, 329], ["H2O", "CHEMICAL", 28, 31], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 330, 338], ["H2O", "TREATMENT", 28, 31], ["the PCR", "TEST", 48, 55], ["Analysis", "TEST", 120, 128], ["spiked parasite gDNA", "PROBLEM", 132, 152], ["a mean Leishmania parasite load", "TEST", 236, 267], ["parasite gDNA", "OBSERVATION", 139, 152], ["parasite load", "OBSERVATION", 254, 267], ["visceral", "ANATOMY", 307, 315], ["leishmaniasis", "OBSERVATION", 316, 329]]], ["In order to determine if the sensitivity of the Spin-Tube is able to detect the levels of infections reported by Verma et al., a spike-in experiment was performed.", [["infections", "DISEASE", 90, 100], ["the Spin-Tube", "TREATMENT", 44, 57], ["infections", "PROBLEM", 90, 100], ["a spike", "TEST", 127, 134], ["Tube", "OBSERVATION", 53, 57], ["infections", "OBSERVATION", 90, 100]]], ["Two human blood samples were spiked-in with 10 and 0.1 ng of L. major gDNA and total DNA was extracted.", [["blood samples", "ANATOMY", 10, 23], ["human", "ORGANISM", 4, 9], ["blood samples", "ORGANISM_SUBSTANCE", 10, 23], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["Two human blood samples", "TEST", 0, 23], ["total DNA", "TREATMENT", 79, 88]]], ["Those extracted DNAs were used as template for PCR amplifications and the generated amplicons were analyzed by capillary electrophoresis (Fig. 7A) and by the Spin-Tube (Fig. 7B).", [["DNAs", "ANATOMY", 16, 20], ["capillary", "TISSUE", 111, 120], ["Those extracted DNAs", "TREATMENT", 0, 20], ["PCR amplifications", "TEST", 47, 65], ["the generated amplicons", "TREATMENT", 70, 93], ["capillary electrophoresis", "TEST", 111, 136], ["Tube", "OBSERVATION", 163, 167]]], ["The results confirmed that the Spin-Tube is able to detect a minimum of 0.1 ng of L. major gDNA spiked-in 200 \u03bcL of whole blood that equals to 5,000 parasite per mL of blood according the previous publication44.Direct sequence analysis of ribosomal RNA ::: Results and DiscussionSince the target nucleic acid of the assay was the sense strand DNA of the gene coding for the 28S rRNA delta unit, RNA could also be used as a target nucleic acid using the dynamic chemistry approach (Fig. 8A).", [["blood", "ANATOMY", 122, 127], ["blood", "ANATOMY", 168, 173], ["ribosomal", "ANATOMY", 239, 248], ["nucleic acid", "CHEMICAL", 296, 308], ["nucleic acid", "CHEMICAL", 430, 442], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["ribosomal", "CELLULAR_COMPONENT", 239, 248], ["DNA", "CELLULAR_COMPONENT", 343, 346], ["28S", "CELLULAR_COMPONENT", 374, 377], ["ribosomal RNA", "RNA", 239, 252], ["28S rRNA delta unit", "DNA", 374, 393], ["the Spin-Tube", "TREATMENT", 27, 40], ["Direct sequence analysis", "TEST", 211, 235], ["the assay", "TEST", 312, 321], ["the 28S rRNA delta unit", "TREATMENT", 370, 393], ["RNA", "TREATMENT", 395, 398], ["a target nucleic acid", "TREATMENT", 421, 442], ["Tube", "OBSERVATION", 36, 40], ["ribosomal RNA", "OBSERVATION", 239, 252]]], ["Recently, the dynamic chemistry approach was used to quantify circulating miRNAs41, demonstrating its feasibility to detect both DNA and RNA molecules.", [["miRNAs41", "GENE_OR_GENE_PRODUCT", 74, 82], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["miRNAs41", "PROTEIN", 74, 82], ["RNA molecules", "PROTEIN", 137, 150], ["the dynamic chemistry approach", "TEST", 10, 40], ["circulating miRNAs41", "TEST", 62, 82], ["both DNA and RNA molecules", "PROBLEM", 124, 150], ["RNA molecules", "OBSERVATION", 137, 150]]], ["Direct detection of ribosomal RNA would avoid performing DNA pre-amplification steps by PCR and denaturation and could significantly simplify and shorten the protocol.", [["ribosomal", "ANATOMY", 20, 29], ["ribosomal", "CELLULAR_COMPONENT", 20, 29], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["ribosomal RNA", "RNA", 20, 33], ["ribosomal RNA", "PROBLEM", 20, 33], ["PCR", "TEST", 88, 91], ["denaturation", "PROBLEM", 96, 108], ["the protocol", "TREATMENT", 154, 166], ["ribosomal RNA", "OBSERVATION", 20, 33]]], ["This would allow its implementation in developing and resources-limited countries.Direct sequence analysis of ribosomal RNA ::: Results and DiscussionA proof-of-concept study was carried out using RNA as the templating nucleic acid.", [["ribosomal", "ANATOMY", 110, 119], ["nucleic acid", "CHEMICAL", 219, 231], ["ribosomal", "CELLULAR_COMPONENT", 110, 119], ["ribosomal RNA", "RNA", 110, 123], ["Direct sequence analysis", "TEST", 82, 106], ["concept study", "TEST", 161, 174], ["RNA", "TREATMENT", 197, 200], ["the templating nucleic acid", "TREATMENT", 204, 231], ["ribosomal RNA", "OBSERVATION", 110, 123]]], ["Total RNA from both parasites L. major and T. cruzi was used.", [["L. major", "ORGANISM", 30, 38], ["T. cruzi", "ORGANISM", 43, 51], ["L. major", "SPECIES", 30, 38], ["T. cruzi", "SPECIES", 43, 51], ["L. major", "SPECIES", 30, 38], ["T. cruzi", "SPECIES", 43, 51], ["Total RNA", "PROBLEM", 0, 9], ["T. cruzi", "TEST", 43, 51], ["T. cruzi", "OBSERVATION", 43, 51]]], ["RNA quality and quantitation were determined using an Agilent 2100 Bioanalyzer and RNA 6000 Nano kit (Fig. S7 in SI).", [["S7", "PROTEIN", 107, 109], ["quantitation", "TEST", 16, 28], ["an Agilent 2100 Bioanalyzer", "TREATMENT", 51, 78]]], ["Total RNA was fragmented enzymatically, breaking down RNA strands into small segments to facilitate the subsequent hybridization with complementary abasic PNA probes.", [["RNA strands", "RNA", 54, 65], ["complementary abasic PNA probes", "DNA", 134, 165], ["Total RNA", "PROBLEM", 0, 9], ["the subsequent hybridization", "TREATMENT", 100, 128], ["complementary abasic PNA probes", "PROBLEM", 134, 165], ["fragmented", "OBSERVATION_MODIFIER", 14, 24], ["enzymatically", "OBSERVATION_MODIFIER", 25, 38], ["small segments", "ANATOMY_MODIFIER", 71, 85], ["abasic", "OBSERVATION_MODIFIER", 148, 154], ["PNA", "OBSERVATION", 155, 158]]], ["RNA fragmentation was checked using RNA Pico kit on an Agilent 2100 Bioanalyzer as shown in SI, Fig. S8.", [["S8", "GENE_OR_GENE_PRODUCT", 101, 103], ["S8", "PROTEIN", 101, 103], ["RNA fragmentation", "PROBLEM", 0, 17], ["an Agilent 2100 Bioanalyzer", "TREATMENT", 52, 79], ["fragmentation", "OBSERVATION", 4, 17]]], ["Dynamic incorporation of SMART-C-Biotin was performed using 10 \u00b5M of SMART-C-Biotin and 1 mM of sodium cyanoborohydride for 1 hour.", [["SMART-C-Biotin", "CHEMICAL", 25, 39], ["sodium cyanoborohydride", "CHEMICAL", 96, 119], ["sodium cyanoborohydride", "CHEMICAL", 96, 119], ["SMART-C-Biotin", "GENE_OR_GENE_PRODUCT", 25, 39], ["SMART-C-Biotin", "SIMPLE_CHEMICAL", 69, 83], ["sodium cyanoborohydride", "SIMPLE_CHEMICAL", 96, 119], ["SMART", "PROTEIN", 25, 30], ["SMART", "PROTEIN", 69, 74], ["SMART-C-Biotin", "TREATMENT", 25, 39], ["SMART-C-Biotin", "TREATMENT", 69, 83], ["1 mM of sodium cyanoborohydride", "TREATMENT", 88, 119]]], ["The results obtained coincided with those obtained when using PCR products.", [["PCR products", "TREATMENT", 62, 74]]], ["L. major gave positive results for PNA1 and T. cruzi provided a positive signal for both PNA probes (Fig. 8B).", [["PNA1", "GENE_OR_GENE_PRODUCT", 35, 39], ["T. cruzi", "ORGANISM", 44, 52], ["PNA1", "PROTEIN", 35, 39], ["T. cruzi", "SPECIES", 44, 52], ["T. cruzi", "SPECIES", 44, 52], ["PNA1", "PROBLEM", 35, 39], ["T. cruzi", "PROBLEM", 44, 52], ["a positive signal", "PROBLEM", 62, 79], ["both PNA probes", "PROBLEM", 84, 99], ["PNA", "OBSERVATION", 89, 92]]], ["This was a breakthrough achievement, demonstrating for the first time that direct, PCR free parasite identification from RNA samples was achieved.", [["samples", "ANATOMY", 125, 132], ["direct, PCR free parasite identification", "TEST", 75, 115], ["RNA samples", "TEST", 121, 132]]], ["In addition, a much shorter protocol was developed while at the same time reducing the possibility of cross-contamination.", [["a much shorter protocol", "TREATMENT", 13, 36], ["cross-contamination", "PROBLEM", 102, 121], ["cross-contamination", "OBSERVATION", 102, 121]]], ["This demostrated that RNA can also be considered as a biomarker source for the ChemNAT approach and a future application of the Spin-Tube.General ::: Material and MethodsAll chemicals were obtained from Sigma Aldrich and used as received.", [["RNA", "PROBLEM", 22, 25], ["the ChemNAT approach", "TREATMENT", 75, 95], ["the Spin-Tube", "TREATMENT", 124, 137], ["Tube", "OBSERVATION", 133, 137]]], ["SCD buffer was prepared from 2x saline sodium citrate (SSC) and 0.1% sodium dodecyl sulphate (SDS) with the pH adjusted to 6.0 using HCl.", [["SCD", "DISEASE", 0, 3], ["sodium citrate", "CHEMICAL", 39, 53], ["sodium dodecyl sulphate", "CHEMICAL", 69, 92], ["HCl", "CHEMICAL", 133, 136], ["sodium citrate", "CHEMICAL", 39, 53], ["sodium dodecyl sulphate", "CHEMICAL", 69, 92], ["SDS", "CHEMICAL", 94, 97], ["HCl", "CHEMICAL", 133, 136], ["saline sodium citrate", "SIMPLE_CHEMICAL", 32, 53], ["sodium dodecyl sulphate", "SIMPLE_CHEMICAL", 69, 92], ["HCl", "SIMPLE_CHEMICAL", 133, 136], ["SCD buffer", "TREATMENT", 0, 10], ["2x saline sodium citrate (SSC)", "TREATMENT", 29, 59], ["0.1% sodium dodecyl sulphate", "TREATMENT", 64, 92], ["the pH", "TEST", 104, 110], ["HCl", "TREATMENT", 133, 136]]], ["All synthetic DNA oligomers (desalted) were purchased from Microsynth AG (Balgach, Switzerland).", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["All synthetic DNA oligomers", "PROBLEM", 0, 27]]], ["The two abasic PNA probes (Abasic PNA1 and PNA2) were synthesized by DestiNA Genomica SL (Spain) using standard solid-phase synthesis techniques on an Intavis Bioanalytical Instruments MultiPrep CF Synthesizer (Intavis AG GmH, Germany).", [["Abasic PNA1", "SIMPLE_CHEMICAL", 27, 38], ["PNA2", "SIMPLE_CHEMICAL", 43, 47], ["abasic PNA probes", "DNA", 8, 25], ["The two abasic PNA probes", "TREATMENT", 0, 25], ["Abasic PNA1 and PNA2", "TREATMENT", 27, 47], ["standard solid-phase synthesis techniques", "TREATMENT", 103, 144], ["an Intavis Bioanalytical Instruments", "TREATMENT", 148, 184], ["two", "OBSERVATION_MODIFIER", 4, 7], ["abasic", "OBSERVATION_MODIFIER", 8, 14], ["PNA", "OBSERVATION", 15, 18], ["Abasic PNA1", "OBSERVATION", 27, 38]]], ["Aqueous solutions of abasic PNA probes were prepared and concentrations were determined using a NanoDrop ND-1000 spectrophotometer version 3.3.1.", [["PNA", "SIMPLE_CHEMICAL", 28, 31], ["Aqueous solutions", "TREATMENT", 0, 17], ["abasic PNA probes", "TREATMENT", 21, 38], ["a NanoDrop ND", "TREATMENT", 94, 107], ["abasic", "OBSERVATION_MODIFIER", 21, 27], ["PNA", "OBSERVATION", 28, 31]]], ["(Thermo Fisher Scientific) using as extinction coefficient values (\u0190260) either 6.6, 8.8, 13.7 and 11.7 (mM\u22121 cm\u22121) for C, T, A, G, respectively.", [["extinction coefficient values", "TEST", 36, 65], ["mM", "TEST", 105, 107], ["C", "TEST", 120, 121]]], ["SMART-C-Biotin was prepared by DestiNA Genomica SL (Spain) as reported elsewhere28.", [["SMART-C-Biotin", "CHEMICAL", 0, 14], ["SMART-C-Biotin", "GENE_OR_GENE_PRODUCT", 0, 14], ["C-Biotin", "TREATMENT", 6, 14]]], ["Buffers and dilution reagents were provided by Master Diagnostica SL (Spain).", [["Master Diagnostica SL", "ORGANISM", 47, 68], ["Buffers and dilution reagents", "TREATMENT", 0, 29]]], ["The composition of reagents I to VI is property of Vitro SA (Spain).Genomic DNA samples ::: Material and MethodsParasitic protozoa genomic DNAs (gDNAs) were purchased from the American Type Culture Collection (ATCC).", [["samples", "ANATOMY", 80, 87], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["MethodsParasitic protozoa genomic DNAs", "DNA", 105, 143], ["gDNAs", "DNA", 145, 150], ["Material and MethodsParasitic protozoa genomic DNAs (gDNAs)", "PROBLEM", 92, 151], ["protozoa genomic DNAs", "OBSERVATION", 122, 143]]], ["Respectively, gDNA from T. cruzi strain Tulahuen with ATCC ID 30266D and gDNA from L. major with ATCC ID 30012D.", [["gDNA", "CELLULAR_COMPONENT", 14, 18], ["T. cruzi", "ORGANISM", 24, 32], ["strain Tulahuen", "ORGANISM", 33, 48], ["T. cruzi", "SPECIES", 24, 32], ["L. major", "SPECIES", 83, 91], ["T. cruzi", "SPECIES", 24, 32], ["ATCC ID 30266D", "SPECIES", 54, 68], ["L. major", "SPECIES", 83, 91], ["ATCC ID 30012D", "SPECIES", 97, 111]]], ["Human gDNA was extracted from MUM-2B cell line provided by J.C. Rodr\u00edguez-Manzaneque\u2019s laboratory.Target nucleic acid selection ::: Material and MethodsMultiple sequence alignment of the 28S rRNA delta genes of L. major vs. T. cruzi was carried out using the Clustal Omega, a free on-line available multiple sequence alignment tool offered by EMBL-EBI.Target nucleic acid selection ::: Material and MethodsBLAST studies were carried out with the NCBI primer BLAST tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/primertool.cgi?ctg_time=1534265329&job_key=NT_qawTpCUEufxN6Hho3SGQBJnpJEj1nSA).PCR Amplification ::: Material and MethodsAlignment results were used to design a single pair of primers able to amplify the target region of both parasites.", [["MUM-2B cell line", "ANATOMY", 30, 46], ["nucleic acid", "CHEMICAL", 105, 117], ["nucleic acid", "CHEMICAL", 359, 371], ["Human", "ORGANISM", 0, 5], ["gDNA", "CELL", 6, 10], ["MUM-2B cell line", "CELL", 30, 46], ["28S rRNA delta", "GENE_OR_GENE_PRODUCT", 187, 201], ["L. major", "ORGANISM", 211, 219], ["T. cruzi", "ORGANISM", 224, 232], ["MUM-2B cell line", "CELL_LINE", 30, 46], ["28S rRNA delta genes", "DNA", 187, 207], ["Clustal Omega", "DNA", 259, 272], ["Human", "SPECIES", 0, 5], ["L. major", "SPECIES", 211, 219], ["T. cruzi", "SPECIES", 224, 232], ["Human", "SPECIES", 0, 5], ["L. major", "SPECIES", 211, 219], ["T. cruzi", "SPECIES", 224, 232], ["Human gDNA", "TREATMENT", 0, 10], ["2B cell line", "TREATMENT", 34, 46], ["MethodsMultiple sequence alignment", "TEST", 145, 179], ["the 28S rRNA", "TEST", 183, 195], ["T. cruzi", "PROBLEM", 224, 232], ["the Clustal Omega", "TREATMENT", 255, 272], ["MethodsBLAST studies", "TEST", 399, 419], ["a single pair of primers", "TREATMENT", 677, 701], ["acid selection", "OBSERVATION", 113, 127], ["acid selection", "OBSERVATION", 367, 381], ["both", "ANATOMY_MODIFIER", 739, 743], ["parasites", "OBSERVATION", 744, 753]]], ["Primers (5'-3') sequences were: Forward: GATTGTGAAGGGATCTCGCAG and Reverse: TCTGGCTTAGAGGCGTTCA.", [["5'-3') sequences", "DNA", 9, 25]]], ["PCR amplification was performed on a Veriti 96-well Thermal cycler (Thermo Fisher Scientific).", [["PCR amplification", "TEST", 0, 17], ["a Veriti", "TEST", 35, 43]]], ["Cycling conditions for PCR were as follows: (1) initial denaturation at 96 \u00b0C for 3 min; (2) 40 cycles of (a) denaturation 96 \u00b0C for 30 sec, (b) annealing at 61 \u00b0C for 30 sec, and (c) extension at 72 \u00b0C for 30 sec; (3) final extension at 72 \u00b0C for 10 sec; (4) final hold at 4 \u00b0C. 5 \u00b5L of gDNA solutions containing different amounts of gDNA solution for L. major or T. cruzi were amplified using 1X PCR master mix (Thermo Fisher Scientific), 0.15 \u00b5M forward and reverse primers per reaction with a final volume of 50 \u00b5L.", [["L. major", "ORGANISM", 353, 361], ["T. cruzi", "ORGANISM", 365, 373], ["L. major", "SPECIES", 353, 361], ["T. cruzi", "SPECIES", 365, 373], ["L. major", "SPECIES", 353, 361], ["T. cruzi", "SPECIES", 365, 373], ["PCR", "TEST", 23, 26], ["initial denaturation", "PROBLEM", 48, 68], ["denaturation", "TEST", 110, 122], ["gDNA solutions", "TREATMENT", 288, 302], ["different amounts of gDNA solution", "TREATMENT", 314, 348], ["T. cruzi", "PROBLEM", 365, 373], ["a final volume", "TEST", 495, 509]]], ["DNA templates were replaced with water for negative controls.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA templates", "DNA", 0, 13], ["DNA templates", "TREATMENT", 0, 13]]], ["PCR reactions were confirmed by capillary electrophoresis using the Agilent 2100 Bioanalyzer and DNA 1000 Kit.RNA fragmentation ::: Material and MethodsRNA was extracted from parasites as described elsewhere45.", [["capillary", "TISSUE", 32, 41], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["PCR reactions", "TEST", 0, 13], ["capillary electrophoresis", "TEST", 32, 57], ["the Agilent 2100 Bioanalyzer", "TREATMENT", 64, 92], ["MethodsRNA", "PROBLEM", 145, 155], ["parasites", "PROBLEM", 175, 184], ["fragmentation", "OBSERVATION", 114, 127], ["parasites", "OBSERVATION", 175, 184]]], ["RNA quality assessment and quantitation were determined using the Agilent 2100 Bioanalyzer and RNA 6000 Pico Kit (Fig. S7 in SI).", [["S7", "PROTEIN", 119, 121], ["RNA quality assessment", "TEST", 0, 22], ["quantitation", "TEST", 27, 39], ["the Agilent 2100 Bioanalyzer", "TREATMENT", 62, 90]]], ["NEBNext Magnesium RNA Fragmentation Module Protocol was used to fragment RNA.", [["Magnesium", "CHEMICAL", 8, 17], ["Magnesium", "CHEMICAL", 8, 17], ["NEBNext", "TREATMENT", 0, 7], ["Magnesium RNA Fragmentation Module Protocol", "TREATMENT", 8, 51], ["fragment RNA", "PROBLEM", 64, 76]]], ["The following reagents were mixed in a sterile PCR tube: 1\u201318 \u00b5L of purified RNA containing 2\u201350 \u00b5g of total RNA, 2 \u00b5L of RNA fragmentation buffer and complete with nuclease-free water up to 20 \u00b5L.", [["purified RNA", "RNA", 68, 80], ["total RNA", "RNA", 103, 112], ["nuclease", "PROTEIN", 165, 173], ["a sterile PCR tube", "TREATMENT", 37, 55], ["purified RNA", "TREATMENT", 68, 80], ["total RNA", "TREATMENT", 103, 112], ["RNA fragmentation buffer", "TREATMENT", 122, 146], ["nuclease-free water", "TREATMENT", 165, 184]]], ["The mixture was incubated at 94 \u00b0C for 5 minutes (to get fragments of around 200-mer length).", [["fragments", "ANATOMY", 57, 66], ["fragments", "PROBLEM", 57, 66]]], ["Then the tube was transferred to ice and 2 \u00b5L of RNA Fragmentation stop solution were added.", [["tube", "ANATOMY", 9, 13], ["tube", "TISSUE", 9, 13], ["the tube", "TREATMENT", 5, 13], ["ice", "TREATMENT", 33, 36], ["RNA Fragmentation stop solution", "TREATMENT", 49, 80], ["tube", "OBSERVATION", 9, 13]]], ["The fragmented RNA was cleaned up using ethanol precipitation: 22 \u00b5L of fragmented RNA, 2 \u00b5L of 3 M sodium acetate pH 5.2 and 60 \u00b5L of 100% ethanol.", [["ethanol", "CHEMICAL", 40, 47], ["sodium acetate", "CHEMICAL", 100, 114], ["ethanol", "CHEMICAL", 140, 147], ["ethanol", "CHEMICAL", 40, 47], ["sodium acetate", "CHEMICAL", 100, 114], ["ethanol", "CHEMICAL", 140, 147], ["ethanol", "SIMPLE_CHEMICAL", 40, 47], ["sodium acetate", "SIMPLE_CHEMICAL", 100, 114], ["ethanol", "SIMPLE_CHEMICAL", 140, 147], ["The fragmented RNA", "PROBLEM", 0, 18], ["ethanol precipitation", "TREATMENT", 40, 61], ["fragmented RNA", "TREATMENT", 72, 86], ["3 M sodium acetate pH", "TREATMENT", 96, 117], ["fragmented", "OBSERVATION_MODIFIER", 4, 14], ["RNA", "OBSERVATION_MODIFIER", 15, 18]]], ["The mixture was incubated at -80 \u00b0C for 30 minutes and then centrifuged at 14,000 r.p.m. for 25 minutes at 4 \u00b0C and ethanol was removed carefully.", [["ethanol", "CHEMICAL", 116, 123], ["ethanol", "CHEMICAL", 116, 123], ["ethanol", "SIMPLE_CHEMICAL", 116, 123], ["ethanol", "TREATMENT", 116, 123]]], ["The pellet was washed with 300 \u00b5L of 70% ethanol, centrifuged and removed the ethanol.", [["pellet", "ANATOMY", 4, 10], ["ethanol", "CHEMICAL", 41, 48], ["ethanol", "CHEMICAL", 78, 85], ["ethanol", "CHEMICAL", 41, 48], ["ethanol", "CHEMICAL", 78, 85], ["ethanol", "SIMPLE_CHEMICAL", 41, 48], ["ethanol", "SIMPLE_CHEMICAL", 78, 85], ["pellet", "OBSERVATION", 4, 10]]], ["Finally, the pellet was air-dry for up to 10 minutes at room temperature and re-suspended in 13.5 \u00b5L of nuclease-free water.", [["nuclease", "PROTEIN", 104, 112], ["nuclease-free water", "TREATMENT", 104, 123], ["air", "OBSERVATION", 24, 27]]], ["To assess the yield and size distribution of the fragmented RNA, 1 \u00b5L of a 10-fold dilution was analyzed using the Agilent 2100 Bioanalyzer and RNA 6000 Pico Kit analysis (Fig. S8 in SI).Abasic PNA probes spotting ::: Material and MethodsAn automatic immobilization of the probes on the membranes was done using Personal Arrayer 16 (CapitalBio Corporation, China).", [["membranes", "ANATOMY", 287, 296], ["membranes", "CELLULAR_COMPONENT", 287, 296], ["fragmented RNA", "RNA", 49, 63], ["S8", "PROTEIN", 177, 179], ["the fragmented RNA", "PROBLEM", 45, 63], ["a 10-fold dilution", "TREATMENT", 73, 91], ["the Agilent 2100 Bioanalyzer", "TREATMENT", 111, 139], ["Abasic PNA probes spotting", "PROBLEM", 187, 213], ["Material", "TREATMENT", 218, 226], ["MethodsAn automatic immobilization", "TREATMENT", 231, 265], ["Personal Arrayer", "TREATMENT", 312, 328], ["size", "OBSERVATION_MODIFIER", 24, 28], ["distribution", "OBSERVATION_MODIFIER", 29, 41], ["fragmented RNA", "OBSERVATION", 49, 63], ["PNA", "OBSERVATION", 194, 197]]], ["Abasic PNA probe spotting solutions were prepared to have the following final reagents concentrations 0.2025 mg/mL amaranth dye, 0.125 M sodium bicarbonate, 30% of DMSO and 15 \u00b5M abasic PNA probe.Spin-Tube: SMART-C-Biotin dynamic incorporation reaction on membranes and colorimetric readout ::: Material and MethodsReaction mixtures with a final volume of 300 \u00b5L were prepared by mixing: 45 \u00b5L of PCR products, 15 \u00b5L of SMART-C-Biotin (200 \u00b5M), 20 \u00b5L of sodium cyanoborohydride (NaBH3CN) - 15 mM in water, and 220 \u00b5L of SCD buffer.", [["membranes", "ANATOMY", 256, 265], ["sodium bicarbonate", "CHEMICAL", 137, 155], ["DMSO", "CHEMICAL", 164, 168], ["SMART-C-Biotin", "CHEMICAL", 420, 434], ["sodium cyanoborohydride", "CHEMICAL", 454, 477], ["NaBH3CN", "CHEMICAL", 479, 486], ["sodium bicarbonate", "CHEMICAL", 137, 155], ["DMSO", "CHEMICAL", 164, 168], ["sodium cyanoborohydride", "CHEMICAL", 454, 477], ["NaBH3CN", "CHEMICAL", 479, 486], ["amaranth dye", "SIMPLE_CHEMICAL", 115, 127], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 137, 155], ["DMSO", "SIMPLE_CHEMICAL", 164, 168], ["SMART-C-Biotin", "SIMPLE_CHEMICAL", 207, 221], ["membranes", "CELLULAR_COMPONENT", 256, 265], ["SMART-C-Biotin", "SIMPLE_CHEMICAL", 420, 434], ["sodium cyanoborohydride", "SIMPLE_CHEMICAL", 454, 477], ["NaBH3CN", "SIMPLE_CHEMICAL", 479, 486], ["Abasic PNA probe spotting solutions", "TREATMENT", 0, 35], ["final reagents concentrations", "TREATMENT", 72, 101], ["sodium bicarbonate", "TREATMENT", 137, 155], ["DMSO", "TREATMENT", 164, 168], ["abasic PNA probe", "TREATMENT", 179, 195], ["C-Biotin dynamic incorporation reaction", "TREATMENT", 213, 252], ["MethodsReaction mixtures", "TREATMENT", 308, 332], ["PCR products", "TREATMENT", 397, 409], ["SMART-C-Biotin", "TREATMENT", 420, 434], ["sodium cyanoborohydride (NaBH3CN)", "TREATMENT", 454, 487], ["SCD buffer", "TREATMENT", 520, 530], ["PNA", "OBSERVATION", 7, 10], ["PNA", "OBSERVATION", 186, 189], ["Tube", "OBSERVATION", 201, 205]]], ["Protocol: All steps were performed using 300 \u00b5L and Spin-Tube devices were centrifuged to discard the solutions between each step.", [["Spin-Tube devices", "TREATMENT", 52, 69]]], ["Membranes were incubated for 2 minutes at 45 \u00b0C with 300 \u00b5L of SCD buffer.", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["SCD buffer", "TREATMENT", 63, 73]]], ["The reaction mixture was added and incubated at 45 \u00b0C for 60 minutes.", [["The reaction mixture", "TREATMENT", 0, 20]]], ["Upon completion of the incubation, three post-reaction washing steps were carried out using reagent I (pre-heated at 45 \u00b0C).", [["the incubation", "TREATMENT", 19, 33], ["three post-reaction washing steps", "TREATMENT", 35, 68]]], ["This was followed by a blocking step in which membranes were incubated with reagent II for 5 minutes at RT.", [["membranes", "ANATOMY", 46, 55], ["membranes", "CELLULAR_COMPONENT", 46, 55], ["a blocking step", "TREATMENT", 21, 36], ["reagent II", "TREATMENT", 76, 86]]], ["The enzymatic reaction was carried out by incubating the membranes with reagent III at RT for 5 minutes.", [["membranes", "ANATOMY", 57, 66], ["membranes", "CELLULAR_COMPONENT", 57, 66], ["The enzymatic reaction", "PROBLEM", 0, 22], ["reagent III at RT", "TREATMENT", 72, 89], ["enzymatic reaction", "OBSERVATION", 4, 22]]], ["Four post-enzymatic reaction washing steps with reagent IV were carried out.", [["Four post-enzymatic reaction", "TREATMENT", 0, 28], ["reagent IV", "TREATMENT", 48, 58]]], ["The chromogen solution (reagent V) was added to the membranes and left at 41 \u00b0C for 5 minutes.", [["membranes", "ANATOMY", 52, 61], ["chromogen", "CHEMICAL", 4, 13], ["chromogen", "SIMPLE_CHEMICAL", 4, 13], ["membranes", "CELLULAR_COMPONENT", 52, 61], ["The chromogen solution (reagent V)", "TREATMENT", 0, 34], ["left", "ANATOMY_MODIFIER", 66, 70]]], ["Finally, three post-chromogen washing steps with reagent VI were carried out.", [["reagent VI", "TREATMENT", 49, 59]]], ["Membranes were able to be analyzed.Sensitivity and specificity of the assay ::: Material and MethodsTo assess the specificity of the assay, four tests were carried out: (1) one in which the PCR contained water instead of gDNAs and (2) another one in which 20 ng of human gDNA was used as template; and two more tests in which 20 ng of human gDNA were mixed with other 20 ng of each parasite (Fig. 5).", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["human", "ORGANISM", 265, 270], ["gDNA", "CELL", 271, 275], ["human", "ORGANISM", 335, 340], ["gDNA", "CELL", 341, 345], ["human gDNA", "DNA", 265, 275], ["human gDNA", "DNA", 335, 345], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 335, 340], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 335, 340], ["Sensitivity", "TEST", 35, 46], ["the assay", "TEST", 129, 138], ["four tests", "TEST", 140, 150], ["the PCR", "TEST", 186, 193], ["human gDNA", "TREATMENT", 265, 275], ["two more tests", "TEST", 302, 316], ["human gDNA", "TREATMENT", 335, 345]]], ["On the other hand, for the sensitivity study, a range of PCR amplification reactions were performed using decreasing amounts of starting T. cruzi gDNA.", [["T. cruzi", "ORGANISM", 137, 145], ["gDNA", "ORGANISM", 146, 150], ["T. cruzi", "SPECIES", 137, 145], ["T. cruzi", "SPECIES", 137, 145], ["the sensitivity study", "TEST", 23, 44], ["PCR amplification reactions", "PROBLEM", 57, 84], ["T. cruzi gDNA", "PROBLEM", 137, 150]]], ["Six different concentration points (10-fold dilutions) plus a negative control (water) were used in triplicate.", [["a negative control (water)", "TREATMENT", 60, 86], ["concentration", "OBSERVATION_MODIFIER", 14, 27]]], ["All PCR amplification products were analyzed by capillary electrophoresis to determine the amount, if any, of amplicon had been generated (Fig. 5 for specificity and Fig. 6 and Table S1 for sensitivity).", [["capillary", "TISSUE", 48, 57], ["PCR amplification products", "DNA", 4, 30], ["All PCR amplification products", "TREATMENT", 0, 30], ["capillary electrophoresis", "TEST", 48, 73], ["amplicon", "PROBLEM", 110, 118], ["specificity", "TEST", 150, 161], ["Fig.", "TEST", 166, 170], ["sensitivity", "TEST", 190, 201]]], ["Expected size of amplicons were detected when the PCR was performed using the four highest amount of parasitic gDNAs while no bands were detected neither when using just human gDNA nor when using 0.1 and 0.01 pg/\u00b5L (Fig. 6B).", [["gDNAs", "GENE_OR_GENE_PRODUCT", 111, 116], ["human", "ORGANISM", 170, 175], ["parasitic gDNAs", "RNA", 101, 116], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["Expected size of amplicons", "PROBLEM", 0, 26], ["the PCR", "TEST", 46, 53], ["parasitic gDNAs", "PROBLEM", 101, 116], ["bands", "PROBLEM", 126, 131], ["size", "OBSERVATION_MODIFIER", 9, 13], ["amplicons", "OBSERVATION", 17, 26], ["parasitic gDNAs", "OBSERVATION", 101, 116]]], ["Negative control (water) has not shown any signal, being truly a negative and so being effectively called as parasite free.L. major gDNA spike-in experiments on blood ::: Material and MethodsDNA was extracted from 200 \u00b5L of human whole blood samples using QIAamp DNA Blood mini kit (Qiagen, Germany) following manufacturer\u2019s guidelines.", [["blood", "ANATOMY", 161, 166], ["whole blood samples", "ANATOMY", 230, 249], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["human", "ORGANISM", 224, 229], ["whole", "ORGANISM_SUBSTANCE", 230, 235], ["blood samples", "ORGANISM_SUBSTANCE", 236, 249], ["QIAamp DNA", "ORGANISM_SUBSTANCE", 256, 266], ["Blood", "ORGANISM_SUBSTANCE", 267, 272], ["human", "SPECIES", 224, 229], ["human", "SPECIES", 224, 229], ["L. major gDNA spike", "PROBLEM", 123, 142], ["blood samples", "TEST", 236, 249], ["negative", "OBSERVATION", 65, 73], ["gDNA spike", "OBSERVATION", 132, 142]]], ["After proteinase K treatment, two samples were spiked with 10 and 0.1 ng of L. major gDNA.", [["samples", "ANATOMY", 34, 41], ["K", "CHEMICAL", 17, 18], ["proteinase K", "GENE_OR_GENE_PRODUCT", 6, 18], ["proteinase K treatment", "TREATMENT", 6, 28], ["two samples", "TEST", 30, 41]]], ["Then, the next steps of the DNA extraction protocol were followed as recommended.", [["DNA", "CELLULAR_COMPONENT", 28, 31], ["the DNA extraction protocol", "TREATMENT", 24, 51]]], ["Samples were eluted in 30 \u00b5L of elution buffer AE.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["DNA was quantified with NanoDrop ND-1000 spectrophotometer version 3.3.1.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "PROBLEM", 0, 3], ["NanoDrop ND", "TREATMENT", 24, 35], ["spectrophotometer version", "TEST", 41, 66]]], ["PCR reactions were performed with a fix amount of DNA, 450 ng.", [["DNA", "CELLULAR_COMPONENT", 50, 53], ["PCR reactions", "TEST", 0, 13], ["DNA", "PROBLEM", 50, 53]]], ["After that, PCR were analyzed by capillary electrophoresis (using the Agilent 2100 Bioanalyzer and DNA 1000 Kit) and by the Spin-Tube.ConclusionsOur previous SNF sequence analysis by mass-based assay (MALDI-ToF) for trypanosomiasis identification has been further developed onto a new ultra-low-cost, easy and fast to use (~3 hours/test) Spin-Tube device.", [["trypanosomiasis", "DISEASE", 216, 231], ["capillary", "TISSUE", 33, 42], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["SNF sequence", "DNA", 158, 170], ["PCR", "TEST", 12, 15], ["capillary electrophoresis", "TEST", 33, 58], ["the Agilent 2100 Bioanalyzer", "TREATMENT", 66, 94], ["the Spin-Tube", "TREATMENT", 120, 133], ["ConclusionsOur previous SNF sequence analysis", "TEST", 134, 179], ["mass", "TEST", 183, 187], ["based assay", "TEST", 188, 199], ["MALDI", "TEST", 201, 206], ["trypanosomiasis", "PROBLEM", 216, 231], ["a new ultra", "TEST", 279, 290], ["Spin-Tube device", "TREATMENT", 338, 354], ["Tube", "OBSERVATION", 129, 133], ["Tube device", "OBSERVATION", 343, 354]]], ["This novel device was designed to combine the dynamic chemical approach for nucleic acid reading (ChemNAT technology) with a colorimetric method in a plastic column and nylon membrane device (Spin-Tube).", [["membrane", "ANATOMY", 175, 183], ["nucleic acid", "CHEMICAL", 76, 88], ["nucleic acid", "SIMPLE_CHEMICAL", 76, 88], ["This novel device", "TREATMENT", 0, 17], ["nucleic acid reading", "TEST", 76, 96], ["a colorimetric method", "TREATMENT", 123, 144], ["a plastic column", "TREATMENT", 148, 164], ["nylon membrane device (Spin-Tube", "TREATMENT", 169, 201], ["plastic column", "OBSERVATION", 150, 164], ["nylon membrane device", "OBSERVATION", 169, 190]]], ["The Spin-Tube accurately distinguish and identify Chagas disease vs. Leishmaniasis.", [["Chagas disease", "DISEASE", 50, 64], ["Leishmaniasis", "DISEASE", 69, 82], ["The Spin-Tube", "TREATMENT", 0, 13], ["Chagas disease", "PROBLEM", 50, 64], ["Leishmaniasis", "PROBLEM", 69, 82], ["Tube", "OBSERVATION", 9, 13]]], ["The test consists of a singleplex PCR to amplify a highly conserved sequence of DNA, that encodes the RNA component of the large ribosome subunit containing SNFs from the two different parasite species under interrogation.", [["DNA", "CELLULAR_COMPONENT", 80, 83], ["SNFs", "GENE_OR_GENE_PRODUCT", 157, 161], ["singleplex PCR", "DNA", 23, 37], ["ribosome subunit", "PROTEIN", 129, 145], ["SNFs", "PROTEIN", 157, 161], ["a singleplex PCR", "TEST", 21, 37], ["DNA", "PROBLEM", 80, 83], ["the large ribosome subunit containing SNFs", "PROBLEM", 119, 161], ["the two different parasite species", "PROBLEM", 167, 201], ["large", "OBSERVATION_MODIFIER", 123, 128], ["ribosome subunit", "OBSERVATION", 129, 145], ["SNFs", "OBSERVATION_MODIFIER", 157, 161], ["two different", "OBSERVATION_MODIFIER", 171, 184], ["parasite species", "OBSERVATION", 185, 201]]], ["Dynamic chemistry enables preformans in a simple Spin-Tube.", [["a simple Spin-Tube", "TREATMENT", 40, 58], ["Tube", "OBSERVATION", 54, 58]]], ["The assay allows for a naked-eye read-out of the unique colorimetric patterns coming for sample analysis.", [["eye", "ANATOMY", 29, 32], ["eye", "ORGAN", 29, 32], ["The assay", "TEST", 0, 9], ["a naked-eye read", "TEST", 21, 37], ["sample analysis", "TEST", 89, 104]]], ["Clinical treatment decisions can be made without any ancillary equipment.", [["Clinical treatment", "TREATMENT", 0, 18]]], ["The proposed Spin-Tube assay not only allows the detection of the presence of Trypanosomatid pathogens, but also differential diagnosis of Leishmaniasis vs. Chagas disease.", [["Leishmaniasis", "DISEASE", 139, 152], ["Chagas disease", "DISEASE", 157, 171], ["The proposed Spin-Tube assay", "TEST", 0, 28], ["Trypanosomatid pathogens", "PROBLEM", 78, 102], ["Leishmaniasis", "PROBLEM", 139, 152], ["Chagas disease", "PROBLEM", 157, 171], ["Tube", "OBSERVATION", 18, 22], ["Trypanosomatid pathogens", "OBSERVATION", 78, 102], ["Leishmaniasis", "OBSERVATION", 139, 152]]], ["Multiplexing is achieved by coupling various target-specific abasic probes onto nylon membranes using different array layouts and patterns.", [["nylon membranes", "ANATOMY", 80, 95], ["membranes", "CELLULAR_COMPONENT", 86, 95], ["nylon membranes", "TREATMENT", 80, 95], ["different array layouts", "TREATMENT", 102, 125]]], ["Incorporation of SMART-Biotin only into target sequences ensure high specificity.", [["SMART-Biotin", "GENE_OR_GENE_PRODUCT", 17, 29], ["SMART", "PROTEIN", 17, 22], ["target sequences", "DNA", 40, 56], ["SMART-Biotin", "TREATMENT", 17, 29], ["target sequences", "TEST", 40, 56]]], ["Clinically relevant sensitivity was obtained using our amplification and detection platform, down to a level of detection of 0.001 ng/\u00b5L (8.7 copies per \u00b5L) of gDNA from pathogen.", [["our amplification", "TEST", 51, 68], ["detection platform", "TEST", 73, 91], ["detection", "TEST", 112, 121], ["gDNA", "PROBLEM", 160, 164], ["pathogen", "PROBLEM", 170, 178]]], ["Moreover, 0.1 ng of L. major gDNA was successfully detected when spiked-in with human blood samples.", [["blood samples", "ANATOMY", 86, 99], ["human", "ORGANISM", 80, 85], ["blood samples", "ORGANISM_SUBSTANCE", 86, 99], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["human blood samples", "TEST", 80, 99]]], ["The assay has demonstrated a clinically relevant sensitivity and specificity44.", [["The assay", "TEST", 0, 9]]], ["A remarkable achievement was for the first time to succeed in the direct detection of ribosomal RNA.", [["ribosomal", "ANATOMY", 86, 95], ["ribosomal", "CELLULAR_COMPONENT", 86, 95], ["ribosomal RNA", "RNA", 86, 99], ["ribosomal RNA", "PROBLEM", 86, 99], ["ribosomal RNA", "OBSERVATION", 86, 99]]], ["It opens up the possibility for direct detection of Trypanosomatids from biological fluids without any pre-amplification or pre-labelling of target nucleic acids.", [["nucleic acids", "CHEMICAL", 148, 161], ["Trypanosomatids", "SIMPLE_CHEMICAL", 52, 67], ["nucleic acids", "SIMPLE_CHEMICAL", 148, 161], ["Trypanosomatids", "PROBLEM", 52, 67], ["biological fluids", "TREATMENT", 73, 90], ["target nucleic acids", "TREATMENT", 141, 161]]], ["This breakthrough provides a prototype assay for an innovative PCR free product with many inherent benefits such as lower cross-contamination risk, simplification of protocol, reduction of time-to-results, significantly lower cost, to insure far lower risk of assay result errors.", [["a prototype assay", "TEST", 27, 44], ["an innovative PCR free product", "TREATMENT", 49, 79], ["lower cross-contamination risk", "PROBLEM", 116, 146], ["simplification of protocol", "TREATMENT", 148, 174]]], ["Concluding, we believe that the Spin-Tube developed by our group provides an accurate tool conbianing high sensitivity and specificity, permitting rapid identification and differential diagnosis of Chagas disease and Leishmaniasis.", [["Chagas disease", "DISEASE", 198, 212], ["Leishmaniasis", "DISEASE", 217, 230], ["the Spin-Tube", "TREATMENT", 28, 41], ["Chagas disease", "PROBLEM", 198, 212], ["Leishmaniasis", "PROBLEM", 217, 230], ["Tube", "OBSERVATION", 37, 41], ["Chagas disease", "OBSERVATION", 198, 212], ["Leishmaniasis", "OBSERVATION", 217, 230]]], ["Its clinical value will be an improved patient monitoring and therapeutic decision making.", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["patient monitoring", "TEST", 39, 57]]], ["The Spin-Tube opens-up the promise of repertoire of assays for other infectious diseases, such as malaria and tuberculosis.", [["infectious diseases", "DISEASE", 69, 88], ["malaria", "DISEASE", 98, 105], ["tuberculosis", "DISEASE", 110, 122], ["The Spin-Tube", "TREATMENT", 0, 13], ["other infectious diseases", "PROBLEM", 63, 88], ["malaria", "PROBLEM", 98, 105], ["tuberculosis", "PROBLEM", 110, 122], ["Tube", "OBSERVATION", 9, 13], ["infectious", "OBSERVATION", 69, 79], ["malaria", "OBSERVATION", 98, 105], ["tuberculosis", "OBSERVATION", 110, 122]]]], "10e911da410293ad08a411014b45074cf8c6523e": [["J o u r n a l P r e -p r o o fSince the novel coronavirus disease, named COVID-19, was recognized by the World Health Organization as pandemic on March 11 th , 2020, measures have been taken to try flattening the epidemic curve and to allow healthcare systems to deal with the emergency.J o u r n a l P r e -p r o o fBecause of COVID-19 high contagiousness and spreading through respiratory droplets [1] , it is crucial to identify and promptly isolate COVID-19 patients.", [["respiratory droplets", "ANATOMY", 379, 399], ["coronavirus disease", "DISEASE", 46, 65], ["coronavirus", "ORGANISM", 46, 57], ["patients", "ORGANISM", 462, 470], ["patients", "SPECIES", 462, 470], ["the novel coronavirus disease", "PROBLEM", 36, 65], ["COVID", "TEST", 73, 78], ["flattening the epidemic curve", "PROBLEM", 198, 227], ["COVID", "TEST", 328, 333], ["high contagiousness", "PROBLEM", 337, 356], ["spreading through respiratory droplets", "PROBLEM", 361, 399], ["coronavirus disease", "OBSERVATION", 46, 65]]], ["In Italy, more than 22.000 health care providers resulted positive to COVID-19, and 154 physicians have dead due to the disease (https://portale.fnomceo.it/elenco-dei-medici-caduti-nel-corso-dellepidemia-di-covid-19/), most of them being family doctors.", [["the disease", "PROBLEM", 116, 127], ["disease", "OBSERVATION", 120, 127]]], ["To deal with pandemic, most countries organized constricted security measures, including lockdown, social distancing, and usage of personal protective equipment, partially continued also after the pandemic peak.J o u r n a l P r e -p r o o fIn this context, chest imaging examinations, in particular chest x-ray (CXR) [2] and computed tomography (CT) [3] can play a pivotal role in different settings, to triage in case of unavailability, delay of or first negative result of reverse transcriptase-polymerase chain reaction (RT-PCR) [4] , and to stratify disease severity.", [["reverse transcriptase", "PROTEIN", 476, 497], ["pandemic", "PROBLEM", 13, 21], ["personal protective equipment", "TREATMENT", 131, 160], ["the pandemic peak", "PROBLEM", 193, 210], ["chest imaging examinations", "TEST", 258, 284], ["particular chest x-ray", "TEST", 289, 311], ["CXR", "TEST", 313, 316], ["computed tomography (CT)", "TEST", 326, 350], ["reverse transcriptase-polymerase chain reaction", "PROBLEM", 476, 523], ["RT-PCR", "TEST", 525, 531], ["stratify disease severity", "PROBLEM", 546, 571], ["constricted", "OBSERVATION_MODIFIER", 48, 59], ["chest", "ANATOMY", 258, 263], ["chest", "ANATOMY", 300, 305], ["disease", "OBSERVATION", 555, 562]]], ["We must consider the need to reduce, as much as possible, hospital admission of patients with suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection when they could receive care at home, as well as the access to emergency department of patients without SARS-CoV-2 infection.", [["acute respiratory syndrome coronavirus", "DISEASE", 124, 162], ["infection", "DISEASE", 178, 187], ["SARS-CoV-2 infection", "DISEASE", 292, 312], ["patients", "ORGANISM", 80, 88], ["SARS-CoV-2", "ORGANISM", 166, 176], ["patients", "ORGANISM", 275, 283], ["SARS-CoV-2", "ORGANISM", 292, 302], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 275, 283], ["severe acute respiratory syndrome coronavirus", "SPECIES", 117, 162], ["SARS-CoV-2", "SPECIES", 166, 176], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 117, 162], ["SARS", "PROBLEM", 166, 170], ["infection", "PROBLEM", 178, 187], ["SARS", "PROBLEM", 292, 296], ["CoV", "PROBLEM", 297, 300], ["2 infection", "PROBLEM", 301, 312], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["respiratory syndrome", "OBSERVATION", 130, 150], ["infection", "OBSERVATION", 303, 312]]], ["Indeed, the former may increase the infection outbreak, the latter may be unnecessarily exposed to risk of infection.", [["infection", "DISEASE", 36, 45], ["infection", "DISEASE", 107, 116], ["the infection outbreak", "PROBLEM", 32, 54], ["infection", "PROBLEM", 107, 116], ["infection", "OBSERVATION", 36, 45], ["infection", "OBSERVATION", 107, 116]]], ["The weakness of an effective community medicine practice, including home healthcare, has been judged as a strategic issue in the discussion on the pandemic outbreak in Italy, in particular in Lombardy.J o u r n a l P r e -p r o o fThe use of mobile x-ray equipment could represent a safe approach, enabling imaging of suspected or confirmed COVID-19 patients, performing examinations in their house or nursing home, reducing social contacts [5] .", [["patients", "ORGANISM", 350, 358], ["patients", "SPECIES", 350, 358], ["The weakness", "PROBLEM", 0, 12], ["mobile x-ray equipment", "TREATMENT", 242, 264], ["enabling imaging", "TEST", 298, 314], ["performing examinations", "TEST", 360, 383], ["weakness", "OBSERVATION", 4, 12]]], ["Of note, it has been already shown that x-ray examinations performed at home (or in the nursing home) using modern mobile equipment provide an image quality at least comparable to those obtained at hospital [6, 7] .J o u r n a l P r e -p r o o fWe picture the following sequence of events ( Figure 1 ): 1) a case of suspected COVID-19 patient is detected by any telephone service or doctor requested of a visit in the presence of symptoms or contact with a confirmed COVID-19 case; 2) a team composed by a radiographer and a nurse go to patient's home to perform CXR using a mobile equipment, nasopharyngeal swab (and, if needed, also a blood sample); 3) clinical information and CXR images are sent to a radiology department through a protected web-based tool; 4) a radiologist immediately reports the examination; 5) the report is sent to the general practitioner or any other clinician for the best decision-making; 6) the team, being still at patient's home, can explain to patients and her/his family what to do and, if necessary, to start applying home isolation.", [["nasopharyngeal swab", "ANATOMY", 593, 612], ["blood sample", "ANATOMY", 637, 649], ["patient", "ORGANISM", 335, 342], ["patient", "ORGANISM", 537, 544], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 593, 612], ["blood", "ORGANISM_SUBSTANCE", 637, 642], ["patient", "ORGANISM", 947, 954], ["patients", "ORGANISM", 978, 986], ["patient", "SPECIES", 335, 342], ["patient", "SPECIES", 537, 544], ["patient", "SPECIES", 947, 954], ["patients", "SPECIES", 978, 986], ["x-ray examinations", "TEST", 40, 58], ["modern mobile equipment", "TREATMENT", 108, 131], ["symptoms", "PROBLEM", 430, 438], ["CXR", "TEST", 563, 566], ["a mobile equipment", "TREATMENT", 573, 591], ["nasopharyngeal swab", "TEST", 593, 612], ["a blood sample", "TEST", 635, 649], ["CXR images", "TEST", 680, 690], ["the examination", "TEST", 799, 814], ["home isolation", "TREATMENT", 1054, 1068]]], ["The RT-PCR result will be considered as soon as it is available and a diagnostic pathway including history of contacts with COVID-19 patients, symptoms, CXR and RT-PCR result may guide the clinical decision-making.J o u r n a l P r e -p r o o fTo reduce health care workers potential exposure to COVID-19, general precautions should be adopted while performing CXR and pharyngeal swab.", [["pharyngeal swab", "ANATOMY", 369, 384], ["patients", "ORGANISM", 133, 141], ["pharyngeal swab", "MULTI-TISSUE_STRUCTURE", 369, 384], ["CXR", "PROTEIN", 361, 364], ["patients", "SPECIES", 133, 141], ["The RT-PCR", "TEST", 0, 10], ["symptoms", "PROBLEM", 143, 151], ["CXR", "TEST", 153, 156], ["RT-PCR", "TEST", 161, 167], ["COVID", "TEST", 296, 301], ["general precautions", "TREATMENT", 306, 325], ["CXR", "TEST", 361, 364], ["pharyngeal swab", "TEST", 369, 384], ["pharyngeal swab", "ANATOMY", 369, 384]]], ["The worker should wear a N95 mask or higher, disposable fluid-resistant gown, a pair of disposable gloves, goggles or visor for eyeprotection.", [["eyeprotection", "DISEASE", 128, 141], ["a N95 mask", "TREATMENT", 23, 33], ["disposable fluid-resistant gown", "TREATMENT", 45, 76], ["disposable gloves", "TREATMENT", 88, 105], ["goggles", "TREATMENT", 107, 114], ["visor", "TREATMENT", 118, 123], ["eyeprotection", "PROBLEM", 128, 141]]], ["CXR machine should be covered with plastic sheeting to facilitate disinfection.", [["CXR machine", "TREATMENT", 0, 11], ["plastic sheeting", "TREATMENT", 35, 51], ["disinfection", "PROBLEM", 66, 78], ["disinfection", "OBSERVATION", 66, 78]]], ["After acquisition, CXR machine must be disinfected with low-or intermediate-level disinfectant, disposables properly disposed, and workers washed their hands [8] .J o u r n a l P r e -p r o o fThis approach brings healthcare to patient's home, reducing the risk of infected subjects referring to family doctors' office or emergency departments.", [["patient", "ORGANISM", 228, 235], ["patient", "SPECIES", 228, 235], ["CXR", "TEST", 19, 22], ["fThis approach", "TREATMENT", 192, 206]]], ["Further advantages include the following: a) cleaning and disinfecting of all imaging equipment, including mobile x-ray machine and detectors can be performed quietly and carefully during the wait of the radiological report; b)", [["a) cleaning", "TREATMENT", 42, 53], ["all imaging equipment", "TEST", 74, 95], ["mobile x-ray machine", "TREATMENT", 107, 127]]]]}